Regulation of mouse hepatic glutathione S-transferases by Dolan, Catherine






I declare that the work presented within
own.
this thesis, unless stated otherwise, is my
Catherine Dolan
June 1990
To Mum and Dad.
Abstract Of Thesis
The glutathione S-transferases (GST) are a multi-gene family of dimeric proteins
which catalyse the conjugation of glutathione to a wide range of electrophilic
compounds. Three classes of mouse cytosolic GST have been isolated, alpha, mu and
pi, comprising Ya-, Yb- and Yf-type subunits respectively. A marked sexual
dimorphism in mouse hepatic GST has been observed. The YfYf GST is the most
abundant form in the male, constituting approximately 70% of total hepatic GST
content. By contrast, the Yf subunit represents only a minor form in the livers of
female mice. The hormonal controls which regulate the expression of the YfYf GST in
mouse liver have been investigated. Testosterone, the major male sex hormone, is
found to regulate the levels of Yf in mouse liver. Castration of the male leads to a
decline in the levels of Yf to that observed in females. Replacement therapy with
testosterone partially restores the levels of Yf. Testosterone treatment induces
expression of this subunit in the female.
Growth hormone secretion from the pituitary gland differs markedly between the
sexes. Androgens act to produce the male pattern of growth hormone secretion which
regulates the sex-specific expression of numerous hepatic proteins. Male "little
mice", specifically defective in the production of growth hormone, exhibit a feminine
pattern of GST expression, despite having normal levels of testosterone. Testosterone
treatment has no effect on the expression of YfYf in little mice. In contrast, growth
hormone replacement therapy, administered to simulate the male-specific pattern
causes an increase in the expression of the Yf subunit. These findings strongly
suggest that testosterone regulates the hepatic expression of the Yf subunit indirectly
through the male-specific pattern of growth hormone secretion.
(i)
The effects of the xenobiotics, phenobarbital, dexamethasone and 1,4-Bis{2-(3,5-
dichloropyridyloxy)]-benzene (TCBOP) on mouse hepatic GST content have been
investigated in two strains of mice, C57BL/6 and DBA/2. All three compounds were
found to induce hepatic GST in both strains and sexes, predominantly affecting
expression of members of the mu class. TCBOP was the most potent inducer.
Hypophysectomy did not significantly affect induction of GST by these compounds.
(ii)
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Chapter 1 - Introduction
1.01 General Introduction
The chemical complexity of the environment today has profound significance for life
at all levels in the evolutionary scale. It has been estimated that around three
thousand new chemicals are synthesized each year to add to the existing hundreds of
thousands of foreign compounds already in widespread use. A number of these
compounds have been found to have adverse effects on biological systems and many
pathological conditions such as cancer are caused by exposure to these toxic agents.
How chemicals affect living organisms, how they are metabolised and how the body
protects against their possible toxic effects are therefore key areas of research1.
Many foreign compounds are so hydrophobic that they would remain within the body
indefinitely were it not for the drug-metabolising enzyme systems which are
localised primarily within the liver. Two phases in the metabolism of drugs can be
2
distinguished, which are illustrated in figure 1.01. During phase I drug-
metabolism, one or more polar groups, for example, a hydroxyl group, are
introduced into the parent molecule. In many cases, relatively inert hydrophobic
molecules are "activated" at this stage and are capable of interacting with cellular
components which may result in toxicity and cell death or mutagenesis and cancer. In
addition, conjugating enzymes such as the glutathione S-transferases (GST), the
UDP-glucuronyltransferases or the suiphotransferases can inactivate reactive
electrophilic intermediates and prevent attack on cellular macromolecules. These
enzyme systems constitute the second phase of drug-metabolism. Not only are the
reactive groups of the compound "neutralised" but the increased polarity of the
resulting conjugate aids excretion from the body.
1- for general reviews on drug metabolism refer to Jakoby, Bend and Caldwell,
1982, Anders (1985) and Gibson and Skett, 1986).
2- Williams (1959).
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Metabolism of a parent compound by the cytochrome P-450 monooxygenase family
can lead to the detoxification of a toxic species. In some cases however, oxidative
metabolism of a foreign compound may result in the creation of a reactive
intermediate from a relatively inert starting compound. If this species is not
detoxified by phase II drug metabolising enzymes, this compound can interact with
cellular components and cause damage.
2
The cytochrome P-450-mediated monooxygenase system (cytochrome P-450, P-
450) constitutes the largest group of phase I enzymes. This diverse multi-gene
family of membrane-bound enzymes can interact with a wide variety of compounds
both endogenous and exogenous. Although their purpose is to generate an electrophilic
moiety for the phase II conjugating enzymes, metabolism of foreign compounds by
cytochrome P-450s may potentiate the detrimental effects of an inert compound by
activating it to a reactive toxic intermediate.
Thus, the balance within a cell between the enzymes responsible for the two phases
of drug-metabolism will help determine how susceptible that cell will be to the
effects of a given cytotoxic agent. Many factors can alter this equilibrium such as the
genetic make-up of the individual, age, hormonal balance, nutrition, circadian
rhythm, stress response and previous exposure to foreign compounds. It should also
be emphasised that species differences exist in the regulation of drug-metabolising
enzymes and this adds yet a further level of complexity to the situation (Eisen et al., 1983).
The regulation of the Phase I cytochrome P-450 system has received considerable
attention, however, less is known of the regulatory factors which can modulate the
expression of Phase II enzyme systems. This information could potentially prove
invaluable to our understanding of the factors which can modulate the susceptibility
of an individual to environmental toxins, and may, hopefully prove useful in future
clinical strategies which aim to increase protection against environmental toxins
and their detrimental side-effects by increasing the Phase II type metabolism of
drugs. (Wattenberg, 1978; 1985).
The work presented within this thesis is mainly concerned with the identification of
endogenous factors which control the expression the glutathione S-transferases
3-for reviews see Wolf, 1986; Nebert and Gonzalez, 1987).
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(GST, EC 2.5.18), an important group of phase II drug-metabolising enzymes. The
model system studied was the mouse and the investigation concentrated solely on the
liver, which is the major site for detoxification within the body. The effect of
exogenous compounds on this system was also studied.
1.02 Glutathione coniuoation - a maior step in the mercapturic acid pathway
Glutathione, the major non-protein thiol species within the cell, is universally
present in all aerobic forms of life (for review, see Arias and Jakoby, 1976). It
exists in either the reduced form (GSH) or in the oxidised state (GSSG). Reduced
glutathione is a tripeptide consisting of the amino acids y-g'utamic acid, cysteine and
glycine. The y-glutamyl linkage is thought to protect against degradation. The
structure is shown in figure 1.02. Although the GSH concentration varies between
tissues, this species is relatively abundant and normally exists in the reduced form
(GSH), however it can readily undergo conversion to the oxidised form (figure
1.02). At physiological pH, GSH has a net negative charge and is highly water
soluble. The nucleophilic thiol group present on the cysteine moiety confers
reactivity towards electrophiles (Boyland and Chasseaud, 1969).
The mercapturic acid pathway is a major route in the biotransformation and
excretion of foreign compounds. The conjugation of GSH to reactive electrophilic
intermediates constitutes the first step in this pathway, which is depicted in figure
1.03. Booth et at. (1961) described an activity in the liver which catalysed this
conjugation reaction and subsequently the enzymes which catalyse these reactions
have been known as the glutathione S-transferases. The GSH conjugate once formed
can be excreted directly or can undergo further metabolism to yield the























SnurP 1.02 - Structure Of Glutathione
The inter-relationship between reduced glutathione and oxidised glutathione
(glutathione bisulphide; GSSG) and their chemical structures.
[ (1) - v-giutamyl peptide link]
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Figure 1.03 Mercanturir Acid Pathway.
Conjugation of an electrophiiic compound (RX) with glutathione is catalysed by the
glutathione S-transferases. The conjugate may be directly excreted into bile.
Alternatively, the glutathione conjugate may undergo further metabolism. In the
kidney, the enzyme -y-glutamyl transferase catalyses the transfer of the 7-glutamyl
moiety to neutral amino acids (AA) or peptides. After which, cysteinyl-glycinase
(dipeptidase) catalyses the hydrolysis of the cysteinyl-glycine peptide bond, with
the release of glycine. N-acetlylation of the cysteinly derivative catalysed by the
enzyme N-acetly transferase yields the mercapturic acid. Alternatively, the cysteine
conjugate may be cleaved to a mercaptan by the elimination of pyruvate and ammonia.
6
After conjugation of the foreign compound with GSH, the glutamic acid residue is
transferred by the microsomal enzyme, y-glutamyltransferase to neutral amino acid
or peptide acceptors. Following removal of the glutamic acid, the glycine residue may
also be lost from the remaining cysteinylglycine conjugate. Finally, the cysteine
derivative is acetylated to yield the mercapturic acid, a classical excretion product of
xenobiotics. An alternative metabolic route leads to the formation of the mercaptan
through cleavage of the cysteine conjugate and the elimination of pyruvate and
ammonia.
1.03 Nomenclature and classification of GST
Initial reports by Booth et al. (1961) demonstrated the presence in rat liver cytosol
of an enzymatic activity which catalysed the formation of GSH conjugates with a
variety of compounds. Soon after it was recognised that several distinct enzymatic
activities exist (Johnson et al., 1963). Early attempts to classify these enzymes
were based on their activity towards certain classes of substrate hence the terms
aryltransferase, epoxide transferase, alkytransferase, aralkytransferase and
alkenetransferase. However, as purification schemes were developed, it became clear
that individual forms each exhibit a broad, overlapping substrate specificity that
were not restricted towards a certain class of chemical. Thus, the early substrate-
based nomenclature was rendered obsolete and replaced by enzyme designations
which reflected the chromatographic properties of GST (Fjellstedt et al., 1973;
Habig et al., 1974; Pabst et al., 1973).
More recently, the chromatography-based designations have been superseded and the
two major nomenclatures in use today reflect the quaternary structure of the
glutathione S-transferase isoenzymes. Cytosolic GST forms consist of two subunits.
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Homo- and heterodimeric combinations of individual subunits give rise to a
multiplicity of GST isoenzymes, each with a unique spectrum of catalytic activity
(Hayes et al., 1981; Mannervik and Jensson, 1982). In the rat, which has been the
most fully characterised system to date, many distinct subunits have been identified
and characterised. The nomenclature system which has been employed throughout the
course of this thesis is based on the work of Bass et al. (1977), where subunits
were designated according to their mobility on SDS/PAGE. The subunit forms
originally observed in rat liver preparations were named Ya, Yb and Yc in order of
their decreasing mobility on SDS/PAGE. This nomenclature has since been extended
to incorporate other GST subunits which have since been identified (Hayes,1983;
Hayes and Mantle, 1986a,b; Ishikawa et al., 1987). The relative mobilities of GST
subunits on SDS/PAGE using a 12% polyacrylamide gel (Ceis 2.6%) are Yf > Yk > Ya
> Yn > Yb > Yc (Hayes, 1986; Hayes and Mantle, 1986)
In the other major nomenclature system proposed by Jakoby et al. (1984),
individual subunits have been assigned Arabic numerals. The relationship between
these current nomenclatures is given in table 1.01, this table has also been extended
to include older nomenclatures based on purification schemes. In section 1.07, the
rat GST forms are related to those forms found in the mouse and the nomenclature has
been further extended to encompass this species.
1.04 The glutathione S-transferases - a multi-oene family of proteins
Cytosolic glutathione S-transferases can be divided into three distinct families on the
basis of their structural, immunochemical and catalytic activities (Mannervik,
198&,' 1988). These properties ultimately depend on the primary sequence of the
8
Table 1.01 GST Nomenclatures (for rat)
Class GST* 12 3 4
alpha YaYa 1 -1 Ligandin
YaYc 1 -2 B B
YaYc 2-2 M
YkYk 8-8 K






pi YfYf 7-7 P
ND 5 - 5 E
ND - no designation
* Nomenclature utilised throught the course of this thesis.
1 - Jakoby et al. (1984)
2 - Fjellstedt et al. (1973), Habig et al. (1974, 1976)
3 - Hayes et al. (1979)
Hayes (1984, 1986)
4 - Kitihara et al. (1984)
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protein. Within gene families a high degree of primary sequence homology exists,
greater than 80%. Individual subunits from the same gene family display a high
degree of cross-reactivity at both the protein and nucleic acid levels. The primary
sequence homology between families is poor (less than 30%). Heterodimeric forms
can arise from the hybridisation of different subunit types, however only subunits
within the same gene family can form binary combinations (Hayes et al., 1981;
Mannervik and Jensson, 1982; Hayes et al., 1984). Between families no cross-
reactivity is observed at either the protein or nucleic acid level. The three cytosolic
gene families have been designated alpha, mu and pi (Mannervik et al., 1985) or
Groups I, II, III (Hayes and Mantle, 1986b). The alpha class family consists of the
Ya, Yc and Yk subunits, the mu class GST contain Yb- and Yn-type subunits and the
YfYf GST constitutes the pi class GST. Members of these families are listed in table
1.02. The microsomal GST (Morgenstern et al., 1979, 1980, 1982) constitutes a
fourth gene family, which was not studied during this thesis.
Class Alpha
The alpha class comprises Ya-, Yc- and Yk-type subunits. The primary amino acid
sequence for both Ya and Yc have been deduced from full-length cDNA clones (Pickett
et al., 1984; Telakowski-Hopkins et al., 1985). The overall nucleotide sequence
identity between Ya and Yc is 66%. Within the protein coding region, this identity is
higher (75%). The overall amino acid sequence identity between the Ya and Yc
subunits is 68%.
Southern blot analysis of rat genomic DNA using specific probes to the 5' and 3'
regions of the rat Ya and Yc genes also indicate the presence of multiple genes
encoding both these subunits. It has been estimated that at least five Ya genes and two
10
Table 1.02 GST Gene Family Members




Alpha (1) Ya 25,500 68%
Yc 27,500
Yk 25,000
Mu (II) Ybi 26,300
Yb2 26,300 > 80%
Yn 26,000
Pi (III) Yf 24,800 80%*
FAEE sythetase 26,000
* Homology at the amino acid level.
** N-terminal amino acid homology, (Bora et al., 1989)
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Yc genes are to be found within the rat genome (Rothkopf et al., 1986). cDNA clones
encoding the rat Ya subunit have been isolated by various laboratories, these clones
fall into two distinct types which differ by 8 amino acids out of 222 residues. The
"prototype" clones for the these types of gene are pGTB38 isolated by Pickett et al.
(1984) and pGTR261 isolated by Lai et al. (1984). A third cDNA isolated again by
Pickett and his colleagues is identical in the protein region to the cDNA clone
described by Lai et al. (1984), however, its 3' untranslated region is extended in
length and contains a type 2 alu repetitive element (Rothkopf et al., 1986).
The presence of multiple genes in this family was also confirmed by the isolation of
four unique genomic fragments from a rat genomic library (Rothkopf et al., 1986).
One of the isolates X GTB45-15 was found to encode a Ya subunit. This gene spanning
10kb in length comprises 7 exons separated by 6 introns. To date, this has been the
only report of an alpha class genomic clone (Telakowski- Hopkins et al., 1986).
Evidence also exists at the protein level for microheterogeneity within subunit
types. Sheehan and Mantle (1984) provided evidence for two forms of Ya subunit,
which appear structurally very similar but are quite distinct in their kinetic
parameters and their inducibility with phenobarbital.
More recently, Hayes et al. (1990) have used reverse-phase h.p.l.c. to resolve two
separate Ya-type subunits from rat liver and demonstrated their distinct genetic
origins by amino acid sequencing. The subunits were designated Yai and Ya2 and their
primary structures suggest that they are encoded by pGTR261 and pGTB38,
respectively. Interestingly, Ya2 is preferentially induced in aflatoxin Bi-induced
nodule-bearing livers but the relationship between Yai and Ya2 and the two forms of
Ya described by Sheehan and Mantle (1984) is unclear.
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Amino acid composition and immunochemical data (Hayes, 1986; Hayes and Mantle,
a
1986) suggest that the Yk subunit shares sequence homology with the Ya and Yc
subunits, it has therefore been placed within this group. However, a closer degree of
homology exists between Ya and Yc than these subunits share with Yk and Alin et al.
(1989) have reported that Yk possesses 57-60% positional identity with Ya and Yc.
As of yet no rigid criteria exist to define what constitutes a gene family. The degree of
primary sequence homology which is "acceptable" between distinct forms within a
family has not been defined. It is therefore uncertain as to whether the Yk subunit
should be classed within the alpha gene family or whether it should be classed as a
member of a separate but related subfamily.
Cass Mu
The mu class family comprises Yb- and Yn-type subunits. cDNA clones encoding the
Ybi and Yb2 subunits have been isolated by Ding et al. (1985a, 1986) and a cDNA
encoding the Yn subunit (also known as Yb3) was cloned by Abramovitz and
Listowsky (1987). Greater than 80% homology exists between these GST subunits at
both the DNA and protein level. Southern blot analysis again indicates the presence of
multiple genes (Lai et al., 1986). Genomic sequences for the Ybi and Yb2 clones have
been obtained but as of yet no genomic clone has been described for the Yn subunit
(Tu et al., 1987). A genomic clone has been isolated by Lai et al. (1988) which
encodes a novel mu class enzyme termed Yb4, which is homologous to, but not
identical to, other mu class GST forms.
At the protein level, Yb-|Yb2 dimers have been found to exist in vivo (Haves. 1983).
In vitro hybridisation studies demonstrated that both Yb subunits can dimerise with
the Yn subunit. Transferase P and transferase S isolated from rat liver correspond to
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the YbiYn and Yb2Yn heterodimers respectively (Hayes and Chalmers, 1983; Hayes,
1984).
Class Pi
Until recently, evidence suggested that the pi class GST family contained only the
member, the Yf subunit. Although multiple bands appear on southern blotting with a
cDNA clone encoding the rat Yf subunit, Okuda et al. (1987) have reported that the
Yf GST was the product of a unique gene locus. All other potential clones isolated were
found to be non-functional pseudogenes. Recently, however, the major FAEE
synthetase, isolated from human heart was found to be 72% identical to the N-
terminal sequence of the rat Yf subunit and 82% homologous to GST YfYf isolated
from human heart (Bora et al., 1989). Subunits within other families, as discussed
above, display similar levels of homology.
Catalytic activities are also interchangeable, in that FAEE synthetase can catalyse the
conjugation of GSH with CDNB and the GST isolated from bovine liver was active in
the formation of FAEE. Further reports on this enzyme and its relationship to the pi
class GST are awaited with considerable interest as this family might be more
complex than was originally thought.
Further Cvtosolic GST Classes?
Subunit 5-5, which as yet has received no designation in the Y nomenclature, may be
related to the Yb\Yn family, although this is not as yet certain (Meyer et al., 1984).
Further molecular characterisation of this subunit form will need to be performed
before it is clear whether it is a member of the alpha, mu, pi or other family of GST.
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1.05 Catalysis
The glutathione S-transferases catalyse the conjugation of GSH to a wide variety of
electrophilic compounds. Many GST substrates are detrimental to the cell due to their
ability to interact with cellular macromolecular components causing cellular
toxicity or in the case of DNA, mutagenesis. A comprehensive review of the wide GST
substrate specificities towards carcinogenic compounds is given by Chasseaud
(1 979).
Although cytosolic GST forms are dimeric, studies on the kinetics of GST catalysis
indicate that each subunit is catalytically independent. No allosteric or cooperative
effects have been described (Danielson and Mannervik, 1985). Each individual
isoenzyme has a unique spectrum of catalytic activity, the additive effects of
individual subunit combinations, i.e., the kinetic properties of the heterodimer can
be predicted from those of the corresponding homodimers (Yalcin et ai, 1983; Tahir
and Mannervik, 1986).
In the case of compounds such as CDNB, the substrate specificities of individual GST
isoenzymes are broadly overlapping, although different forms have a distinct
spectrum of specific substrates activities. The compound CDNB is used as the
"general" GST substrate, although some forms of GST have a very low specific
activity towards this substrate (Clark et a!., 1973).
Glutathione conjugation to certain substrates is restricted to specific enzymatic
forms (Mannervik and Jensson, 1982). These "model" substrates can be used to
distinguish between individual subunit forms within a gene family, which can be
particularly useful when members cannot be distinguished on the basis of molecular
15
weight or immunochemistry. Two substrates which are particularly useful are DCNB
and frans-4-phenyl-3-butene-2-one which are marker substrates for the Ybi and
Yb2 subunit forms.
Two distinct GSH peroxidase activities can be can be distinguished in the liver, a
Selenium-dependent GSH peroxidase and a Selenium-independent GSH peroxidase.
This Se-independent activity is contributed by the alpha class GST, particularly the
Yc subunit (Lawrence and Burk, 1976 ;Carmagol et at., 1983). Both activities can
be distinguished enzymatically by the use of H2O2, which is specific for the Se-
dependent GSH peroxidase activity, whereas both forms are active with the organic
hydroperoxide, cumene hydroperoxide. This substrate is used as a marker substrate
for alpha class Ya, Yc and Yk subunits in the rat.
Table 1.03a lists the model substrates for specific GST subunits. Table 1.03b gives
the specific activities for these substrates with a range of GST isoenzyme forms.
1.O6 Endogenous Compounds as GST substrates,
The emphasis with regards to GST substrates has concentrated on their activity
towards xenobiotic compounds either as tools to discriminate between individual
isoenzyme forms or in their ability to detoxify harmful compounds. It should be
noted that in addition to their role in xenobiotic detoxification, increasing evidence
indicates that the GST family might also play an important part in normal cellular
metabolic processes, particularly in protection against the products of the oxidative
metabolism of endogenous compounds. In addition, these enzymes are probably also
involved in normal biosynthetic pathways within the cell. Potential natural
substrates for the GST are given below.
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Table 1.03 a







































































As has been previously referred to in section 1.05, GST isoenzyme forms are found
to have activity towards the organic peroxide, cumene hydroperoxide, which is used
as a model substrate for the alpha class GST forms, particularly the Yc subunit
(Lawrence and Burk 1976, Mannervik, 1985). Linoleate and arachidonate
hydroperoxides have also been found to have good activity with GST forms, the
uncharacterised form 5-5 having the highest activity with these substrates
(Ketterer et al., 1987). Other compounds, generated in the process of lipid
peroxidation are found to act as substrates for GST. Arachidonic acid gives rise to
several epoxide derivatives which are substrates for GST (Spearman et al., 1985).
Alkenes, yet another by product of lipid peroxidation are also reactive with GST. The
4-hydroxyalkenals, major products of lipid peroxidation, are good substrates for
GST, the Yk subunit (form 8-8) being exceptionally active with these compounds.
The Ya and Yb2 subunits also have high activity with these substrates but several fold
less than the Yk. (Alin et al., 1985, Danielson et al., 1987).
Cholesterol-a-oxide is yet another product of lipid peroxidation, a possible
carcinogen, which has been found to be a substrate for GST. The Ya subunit was found
to have highest activity with this compound (Watabe et al., 1979, Meyer and
Ketterer, 1982) .
Thus one of the major endogenous roles for the glutathione S-transferases might be
in cellular protection against lipid peroxidation. Indeed, Tan et al. (1984) have
shown that the Se-dependent GSH peroxidase and alpha class GST inhibit lipid
peroxidation in vitro.
DNA hydroperoxides have also been shown conjugated to GSH. Peroxidised DNA has
been shown to serve as a substrate for rat GST, highest activity was obtained with the
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mu class ( Tan et at., 1986; Ketterer et at., 1987). This is especially interesting in
the light of the report by Bennet et at. (1986) in which mu class GST was located in
rat liver nuclei. Thus, GST may play a role in the protection of DNA, possibly
preventing peroxidative damage to the cell's nucleic acid.
Quinones may represent a class of reactive compounds which may be detoxified by
GST. Dopaquinone has been found conjugated to GSH in human malignant melanoma
(Agrup et at., 1977). Reactive intermediates of oestradiol metabolism may also
serve as substrates for GST (Jellinck et at., 1967; Marks and Hecker, 1969).
In addition to their general role in protection against reactive cellular
intermediates, these enzymes might also play a normal part in the biosynthesis of
biologically active molecules. The leukotrienes and prostaglandins, signalling
molecules derived from arachidonic acid, are substrates for GST (Christ-Hazelhof et
at., 1976; Tsuchida et ah, 1987). GST isoenzyme forms have been reported to
exhibit prostaglandin isomerase activity including the Ya subunit which has also
been shown to have steroid isomerase activity with A5-androstene-3,17-dione.
(Benson et at., 1977; Meyer and Ketterer, 1987) Certain of the major leukotriene
derivatives with strong physiological activity originate from conjugation with GSH.
GST forms have been found to catalyse the conversion of leukotriene A4 to
leukotriene C4, the class mu Yb2 subunit being most active (Mannervik et at.,
1984). Thus GST may play a role in the complex biological pathways involved in the
synthesis of steroids, prostaglandins and leukotrienes.
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1.07 Mouse Hepatic Glutathione S-Transferases
Mouse glutathione S-transferases have been investigated by several laboratories
(Lee et al., 1981; Pearson et al., 1983; Aigius and Gidari, 1985; Hatayama et al.,
1986; Warholm et al., 1986 ; Hayes et al., 1987; McLellan and Hayes, 1987;
1989; Benson et al., 1989). Early purification studies yielded information that was
unclear and inconsistent. The physical properties of the enzymes isolated by various
laboratories differed making it difficult to determine the number of murine GST and
establish a helpful nomenclature.
Lee et al. (1981) isolated from DBA/2 mice (sex not specified) three major
cytosolic forms termed F1, F2 and F3. Enzymes F1 and F2 both had Mr values of
22,000 and were reported to be charged isomers with pi values of 6.5 and 8.2
respectively. F3 was found to have a Mr of 27,000 and a pi value of 8.8.
The hepatic GST content of CD-1 mice was investigated by Pearson et al. (1983) and
Agius and Gidari (1985). Both groups described the purification of two enzyme
forms. Pearson and his colleagues isolated from female mice treated with butylated
hydroxyanisole (BHA) both a major GST form termed GT 8.7 and a minor cytosolic
GST form, GT 9.3, named on the basis of their isoelectric points. Both forms had Mr
values of 24,000, were immunologically cross-reactive and had a high degree of N-
terminal sequence homology.
Agius and Gidari (1985) described the isolation of two homodimeric forms from the
liver of female CD-1 mice treated with streptozotocin, a drug used to induce diabetes
in animal models. These enzyme forms had Mr values of 27,500 and 28,000 with pi
values of 9.2 and 8.2 respectively. It was thought that these forms corresponded to
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the GT 8.7 and GT 9.3 forms described by Pearson et al. (1983). Discrepancies were
thought to be due to technical factors.
More recently, data by a number of workers (Hatayama et al.,1986; Warholm et al.,
1986; Hayes et al., 1987; McLellan and Hayes, 1987; Benson et al., 1989)
demonstrate that in mouse liver, GST isoenzyme forms exist which have homology to
the rat species described and can be divided into the three gene classes, alpha, mu and
pi. The properties of the enzyme forms isolated and characterised by various
workers are described in table 1.04
Warholm et al. (1986) purified three enzyme forms from the livers of male NMR1
mice. These forms, referred to as Ml, Mil and Mill appeared to be dimers of identical
subunits. Transferase Ml was assigned to the alpha class whereas transferases Mil
and Mill were placed in the pi and mu classes respectively. The specific activities of
the GST isoenzymes isolated from mouse liver with a range of GST substrates are
shown in table 1.05. Activities of the three mouse GST forms towards the model
substrates listed in table 1.03 (a,b) compare closely with those of the rat (refer to
table 1.03b).
Hayes et al.(1987), investigating the hepatic GST content of male LACA mice,
reported similar findings. Three GST forms were isolated which were found to be
homodimeric enzymes comprising Yf-(Mr 24,500), Ya-(Mr 26,000) and Yb (Mr
27,000) type subunits.
Interstrain variation in GST content was proposed to account for the lack of
consistency in early work. Hatayama et al. (1986) and McLellan and Hayes (1987)
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Table 1.04 Characteristics of mouse hepatic, cvtosolic GST isoenzymes isolated
bv different laboratories.













































































Abbreviations : ND - not determined
* GST preparations from untreated, normal mouse liver.
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Table 1,05
Specific activities (umol/min/mg) of constitutive^ expressed mouse hepatic
glutathione S-transferases
Class: alpha mu P'
Substrate
1-chloro-2,4-dinitrobenzene 1 9 1 48 119
1,2-dichloro-4-nitrobenzene 0.062 4.4 0.14
ethacrynic acid 0.025 0.12 1.4
frans-4-phenyl-3-buten-2-one 0.009 0.004 0.013
cumene hydroperoxide 11.6 0.11 0.14
A5-androstene-3,17-dione 0.035 0.043 0.14
Taken from Mannervik and Danielson (1988).
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investigated the hepatic content of several mouse strains to determine if interstrain
differences in hepatic GST content did occur. GST forms homologous to the three rat
cytosolic gene families were isolated and characterised. Both groups however found
no evidence of strain differences in hepatic GST content. However, a marked sex
difference in the expression of the pi class GST was observed. In the male mouse
liver this subunit is the major GST form, constituting approximately 70% of the
total GST content. In contrast, this subunit constitutes only a minor form in the
female mouse liver. This significant difference in the expression of the Yf subunit
between the sexes might account to some extent for the differing results in the early
work.
Many purification schemes isolated hepatic GST from mice which had been treated
with compounds which can induce hepatic GST. This would have led to some confusion
as certain GST forms are not present in significant quantities in uninduced liver.
Pearson et al. (1983) isolated from BHA-treated mice GT 8.7 and 9.3, both proteins
are members of the mu class. GT 8.7 was found to be expressed in normal liver,
however, GT 9.3 expression was found to be very low in mice fed normal diets.
McLellan and Hayes (1989) described the induction of a novel alpha class GST
subunit in DBA/2 mice after treatment with BHA. This subunit, termed Yai, on the
basis of immunological and physical properties was more closely related to the rat Ya
subunit than the constitutively expressed murine Ya subunit (known as Ya3). In the
uninduced liver Yai was barely detectable, after treatment with BHA, this subunit
was induced more than 20-fold.
Recently, Benson et al. (1989) reported the purification from CD-1 mice of enzyme
forms (GT8.7, GT8.8a, GT8.8b, GT9.0, GT10.3 and GT10.6) from all three GST gene
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families. Forms GT 8.7 and 9.3 were identified and confirmed as mu class. Other
forms were also noted which differed slightly in the pi values from GT 8.7 (GT 8.8a,
GT8.8b). Evidence presented indicated that these forms were essentially identical to
GT 8.7 and could be ascribed to the mu class. Form GT 9.0 was classified as pi class.
On the basis of electrophoretic mobility during SDS/PAGE ( Mr not quoted), a
blocked N-terminus and enzymatic activity, GT 10.6 was assigned to the alpha class,
although a high degree of disparity was observed between the amino acid composition
of this species and the alpha class clone pGT41 (Pearson et al.,1988). Another form,
GT 10.3 was described which again was thought to belong to the alpha class. This
species when subject to h.p.l.c. split into two peaks; one peak had a Mr similar to GT
10.6 and the other was 1kd smaller. GT 10.6 was not significantly affected by BHA
treatment, GT 10.3 however was barely detectable in the untreated liver but induced
after treatment. It is possible that these forms correspond to the alpha class GST
subunits characterised by McLellan and Hayes (1987,1989). GT 10.6 might
correspond to the constitutively expressed Ya3 subunit and GT10.3 might correspond
to the Yai subunit.
GT 8.7 was found to be the major GST form induced on treatment with BHA.
Interestingly, however, the Yf subunit was also induced in the female mouse but not
in the male, where this GST is normally the most abundant form. Possibly the Yf GST
in the male is expressed at the highest level possible and can not be induced to any
further extent.
1.08 Molecular analysis of mouse GST.
The first cDNA clone encoding a mouse GST was isolated by Pearson et al. (1983).
The clone, pGT55, was found to be identical to the protein GT 9.3 and highly
26
homologous to GT 8.7 (85% amino acid identity) in the N-terminal region of the
proteins for which sequence information was available. Later, a cDNA clone encoding
the GT 8.7 protein was reported by Pearson et al. (1988). Both clones are highly
homologous to the mu class GST subunits from rat. GT 8.7 is very closely related to
the rat Ybi subunit sharing 92% amino acid sequence identity.
Townsend et al. (1989) isolated from mouse L929 cells two mu class cDNA clones,
pGT10 and pGT2 which encoded proteins termed mGTmul and mGTmu2. Sequence
analysis showed mGTmul to be completely identical except for one amino acid
difference to GT 8.7, this form was more closely related to the rat Ybi subunit than
any mouse mu class GST enzymes isolated to date. The second clone mGTmu2 was
found to be very closely related to the rat Yb2 subunit, sharing 95% sequence
identity at the amino acid level. The cDNA isolated by Pearson et al.(1983), pGT55
was highly homologous to the deduced amino acid sequence for the fourth rat mu class
GST clone described (Lai et al., 1988), which was isolated from a genomic library.
Sequence identity was very high with replacement of only 5% of amino acid residues.
Messenger RNA encoding the mGTmul was found in high levels in normal liver,
whereas mGTmu2 was not detectable.
Southern blot analysis of mouse DNA using a cDNA clone encoding the rat Ya subunit
gives a complex multi-band pattern indicative of a multi-gene family. At least four
genes were estimated to be present in the mouse genome. All hybridising bands were
located to mouse chromosome 9 by the use of somatic cell hybrids and they appeared
to be clustered (Czosnek et al., 1984).
Daniel et al. (1987) reported the isolation of a genomic clone encoding a mouse Ya
subunit which spanned 11 kb of DNA and contained 7 exons. A comparison of the
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deduced amino acid sequence from the mouse genomic clone with the rat alpha class
Yai subunit showed a high degree of conservation with 10 amino acid differences
between species.
Pearson et al.( 1988) described the isolation of a mouse Ya clone pGT41 which is
very similar although not identical to the coding sequence for the genomic clone
isolated by Daniel et al (1987). Nucleotide sequence identity was 97%, with 96%
homology at the amino acid level. This gene is highly homologous to the rat Ya subunit
sharing 95% amino acid identity, homology to the Yc subunit was reported at 72%.
pGT41 and the mouse genomic clone isolated by Daniel could represent two different
species of mouse Ya subunit analogous to the two classes of Ya cDNA clones which have
been isolated in the rat.
Northern blot analysis showed the mRNA species hybridising to pGT41 is present at
very low levels in the uninduced liver. Upon BHA treatment however, a 50-fold
increase in the level of this mRNA has been observed (Pearson et al., 1988). The
BHA-inducible Ya subunit (Yai) described by McLellan and Hayes (1989) is also
present at very low levels in the untreated mouse being induced more than 20-fold
in the BHA-treated animal. This subunit would also appear to be more closely related
to the rat Ya than the constitutive Ya subunit (Ya3) expressed in mouse liver, which
is not significantly affected by BHA-induction. It is therefore probable that the
clones isolated by Pearson et al. (1988) and Daniel et al. (1987) encode Yai-type
subunits rather than Ya3- The cloning strategies employed in both cases used cDNA
clones encoding the rat Ya subunit to probe for mouse alpha class genes. Daniel et al.
(1 98 7) used a mouse genomic library and Pearson et al. (1988) used a cDNA
library from BHA-induced mouse liver. The more closely related GST form would
therefore be preferentially detected on screening these libraries. Protein sequence
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data on both mouse alpha class GST forms will add further light to this situation.
Table 1.06 lists the mouse hepatic subunits characterised to date with their probable
rat equivalents, homologies where known, are quoted.
The mouse would appear at first hand to be a simpler system than the rat in respect
to GST expression. The evidence presented indicates that in normal liver three
homodimeric GST forms are present Ya3, Ybi and Yf, in contrast to the rat where 7
GST subunit forms have been isolated and characterised. Other forms are either not
expressed or found in very low levels. Upon treatment with GST inducing agents not
only is the induction noted of certain of the subunits normally expressed in the liver,
but other forms of GST are induced as well. At least one other alpha class GST is
induced after BHA treatment, together with mu class GST Yb2- Doubtless other forms
are present in the liver or expressed in extrahepatic tissue which have as yet to be
characterised. Information at both the molecular and protein level will provide a
more thorough basis for the classification of the forms which have already been
characterised together with those forms which have as yet to be noted.
1.09 Regulation of Glutathione S-Transferases.
The regulatory factors which determine the expression of the glutathione S-
transferases are complex as is the enzyme system itself. Control is exerted at many
levels. GST expression is regulated during development, tissue specificity in
expression occurs and sexual dimorphism in the level of GST occur. However, little
information is available on the underlying mechanisms which govern GST expression
within the cell. The endogenous factors which regulate these processes remain
largely unidentified.
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*dataobtainedfr mMcLellan&Hayes(1989) "dataobtainedfr mTownsendeta/.,(1989)
allotherd tab ainedfr mMcLellan&Hayes(1987).
Most tissues contain GST in relatively abundant amounts although highest levels are
found in the liver, the major site of detoxification in the body (Hayes and Mantle,
1986). In the adult rat, a marked tissue-specificity in the expression of GST has
been noted by several workers (Hayes and Mantle, 1986; Tu et al., 1987). The Yf
containing GST provides a very notable example of tissue-specific regulation. In the
liver and testis this GST form is present in barely detectable amounts, whereas Yf
constitutes a major form in most other tissues, particularly the spleen and colon
(Hayes and Mantle, 1986). This tissue-specificity in expression is also reflected at
the mRNA level (Tu et al., 1987).
Within a tissue, GST expression might not be uniformly distributed. Redick et al.
(1982) using immunohistochemistry demonstrated that alpha and mu class GST,
together with transferase E, are expressed in the parenchymal cells throughout the
liver. However their concentration was highest in the centrilobular region. In the
bile duct epithelium, transferase E and class mu GST gave positive staining but no
alpha class GST was detected. Again the factors which control the differential
expression of GST within a tissue are not known. Immunohistochemistry will prove
to be an invaluable tool when investigating GST regulation, it will clearly be
important to establish not only the tissue-specificity in the expression of this
enzyme system but also the expression of GST within individual cell-types. This
might possibly provide information on the biological reasons for marked differences
in expression between tissues. As of yet these differences are not known but could
possibly be related to the specialised requirements of a given cell-type.
Major differences in hepatic GST expression have been observed between the sexes in
both the rat and mouse. In rat liver, levels of the Ybi subunit are several-fold
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higher in male liver than in the female. Levels of the Ya subunit, in contrast are
higher in the female than in the male (Hales and Neims 1976, Lamartiniere, 1981
Igarashi et al., 1983,1985, 1987).
In mice, a marked difference in the expression of GST subunits has been observed in
the livers of males and females (Hatayama et al., 1986, McLellan and Hayes, 1987).
In contrast to the rat, where YfYf is barely detectable in the liver, the Yf subunit in
male mouse constitutes over 70% of total hepatic GST. In the female however, this
subunit is a minor form expressed at levels approximately 10-fold lower than in the
male.
In both species, developmental regulation of liver GST expression occurs. In both
mice and rats, levels of hepatic GST are low after birth and no sex differences in GST
content between male and female are observed. At the onset of puberty, however,
levels rise to those seen in the adult and the sex differences described above manifest
themselves. (Hatayama et al., 1986; Igarashi et al., 1985).
The endogenous regulatory mechanisms which determine GST expression will
undoubtedly prove to be complex. To further add to the intricacy of the situation,
dietary factors and exogenous compounds can affect the expression of GST. It is
becoming increasingly apparent that many chemical compounds with vastly different
structures can influence hepatic GST levels. Phenobarbital and 3-
methylcholanthrene, classical inducers of the phase I P-450 monooxygenase system
have been the most extensively studied xenobiotic inducers with respect to the ^
P.ckert" u«ji ,
xenobiotic regulation of GST (for reviews, see Pickett et al., 1987, ). Again,
the rat has been used as the model system for these investigations, comparatively
little is known of their effect on other species.
32
Insights into the molecular mechanisms by which 3-methlycholanthrene can
regulate GST levels within the cell have been obtained by Pickett and his co-workers!*
The mechanism by which phenobarbital can affect GST expression in the liver is not
known. This topic is dealt with in more detail in chapters 5 and 6.
1.10 Aims of thesis
The aims of this thesis were two fold. Firstly, an investigation was undertaken into
the endocrine mechanisms underlying the marked sexually dimorphic expression of
the YfYf GST in mouse liver. Secondly, a study was undertaken to determine the effect
of the xenobiotic phenobarbital, and other phenobarbital-like inducers, on the
expression of GST in mouse liver and to determine if the effects of these foreign
compounds were mediated via the endocrine system.
1- Pickett (1987), Pickett et al. (1987) and Pickett and Lu (1989).
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Chapter 2 - Materials and Methods
2.01 Materials
2.01a Chemicals
These were obtained from the following sources;
Amersham International, Amersfram.BucKs. U,K,
P32 CTP; hexadeoxyribonucleotides
Anderman & Co. Ltd.. Kinoston-Upon-Thames. Surrey. U.K.
Nitrocellulose.
B.D.H. Chemicals Ltd.. Thornliebank. Glasgow. U.K.
Acetic acid; ammonium formate; boric acid; bromophenol blue; chloroform; DEAE-
cellulose paper; formaldehyde; glycerol; glycine; HEPES; hydrogen peroxide;
methanol; NN' methylenebisacrylamide; NNN N'-tetramethyethylenediamine
(TEMED); trichloroacetic acid; orthophosphoric acid; phenobarbital; phenol;
polyacrylamide; sarkosyl; sodium acetate; sodium chloride; sodium citrate; sodium
dihydrogen orthophosphate; sodium dodecyl sulphate; Tris; Whatman 3mm filter
paper; xylene cyanol.
Beechams Research Lab. . Brentford. U.K.
Ampicillin (trade name Penbritin).




EcoRI: formamide; guanidinium thiocyanate; low melting point agarose; Pstl: Sail.
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Difco. Detriot. Michigan. U.S.A
Agar; bactotryptorie; yeast extract.
Koch Light Laboratories. Colinbrook. Berks. U.K.
Cumene hydroperoxide.
KodaK Ltd,, Kirby. Liverpool, U.K-
Kodak Xar film
Miilipore fU.K.t Ltd.. Harrow. Middlesex. U.K.
Membranes (0.45pm) for the ultrafiltration of h.p.l.c. buffers.
Sigma Chemical Co,. Poole. Dorset U.K-
Bovine serum albumin; 1- chloro-2,4-dinitrobenzene; coomassie brilliant blue R;
diethyl pyrocarbonate (depc); dexamethasone; dithiothreitol; ethylenediaminetetra-
acetic acid; ethacrynic acid; ethidium bromide; ficoll; gelatin; glutathione;
glutathione reductase; glutathione sepharose 6B; isoamyalcohol; lysozyme;
magnesium chloride; 2-mercaptoethanol; 3-[N-morpholino]propanesulphonic acid
(MOPS); nicotinamide adenine dinucleotide phosphate (reduced form type X);
potassium acetate; polyvinyloyrrolidine (PVP); tetracycline: testosterone
propionate; polyoxyethylene-sorbitan monolaurate (Tween 20).
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2.01b Non commercially obtained material.
Antisera and protein standards
Antisera raised against rat GST subunits and rat GST protein standards for SDS/PAGE
and western blotting were kindly provided by Dr. J.D. Hayes from this department.
The specificities of the antibodies have been described by Hayes and Mantle (1986a).
Antisera towards mouse GST subunits and mouse GST standards for Western Blotting
were a kind gift from Dr. L.I. McLellan again of this department. The specificity of
the mouse antibodies have also been examined (McLellan and Hayes, 1989).
cDNA Clones
Professor M. Maramatsu, Department of Biochemistry, Tokyo, Dr. C.B.Pickett,
Merck Frosst Centre for Therapeutic Research, Quebec and Dr. J.B.Taylor of the CRC
Molecular Toxicology Group, Middlesex Hospital, London, generously provided cDNA
clones encoding the rat Yf, Ybi and Ya subunits respectively. Details of these clones
are given in section 2.07.
Chemicals
TCBOP was a gift from Dr. Alan Poland of the McArdle Laboratory for Cancer
Research, Maddison, Wisconson, U.S.A.
Human Recombinant Growth Hormone (trade name Genotropin), was a gift from Dr.
Richard Wilde of KabiVitrum Ltd.
RNA




A range of experimental animals were used in the course of this work, the sources
for mutant mouse strains, surgically prepared animals and their appropriate
controls are given below, all other mice were obtained from Banton and Kingman,
Grimstone, Hull U.K.
Surgically prepared animals
Hypophysectomised male and female C57BL/6 mice plus sham operated controls
were obtained from Charles Rivers Laboratories Willmington, Massachusetts, U.S.A.
Castrated C57BL/6 males plus normal females used in testosterone induction
experiments were obtained from Harlon Olac Lmt, Blackthorn, Bicester, U.K.
Castrated and ovarectomised CFLP mice were obtained from Interfauna U.K Ltd.,
Huntingdon, Cambridgeshire, U.K.
Mutant Mice Strains
"Little Mice" (lit/lit) plus the heterozygote and wild-type controls were obtained
from two sources. Preliminary experiments were carried out using mice kindly
provided by Dr Rhea Al-Shawi, Dept. of Genetics, University of Edinburgh.
Subsequently, mice were commercially obtained from the Charles Rivers
Laboratories, Willmington, Massachusetts, U.S.A.
Hypogonadal mice were a kind gift from Professor G. Fink, Brain Metabolism Unit,
Department of Pharmacology, University of Edinburgh.




Adult mice and rats of between 8 and 12 weeks were used in experiments, unless
otherwise stated. Animals were housed at either Clare Hall, University of Oxford or
at the Faculty of Medicine Animal Area, University of Edinburgh. Once transported,
the animals were allowed to acclimatize for at least 2 weeks prior to treatment and
were fed (Banton and Kingman Mouse and Rat maintainance diet) and watered ad
libitum , the animals were kept in quarantine throughout.
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2.02 General Analytical Techniques (Protein)
2.02a Protein determination
The protein concentration of samples was obtained using the method developed by
Bradford (1976), with BSA as a calibration standard.
2. 02b GST Enzvmatic Assays
Enzyme assays were either performed using a Cobas Fara centrifugal analyser or
were determined by manual methods on a Uvikon 860 spectrophotometer.
Glutathione S-transferase activity was determined at 37°C using methods similar to
those described by Habig and Jakoby (1981); the assays were normally performed
in duplicate or triplicate. Information on conditions under which individual assays
for a range of substrates were performed is presented in Table 2.01.
The centrifugal analyser was usually employed to determine the GST activity towards
the general substrate CDNB and the GSH peroxidase activities towards either cumene
hydroperoxide (CuOOH) or hydrogen peroxide (H2O2).
Using this instrument a maximum of 29 samples could be analysed simultaneously
for enzyme activity. In the case of GST activity, samples were preincubated with GSH
prior to the initiation of the reaction by centrifugation of CDNB into the reaction
mixture. Assays were performed in 100mM-sodium phosphate buffer pH6.5 (in a
total volume of 250pl), final concentrations of GSH and CDNB were 2mM and 1mM













































Conditionsf rspectrophotometricassaysofGSTtivi ie .A werperf r edith rm statedllompa tm nt37°C accordingthemetho sof( )Hab g&J k by,1981;bK nnJ k y,78modificationftheethoddescribe Wendel(1979),refertos ction2.02b.
monitoring the absorbance at 340nm. A series of 8 absorbance readings were taken,
the first 10 sec after mixing, followed by 7 readings at 5 sec intervals thereafter.
Total peroxidase activity in the cell cytosolic fraction (i.e. both the Se-dependent and
Se-independent form) was measured using the substrate cumene hydroperoxide
(CuOOH). The Se-dependent GSH peroxidase can be specifically assayed using the
substrate hydrogen peroxide (H2O2) • The difference in peroxidase activity towards
these two substrates provides a approximate measure of the Se-independent GSH
peroxidase activity contributed by the GST (Lawrence and Burk,1976; Carmagol et
at., 1983).
Both assays were carried out on the Cobas Fara centrifugal analyser, using a coupled
reaction based on the method described by Wendel(1979). NADP formation,
monitored by measuring the absorbance at 340nm is used as an indicator of
peroxidase activity by the coupling of 2 reactions, the equations for which are given
below:-
ROOH + 2GSH > H20 + ROH + GSSG (1)
GSSG + NADPH + H+ > 2 GSH + NADP (2)
Samples were preincubated with initial reagent containing GSH (final concentration-
1 mM ), NADPH ( final concentration- 0.25nrM) and GSH reductase (at a final
concentration of 1 unit/pl) in 60mM_-Tris/HCI, 0.12mM.-EDTA (pH 7.6). The
reaction in a total volume of 340pl, was initiated by the addition of substrate, CuOOH
or H2O2 to a final concentration of 1.2mM and 0.6mM respectively. Ten absorbance
readings at 340nm were taken in both assays. In the H2O2 peroxide assay, the
absorbance was monitored 5 sec after the initiation of the reaction, with
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measurements at 5 sec intervals thereafter. Absorbance in the CuOOH hydroperoxide
assay was measured at 10 sec intervals.
Units of enzyme activity for all assays are given as pmoles of product formed /min /
ma protein. Values obtained for the non-enzymic conjugation of substrates with GSH
were subtracted from initial rates. In the case of assays performed manually, the
change in absorbance (aA) was calculated per minute and converted to pmoles of
product formed using the appropriate extinction co-efficient, details of which are
given in Table 2.01.
Linear regression analysis was performed using the manufacturers kinetic rate
programme for those assays undertaken on the Cobas Fara. Using a preprogrammed
conversion factor, data from the CDNB assay was presented as AA/min/ml. As with
manually performed assays, the appropriate extinction co-efficient allowed
conversion of these units to pinoles of product/min/ml. Peroxidase activity was
calculated using a similar programme and presented as pmoles of NADP
formed/min/l.
2.02c SDS/Polyacrylamide-Qel Electrophoresis
This was performed essentially as described by Hayes et at. (1979), using the
discontinuous buffer system developed by Laemmli (1970). Electrophoresis was
carried out at room temperature in a Protean II gel electrophoresis system (Bio-Rad
Lab Watford, U.K.). Vertical polyacrylamide slab gels (dimensions 0.072cm x 20cm
x20cm) were employed which comprised of a resolving gel about 15cm high of 12%
(w/v) polyacrylamide containing 0.32% (w/v) NN" methylenebisacryiamide and
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0.375^,-Tris/HCI buffer pH8.85, over which a 3% (w/v) polyacrylamide stacking
gel of 4.5cm containing 0.125M-Tris/HCI buffer pH6.8 was layered; the resolving
gel was allowed to polymerise before the stacking was cast. SDS (0.1%) was added to
both gel systems.
Cytosols were prepared for electrophoresis by the addition of boiling mix solution
containing 3% (w/v) SDS, 30% glycerol , 2% mercaptoethanol and 0.15M.-
Bromophenol Blue, at a ratio of 2x sample to 1x boiling mix; the final sample
preparation mixture contained 1% (w/v) SDS. Samples were heated at 90°C for
about 5min and appropriate aliquots loaded onto the gel. Samples were subject to
electrophoresis through the stacking gel at a constant 250 volts and then through the
resolving gel at 350 volts. Electrophoresis was stopped when the bromophenol dye
front reached 0.5cm from the edge of the resolving gel. Proteins were visualised by
staining for 30-60min at room temp in a 0.2% (w/v) solution of Coomassie
Brilliant Blue R in a water/methanol/acetic acid solution, (50 : 50 : 7 by volume).
Gels were then destained by passive diffusion in several changes of a
water/methanol/acetic acid solution, (88 : 5 : 7, by volume).
2.02d Western Blotting
Western blotting was carried out using a modified version of the method originally
described by Towbin et al. (1979).
Polypeptides were resolved by SDS/PAGE as described in section 2.02c. Immediately
following electrophoresis the resolving gels were equilibriated for 30min in the
transfer buffer (25mM-Tris,193mM-Glycine pH 8.3) to remove SDS. The proteins
were electrophoretically transferred from the gel to nitrocellulose paper using a
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Bio-Rad Trans-Blot Kit. Transfer was performed at 15°C for 3-4 hours at a
constant current of 0.25 amps, using as a power source Bio-Rad model 250/2.5
power pack (Bio-Rad Laboratories). Unbound sites on the nitrocellulose filter were
blocked by an overnight incubation in a 3% (w/v) solution of gelatin in TBS buffer
(20mM.-Tris/HCI, 500mM.-NaCI pH 7.9).
After washing with TBS to remove gelatin, the nitrocellulose filters were incubated
at room temperature with primary antibody for 1-3 hours. The time of incubation
and antibody titre were dependent on the antisera used; antibodies were diluted in
TBS with 1% (w/v) gelatin and 0.05% (v/v) Tween* Filters were washed (4 x
15min) with TBS to remove unbound first antibody. Primary Antibody - Antigen
complexes were detected with a double antibody EIA system using goat anti-rabbit IgG
horseraddish peroxidse, obtained from Bio-Rad Laboratories, with 4-chloro-1-
Vv
napthol as the substrate, according to the manufacturers instructions.
2.03 Statistics
The degree of statistical significance of results was assessed using Student's t-test
which was performed using the Statworks programme on the Apple Macintosh
microcomputer.
2.04 Cvtosol Preparation
Tissue was finely minced by hand, followed by homogenisation in ice-cold 20mM-
Tris/HCI pH7.8. In the case of pooled samples, tissue was homogenised at a ratio of 1
part tissue to 3 parts buffer. By contrast, livers which were analysed individually
were homogenised in 10 vol homogenisation buffer. Homogenates were centrifuged at
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100,000g for 1 hour. The supernatants obtained after centrifugation were retained,
these are referred to as the cytosolic fraction of the cell. Cytosols were then aliquoted
and stored at -70°C unless destined for GSH affinity chromatography. If purification
of the GST fraction was being undertaken the cytosols were dialysed against 50mM-
Tris/HCI, 200mM-sodium chloride, pH 7.8 containing 0.5mM-DTT over a 16 hour
period.
2.05 GST Purification.
The method used was based on the purification procedure described by Hayes et al.
(1979) using glutathione affinity chromatography followed by hydroxyapatite
h.p.l.c. to resolve individual mouse GST subunits.
2.05a Glutathione Affinity Chromatography
A one-step purification of mouse hepatic GST from the cytosolic fraction of the cell
was undertaken at 4°C using glutathione affinity chromatography (Simons and
Vander Jagt, 1981). The dialysed cytosol was applied to a 1.6cm x 20cm glutathione
Sepharose 6B column, which had previously been equilibriated at 4°C in running
buffer, 50mM_-Tris/HCI, 200mM.-NaCI pH7.8. After application the non-
specifically absorbed material was removed by washing the column with 2-3 column
volumes of column running buffer. Protein that was specifically retained by the
affinity matrix was eluted with one column volume of 250mM.-Tris/HCI buffer
pH8.8 containing 40mM. GSH. The GST-containing fractions were identified by
measuring CDNB activity. The protein content of the eluate was also determined by
the method of Bradford (1976). Fractions containing high CDNB conjugating activity
were combined and prepared for hydroxyapatite chromatography by dialysis at 4°C
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against two changes of 2.5 litres of 10mM.-sodium phosphate buffer pH6.7
containing 0.5mM.-DTT for 16 hours.
2.05b Hydroxyapatite HPLC
Individual isoenzymes were resolved from the GST affinity purified pool purified
using hydroxyapatite h.p.l.c. After dialysis, the pooled GST fractions were injected
onto a Bio-Gel HPHT (h.p.l.c. grade) column (obtained from Bio-Rad Laboratories,
Watford, Herts, U.K). This column was eluted at 0.5ml/min and developed using a 10
- 350mM gradient of sodium phosphate buffer pH6.7; both the running buffer and
the limit buffer contained 0.5mM-DTT and 0.1mM.-calcium chloride throughout.
Peaks were detected by monitoring the eluate at 280nm. Fractions of 0.5ml were
collected and their CDNB-GSH conjugating activity and protein concentrations were
measured.
2.06 Measurement of Plasma Hormone Levels
2.06a Measurement Of Plasma Testosterone Levels
Radioimmunoassay of plasma ether extracts using a specific anti-testosterone
antiserum and I125 testosterone-3-carboxymethy-oxine radiolabel was used to
measure circulating testosterone levels in little mice and control samples according
to the method of Corker et al .(1978).
These assays were very kindly performed by Dr. Sadie Gow from the




Plasma T3 levels were measured using a double antibody RIA as described by
Ratcliffe et at. (1974).
T4 measurements were carried out by Dr. C.J. Henderson from the ICRF Molecular
and Pharmacolgy Laboratory again by the method of Ratcliffe et at., (1974).
2.07 cDNA Clones
Hepatic GST mRNA levels in mouse and rat were investigated by Northern Blot
analysis using as probes cloned cDNAs from each of the three rat cytosolic gene
families. Clones containing complete amino acid sequences for the rat Ybi and Yf
subunits were used to detect mu and pi class liver mRNAs respectively. The alpha
class mRNAs were measured using pGSTr155 which contained a partial cDNA insert
coding for the N-terminal 129 amino acids of the rat Ya subunit. More detailed
information on these clones is given in table 2.02. Figure 2.01 contains the
restriction enzyme maps for GST cDNA inserts cloned.
2.08 Maintenance And Culturina Of Plasmids
2.08a Selection and short term culture
For stable maintenance and culturing, plasmids were transformed using the calcium
chloride method (Mandel and Higa, 1970) into the Eschrichia Coli K12 strain
HB101. Successfully transformed cells were selected and maintained on L-agar





















Table2.02AdescriptionofthratGlutathioneS-TransferasC dfNorth rBl ting.
Figure 2.01. Restriction enzvme maps of oiutathione S-transferase cDNA clones
PGSTM5S. nfiP5 and dGTA/C44
was used to select for transformants containing the plasmids pGTA/C44 and
pGSTr155, whereas ampicillin (100|ig/ml) was used to select for pGP5.
Running cultures were stored at 4°C and single colonies were subcultured every 4
weeks by overnight growth at 37°C.
2.08b Long Term Storage Qf Plasmids
Plasmid-transformed cells were grown overnight at 37°C using the appropriate
selection marker. Sterile glycerol to a concentration of 30% (v/v) was added to the
culture and the resulting solution was divided into aliquots and frozen at -70°C for
storage. Plasmid DNA was also prepared as described in Section 2.09 and stored at
-70°C.
2.08c Bacterial Media
L broth and L agar (Lennox ,1955) were used for liquid and solid phase culture of
HB101 respectively.
L broth (and aaarl
Difco bactotryptone 10g I"1
Difco yeast extract 5g I"1
NaCI 5g I"1
( Difco agar 15g I"1 )
Plasmid-containing HB101 were always cultured in the presence of the selectable
antibiotic.
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2.09 Preparation Of Nucleic Acids
2.09a Large Scale Preparation Qf Plasmid DNA
The procedure used was a modified version of the small scale DNA plasmid
preparation developed by Birmboin and Doly (1979).
A single colony was inoculated into 10ml of L broth which contained the relevant
antibiotic and incubated at 37°C for 6-8 hours. This culture was then added to a flask
containing a further 500ml of L broth and antibiotic. The inoculum was left
overnight at 37°C shaking vigorously. Cells were harvested by centrifugation at
8,000g (4°C) for 5min. The cellular pellet was resuspended in 18ml of Solution A
(see below for recipe) and incubated at room temperature for 10min to lyse the
bacterial cell wall. Solution B (40ml) was added and the mixture left on ice for 5min
after which Solution C (20ml) was added and the preparation left on ice for a further
15min. Treatment with these solutions disrupted the bacterial cell membrane and
precipitated the proteins. The heavy precipitate formed was pelleted by
centrifugation at 8,000g (4°C) for 5min. The plasmid containing supernatant was
retained. To precipitate the DNA, cold isopropanol (0.6 vols) was added to the
supernatant and the solution left at room temperature for 15min. Nucleic acids were
pelleted by a 5 minute centrifugation at 8,000g. The resulting pellet was
resuspended in 6.7ml of TE. To this resuspended solution 74g of ceasium chloride and
1.4ml of a solution of ethidium bromide (10mg/ml) were added. The DNA was banded
by ultracentrifugation at 200,000g for 16hr at 16°C and after centrifugation the
resolved nucleic acid bands were visualised using a short wavelength
transilluminator. The band consisting of closed circular plasmid DNA was collected
using a hypodermic needle inserted into the side of the ultracentrifuge tube as
described in Maniatis et al. (1982). Ethidium bromide was removed by extraction
with isoamylalcohol and the ceasium chloride removed by dialysis against 3 changes
















The extraction of hepatic RNA was undertaken using a modified version of the
guanidinium thiocyanate method described by described by Berger (1987).
In order to avoid RNA degradation by contaminating nucleases, every item of plastic
or glassware brought into contact with the RNA was steeped in water containing 0.1%
depc for 1-2hr and then autoclaved. For reasonable yields of undegraded RNA, it was
also necessary to snap freeze liver tissue in liquid N2 immediately after sacrifice.
Volumes of reagents quoted below are appropriate for the processing of 0.5g of liver.
When more tissue was available, the preparation was scaled up accordingly.
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Liver tissue (0.5g) was minced finely and homogenised, using a teflon glass
homogeniser, in 1ml of Solution D. To this homogenate the following solutions were
added sequentially 0.1ml 2M-sodium acetate (pH4.0)
1.0ml phenol (saturated with depc treated water)
0.2ml chloroform / isoamylalcohol (49:1)
This suspension was mixed thoroughly and cooled on ice for 15min. Samples were
centrifuged at 10,000g for 20min at 4°C. The aqueous phase was transferred to a
clean tube and the RNA precipitated by the addition of an equal volume of cold
isopropanol, this solution was placed at -20°C for 1hr. To pellet the RNA, the
precipitate was centrifuged as described above. The pellet was redissolved in 0.3ml
of Solution D and reprecipitated with isopropanol under the conditions used
previously. An eppendorf microfuge was used to pellet the RNA, spinning for 4 min at
4°C. The pellet was washed twice in 75% ethanol and dried under vacuum. Finally,
the RNA was dissolved in depc treated H2O and stored at -70°C. Measurement of RNA







2.10 Quantitation of DNA and RNA
2.10a Spectrophotometric Determination
DNA and RNA concentrations were measured spectrophotometrically at 260 and
280nm. Concentrations of nucleic acid given below correspond to a change of 1
absorbance unit.
1 absorbance unit at 260nm = 50pg/ml for double stranded DNA
= 40pg/ml for single stranded DNA and RNA
The ratio between absorbance at 260 and 280nm provides an estimate of the
purity of the preparation. For a pure DNA preparation, OD260/OD280 should be 1.8,
for RNA, the ratio should be 2.
2.10b Ethidium Bromide Fluorescent Quantitation Of Double Stranded DNA
DNA concentration was also estimated by running samples on a 0.8% (w/v) midi-
agarose gel using BRL horizontal electrophoresis kit H4 (BRL, Uxbridge U.K.).
Preparation of gels and the conditions under which they were run are as described
for mini-agarose gel electrophoresis in Section 2.11. The amount of U.V. induced-
fluorescence emitted by ethidium bromide molecules intercalated with DNA is
proportional to the total mass of DNA. The quantity of DNA in the sample can be
estimated, therefore, by comparing the fluorescent yield of the sample with that of a
series of standards.
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2.11 Mini-Aaarose Gel Electrophoresis
For the rapid analysis of restriction digests and the isolation of cDNA inserts
(section 2.12b), mini-agarose gels were run on a Bio-Rad gel kit, model H6. Gels
containing 0.8% (w/v) agarose in 1xTBE with 0.5ng/ml (dimensions 50mm
x75mm x 5mm) were cast on a glass tray, transferred to the gel kit and run in
1XTBE buffer at 20v for 2-3hrs. DNA fragments were visualised using a short







2.12a Electrophoretic separation, transfer and hybridisation of RNA
To measure hepatic GST mRNA levels, northern blot analysis was performed using as
probes the rat cDNAs described in section 2.07 (also table 2.02).
RNA was electrophoretically size-fractionated under denaturing conditions using the
system developed by Lehrach et al. (1977). Horizontal 1% (w/v) agarose gels in 1x
gel running buffer with 2.2M.-formaldehyde were prepared (dimensions 20cm x
25.0cm x 0.5cm). Prior to electrophoresis, RNA samples in gel running buffer
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with 2M.-formaldehyde, 50% (v/v) formamide were incubated at 55°C for 15min.
Loading dye (2ml) was added to samples directly after heating. A midi-formaldehyde
gel was prepared to check the quality of the RNA and sample loadings prior to
Northern Biot analysis. After electrophoresis the gels were stained in ethidium
bromide for 1-2hr and the ribosomal bands were visualised using a short
wavelength transilluminator.
Electrophoresis was performed, using BRL horizontal electrophoresis model H1
(BRL, Uxbridge, U.K.) at 45v for approximately 16hr, until the dye front was 5cm
from the edge of the gel. RNA transfer from formaldehyde gel to nitrocellulose
occurred by capillary action in 10xSSC as described by Southern (1975), after
which the filter was baked at 80°C for 2hr in a vacuum-oven to fix the RNA.
To check that transfer had occured successfully, the gel was stained in ethidium
bromide (0.5ng/ml) for 2-3 hr, washed in water and viewed using a short
wavelength transilluminator. When RNA is size fractionated under denaturing
conditions and stained in ethidium bromide, two bands corresponding to 18s and 5s
ribosomal RNA are clearly visible. Absence of these bands after transfer was
indicative that the process had been successful.
After fixing, the nitrocellulose filter was prehybridised at 65°C for 4 -6 hr in a
heat-sealable plastic bag. The prehybridisation solution used was as below:-
Prehybrid'sation Ml*




single stranded herring sperm DNA (10mgs/ml) 0.25ml
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Probes, prepared and radioactively labelled as described in sections 2.12b and
2.12c, were added directly to the prehybridisation solution and allowed to hybridise
for 16-24hr at 65°C in a shaking water bath. Unbound probe was removed by
washing twice in 2xSSPE / 0.1%SDS for 30min at 65°C. The nitrocellulose filters
were air-dried, wrapped in Saranwrap and autoradiographed using Kodak Xar5 film.
Filters were exposed between a few hours and 2 wk depending on the probe and the
samples analysed.


















sodium dihydrogen orthophosphate i 0.18M
2.12b Preparation Of cDNA Probes
cDNA probes for northern blot analysis were radioactively labelled by the 'Oligo-
labelling' technique developed by Feinberg and Vogelstein (1983). DNA probes were
denatured and labelled with the large fragment of DNA Polymerase 1 using random
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oligonucleotides as primers for the DNA synthesis reaction. In the case of pGSTr155,
total plasmid was used as a probe for alpha class mRNA levels. cDNA inserts were
isolated for the plasmids pGP5 and pGTA/C44, labelled and used to probe pi and mu
class mRNAs respectively.
When total plamid is required in the labelling reaction, it is necessary to linearise
the closed circular DNA molecules by restriction with a nuclease which cuts at a
unique site.
pGSTr155 (1.4mgs) was digested with 2 units of the restriction enzyme EcoR1 in a
buffer containing 50mM. Tris-HCI pH8.0, 10mM MgCI2, 100mM NaCI at 37°C for
5 -7hr. The reaction was stopped by heating at 70°C for 10min. This reaction
mixture was stored at -20°C, aliquots being taken and added to the labelling reaction
when required.
To check that digestion had gone to completion, 50ng of digested DNA, together with an
uncut plasmid control was subjected to electrophoresis on a 0.8% mini-agarose gel,
as described in section 2.11. Unrestricted, closed and circular plasmid DNA
segregates into three distinct bands during electrophoresis. These correspond to, in
order of their mobility on an agarose gel, a) the supercoiled form b) the linearised
form of the plasmid and c) partially nicked plasmid. Successfully restricted DNA
runs as one distinct band on electrophoresis, which migrates at the same mobility as
the linearised form.
Plasmids pGP5 and pGTA/C44 were restricted with the appropriate nucleases to
release the cloned cDNA inserts.
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Plasmid pGP5 (1.4mgs) was digested for at 37°C for 5-7hr with 2 units of the
restriction endonucleases, Sail and EcoRI in 50mM.-"Tris/HCI buffer pH8.0
containing 10mM-MgCl2. 100mM-NaCI for 5-7 hr. Digestion released the complete
insert of 725bp
Plasmid pGTA/C44 (1.4mgs) was digested under the same conditions. The restriction
enzyme, Pstl was used to release the insert. As this enzyme works better in a low
salt environment, NaCI to a concentration of 50mM, rather than 100mM. was added
to the restriction buffer used for the Sail and EcoRI.
Due to an internal Pstl site in the Ybi cDNA insert, the insert is cleaved into 2
fragments of 747 bp and 291 bp. The high molecular weight fragment was used as a
probe for northern blot analysis. A detailed restriction map of the cDNA inserts for
the clones used is given in Figure 2.01.
Loading dye ( the recipe is given in section 2.012a) was added to the digests and
samples were subject to electrophoresis in a mini-gel containing 0.8% (w/v) low
melting point agarose and 0.5 pg/ml ethidium bromide using conditions described in
Section 2.11. Segments of the gel containing the desired DNA fragments were excised
and heated to 100°C for 10 min to melt the agarose and denature the DNA. Isolated
fragments of DNA in low melting point agarose were stored at -20°C and reboiled for
3 min prior to an aliquot being added to the labelling reaction.
2.12c Radiolabellina Of cDNA Probes
The 'oligo-labelling' technique described by Feinberg and Vogelstein (1983) allows
the labelling of small amounts of DNA to a high specific activity. Routinely 90ng of
the purified cDNA inserts contained within low melting point agarose were used in
the labelling reaction. For pGSTr155, where both the vector and insert were
labelled, 150ng of linearised plasmid was added to the reaction. Labelling was
performed at room temperature in a total volume of 30pl, the constituents of the




Klenow enzyme 1 unit
P32dCTP 50pCi
90ng of cDNA insert or 150ng total plasmid, made up to a final volume of 30pl with
water.
The radiolabeiling reaction was allowed to proceed for approximately 9hr. The DNA
was then denatured by boiling the solution at 100°C for 5min. Probes were now
ready for hybridisation and were directly added to the prehybridising filter as
described in section 2.12a.
The amount of radioactivity incorporated into DNA was estimated by DEAE-cellulose
paper chromatography in 0.3M.-animoniun formate pH8.0. An aliquot (1pl) of the
labelling reaction was spotted onto DEAE-cellulose paper and allowed to dry. The
chromatograph was run for approximately 30min, air dried, and autoradiographed
for 20min at room temp, using Kodak Xar5 film. Labelled probe remained at the
origin, while unincorporated nucleotides ran close to the solvent front. Incorporation
of radioactive nucleotides routinely ranged from between 50 - 70%.
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OLB is a complex buffer produced from Solutions A, B, C, which are mixed in a ratio
of 2 : 5 : 1. This stock solution can be stored at -20°C for up to 3 months.
Solution A. 625ml 2M.-Tris/HCI (pH 8.0) + 25ml 5M.-MgCI2 + 350ml dH20
+ 18ml mercaptoethanol + 5ml of dATP, dGTP, dTTP.
(Each triphosphate is dissolved in 3mM.-Tris/HCI, 0.2mM. EDTA (pH7,0) at a
concentration of 0.1 M )
Solution B 2M-HEPES titrated to pH6.6 with NaOH. This solution is stored at -
4°C.
Solution C Hexadeoxyribonucleotides evenly suspended in 3m^.-Tris/HCI,
0.2mM_- EDTA (pH7.0) at a concentration giving 90 OD units/ml and stored at -
20°C.
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Chapter 3 Regulation of the Hepatic Yf GST Subunit bv Androgens
3.01 Introduction
3.01a Sexual Differentiation Of Hepatic Proteins
Over the last few decades, it has become increasingly evident that the liver is a
sexually differentiated organ. Numerous examples now exist of a wide range of liver
proteins, involved in many diverse functions, that are expressed at different levels
in males and females. For an excellent review, see Roy and Chatterjee (1983). Table
3.01 contains a list of some of the best documented examples of sexual dimorphism in
both rat and mouse. In some cases this difference can be very slight, for example, the
developmentally regulated cytochrome P-450 f is present at higher levels
(approximately two-fold) in female rat liver microsomes than in male liver
microsomes (Gonzalez et al., 1986). Alternatively, it can be very marked and 02u
globulin presents one of the most dramatic examples of hepatic sexual differentiation
in the rat. This globulin is the major protein species in male urine, constituting
approximately 50% of total protein and is essentially absent from the urine of
female rats; it has been estimated that male rats secrete over 20mg of a2u globulin
per day. Synthesis occurs in the liver where the mRNA species encoding a2u globulin
has been estimated to form 1-2% of total liver mRNA. In the female, the amounts of
this protein synthesized are barely detectable (Roy and Neuhaus, 1966, 1967;
Chattergee and Roy, 1980; Roy and Chattergee, 1983).Examples of sexual
dimorphism in non-gonadal tissues are not simply confined to the liver. Other
tissues, particularly the kidney and brain also display a marked degree of sexual
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Table 3.01 Examples of liver functions showing at least a fivefold sex difference





Mouse major urinary protein +
Enzymes
A4-3-oxostroid 5a-reductase +




P-450 pen 2 +
P-450 a 1 +
P-450 a 2 +
Mouse C-P-450 16a +
Mouse l-P-450 16a +
Mouse P-45015a +
taken from Zaphiropolous et al. (1989).
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differentiation at many levels. The androgenic regulation of various tissues has been
reviewed by Bardin and Caterall (1981).
The liver is also the body's major centre for the detoxification of xenobiotic
compounds. Many of the enzymes expressed in the liver are involved in the
biotransformation of drugs, carcinogens and other environmental pollutants. It has
long been noted that the duration of effect of a variety of drugs was dependent on the
sex of the animal used in the experiment. As long ago as 1932, Nicholas and Barron
(1932) reported a sex difference in the metabolism of the barbituate amobarbital.
These workers showed that female rats required only half the dose of barbituate to
induce anaesthesia as compared to male rats. In a similar vein, Hoick et al. (1937)
noted that the sleeping time for a standard dose of barbituate was longer in females
than in males. This difference in the effect of drug dosage and duration of action was
later shown to be due to faster metabolic clearance of these compounds by the liver in
male rats (Crevier et a/.,1950 ; Pellerin et al., 1954). Many reports now exist in
the literature of other drugs which display a similar dimorphism, a list is given in
Table 3.02
Differences in the metabolism of many compounds result from the sex-specific
expression of individual members of the cytochrome P-450 monooxygenase system.
These enzymes are also responsible for the very marked sex differences also
observed in steroid metabolism, since steroids serve as the natural substrates for
many of the cytochrome P-450s. (For reviews concerning sex differences in drug
and steroid metabolism and the regulatory mechanisms behind these differences see
Skett and Gustafsson, 1979; Gustafsson efa/.,1983; Skett, 1987 )
Although the rat has been the most fully characterised species with respect to sexual
dimorphism and the underlying mechanism whereby these differences are generated,
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Table 3.Q2 Sex differences in xenobiotic metabolism in the rat
Substrate Action



















taken from Skett (1987).
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the sex-specific expression of drug and steroid enzymes has also been described in
man (Pfaffenberg and Horning, 1977; MacLeod et al., 1979) and in mouse
(Noordhoek, 1972; Brown and Greene, 1980; MacLeod and Shapiro,1989). The
mouse, for reasons which will be detailed later, is becoming a very valuable tool for
endocrine research and the evidence presented to date suggests it is very similar to
the rat in respect to the control hepatic sexual differentiation (Norstedt and
Palmiter, 1984; MacCleod and Shapiro, 1989).
Phase II Drug metabolising enzymes have also been reported subject to sexual
dimorphism. Differences in the glutathione S-transferases have been dealt with in
section 1.09 and will be referred to below. Other phase II drug metabolising enzymes
have also been shown to exhibit sexual dimorphism. The glucuronyltransferases
were shown to have higher activity towards certain substrates in males compared to
females (Inscoe and Axelrod; 1960; Graham and Skett,1987). The
sulphotransferases are also subject to sexual differentiation (Skett, 1987).
Most cytochrome P-450 catalysed reactions are performed more efficiently in male
than female rat liver. In the rat, two specific cytochrome P-450s are subject to a
marked sexual differentiation and these have proved to be very valuable in
regulatory studies into the mechanism behind this phenomenon. Cytochrome P-450
16a, which is active in the 16a hydroxylation of testosterone, is regarded as a
male-specific marker, with a level of expression up to 20-fold higher in males
a, b
than is observed in the female (Morgan et al., 1985'V Cytochrome P-450 150,
which is active on steroid sulphates is virtually absent in the male but accounts for
up to 40% of total P-450 in the female liver (Gustafsson and Ingelman-Sundberg,
1974; MacGeoch et al., 1984). These P-450 markers will be used on occasion to
illustrate general points in the regulation of sex differences in the liver. In the
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mouse, sex-specific expression of the cytochrome P-540s has also been reported
but interestingly it occurs in the opposite orientation. Hepatic oxidative metabolism
of xenobiotics is greater in female mice than in male mice(MacCleod and Shapiro,
1989).
3.01b Imprinting Of Hepatic Sex Differences
Differences in drug and steroid metabolism are expressed in a developmental fashion.
In the pre-pubertal period, no significant differences in drug metabolism are noted
between male and female rodents. At the onset of puberty however, the adult pattern
of expression becomes manifest in both sexes. This seems to be the general pattern
for sexually differentiated hepatic proteins. Again a2u globulin serves as a
particularly striking example. This protein is found in trace amounts in the pre¬
pubertal male, less than 4ng/mg of hepatic protein. At the onset of puberty,
expression of a2u globulin rapidly rises resulting in 1000-fold higher levels of the
protein in mature rat livers (Roy, 1973; Chattergee et al., 1979)
Yates et al. (1958) suggested that androgens were involved in the regulation of sex
differences. They reported that A4-3 oxosteroid 5a-reductase activity, which is
more highly expressed in female rat liver, was increased towards female levels in
male rats following castration. Replacement therapy with the major male sex
hormone, testosterone could reverse this effect. Since this work, the ability of
testosterone to overcome the effects of castration has been reported for a number of
sexually differentiated functions. In most cases, castration of the adult male did not
alter enzyme activities completely to the female level but resulted in an activity
which lay somewhere between that of males and females. Administration of
testosterone could induce activities back to normal male levels. However, when the
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castration was performed in the neonatal period, a completely feminised pattern of
drug metabolism was observed in adulthood, which could not be altered by
testosterone replacement either in the pre-pubertal period or in adulthood. If, on the
other hand, the neonatal castrates were administered testosterone directly after
testectomy, enzyme activities were restored to that observed in adult castrated rats.
Further treatment with testosterone completely restored the normal masculine
phenotype. This sequence of events has now been well documented for a number of
drug and steroid activities, see reviews by Skett and Gustafsson,
(1979) and Gustafsson et al (1983).
Thus, the neonatal period is a crucial time in the development of a sexually
differentiated phenotype and access to androgens is critical for the establishment of a
male-specific pattern of drug and steroid metabolism. This early exposure in the
male to androgens has two roles. Firstly, it "imprints" the male pattern of hepatic
protein expression which develops after puberty, if this programming is prevented
then a feminisation of liver metabolism is observed. Secondly, the ability of the adult
to respond to androgen in the adult period is also determined at this time (Einarson et
al., 1973; Gustafsson and Stenberg, 1974 a,b).
To summarise, androgens as regulatory factors in drug metabolism are involved at
two stages. Firstly, they are the imprinting agents which set the male pattern of
expression in the neonatal period. Secondly, they are inducers and regulators of
enzyme levels in the adult period.
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3.01c Regulation Of The Yf GST Subunit In Mouse
Sex differences in hepatic GST content have been reported in both the rat (Kaplowitz
1975; Hales and Neims, 1976;Lamartiniere1981) and the mouse (Hatayama et al.,
1986; McLellan and Hayes, 1987). The mouse displays the most pronounced sex-
specific difference in GST content, with the Yf subunit expressed in male liver at
levels approximately 10-fold higher than the female. In the male, YfYf constitutes
around 70% of total hepatic GST content, whereas in the female it represents only a
minor form. This GST subunit has aroused a great deal of interest because of its
possible role as a tumour marker. In normal rat liver, both male and female, this
subunit is present at essentially undetectable levels, but is found in high
concentrations in hepatic preneoplastic nodules (Kitihara efa/.,1984; Satoh et al.,
1985).
The main objective of the work described in this chapter and the next was to
investigate the mechanism which determines the sexual differentiation in the levels
of the Yf subunit in male and female mouse liver. In view of previous findings with
other drug-metabolising enzymes which have been detailed above, a study was
undertaken to investigate the possible androgenic regulation of the Yf subunit.
Specifically, experiments were performed to determine if the Yf subunit is regulated
by the major male sex hormone testosterone and whether this process is subject to
imprinting. The role of the pituitary in this process was also examined, this subject
will be introduced and the results presented in chapter 4.
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3.Old Strategy
The endocrine system is a complex network consisting of numerous hormones which
are very tightly controlled as the effects they regulate are fundamental to the proper
development and maintenance of the organism and indeed in some cases to its
survival. Two approaches were used to 'dissect' this system and allow the study of a
limited part relating to the the sex steroids.
1. The GST profile of surgically prepared animals, undergoing castration or
ovarectomy was examined and the effect of testosterone replacement therapy was
investigated. Two different strains of mice were investigated. CFLP mice were chosen
as these mice are somewhat larger than the normal inbred strains (approximately
1.5 times larger than normal C57BL/6 mice). A group of these mice were castrated
at 2 weeks of age; the extra size aided surgery. C57BL76 mice were also examined.
This mouse strain is the progenitor strain for the little mouse mutant described in
chapter 4 and has been thoroughly characterised with respect to hepatic GST content.
2. Another line of approach available to the endocrinologist, which is proving an
increasingly powerful tool, is the use of mouse strains defective in specific
endocrine pathways. An excellent account of the endocrine-defective mouse strains
that are available to the experimenter is given by Charlton (1984). The hepatic GST
content of two strains of mice which either did not produce androgen or were
resistant to its effects were examined. Fuller descriptions of the underlying genetic
defects which afflict these mice are given in the appropriate results section (see
section 3.04a). However, to summarise the defects briefly, the hypogonadal mouse
(hpg) is deficient in the production of the pituitary hormones LH and FSH
(Luteinizing Hormone and Follicle Stimulating Hormone). These hormones are
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essential for the stimulation of the production of testosterone from the Leydig cells of
the testes. Thus, these mice do not produce androgen in effective quantities. The
testicular feminised mouse (tfm) is deficient in the androgen receptor, which
mediates many of the varied actions of testosterone. Therefore in tfm mice these
androgen-receptor mediated process do not occur.
3.02 Androgen Regulation of CFLP Mice
3.02a Treatment of animals
Male CFLP mice were sham operated or castrated at 2 or 8 weeks of age. At the age of
11 weeks all animals were either subjected to treatment with testosterone
propionate or with the vehicle, propylene glycol. Animals were injected
subcutaneously with an initial dose of 2mg/kg testosterone propionate which was
followed by 4 daily injections of 1mg/kg. Following a break of 2 days during which
testosterone was not administered, 2 further daily injections of 1mg/kg testosterone
propionate were given. Twenty-four hours after the final injection, animals were
sacrificed by cervical dislocation and liver, kidneys and testes removed quickly
frozen on dry-ice and stored at -70°C.
»
Female CFLP mice were sham operated or ovarectomised post-pubertally. At 11
weeks of age, females were administered either testosterone propionate or vehicle as
has been described above for male CFLP mice. Table 3.03 contains a summary of the
treatment groups which resulted from these divisions and the number of animals per
group.
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Table 3.03 : A summary of the experimental animal treatments described in
Section 3.02a for CFLP mice
Group Treatment No. animals/group
Male sham operated 2 weeks propylene glycol 4
Male sham operated 2 weeks testosterone propionate 3
Male castrated 2 weeks propylene glycol 4
Male castrated 2 weeks testosterone propionate 4
Male sham operated 8 weeks propylene glycol 4
Male sham operated 8 weeks testosterone propionate 4
Male castrated 8 weeks propylene glycol 2
Male castrated 8 weeks testosterone propionate 4
Female sham operated propylene glycol 4
Female sham operated testosterone propionate 4
Female ovarectomised propylene glycol 4
Female ovarectomised testosterone propionate 3
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To aid clarity, results will be presented as 3 sections;
1. Male CFLP mice surgically operated upon at 2 weeks of age.
2. Male CFLP mice surgically operated upon 8 at weeks of age.
3. Female CFLP mice.
Section 3.02b Analysis of the Hepatic GST Complement from CFLP Mice
Hepatic cytosols were prepared (see section 2.04) from CFLP mice treated as
described in section 3.02a. All livers were processed on an individual basis. Analysis
of hepatic GST was carried out using enzyme activities, SDS/PAGE and western
blotting with antisera raised against the mouse Yf subunit.
Specific activities towards CDNB were determined for cytosols prepared from
individual CFLP mice, the results are presented in figure 3.01. Activity in control
sham operated males in both the 2 and 8 week groups were approximately 2.5-fold
higher than in control females. Castration at both 2 and 8 weeks led to a 2-fold
decline in CDNB activity in the 11 week old adult male. Treatment with testosterone
did not markedly reverse this effect. Ovarectomy, testosterone administration or
both treatments combined did not affect the relatively low levels of CDNB in the
female.
Hepatic cytosolic proteins were analysed by SDS/PAGE (figure 3.02). This revealed
the presence a polypeptide Mr 24,800 which co-migrated during electrophoresis
with the subunit from purified mouse GST YfYf. This subunit was highly expressed in
control male mouse livers. SDS/PAGE showed that castrated males, both at 2 weeks
and 8 weeks, possessed markedly reduced levels of this protein in comparison to
control males (figures 3.02a, 3.02b). Testosterone treatment did not significantly
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Figure 3.Q1
Levels of CpNB activity in oonadectomised CFLP mice in combination with
testosterone replacement therapy.
Mean values for each group are quoted.
Degrees of significance are assessed relative to sham operated controls in each group.
* P > 0.01
" P > 0.001
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Figure 3.01
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Electrophoretic analysis of CFLP males surgically operated upon at 2 weeks of aae.
Cytosols (30fxg) from individual male CFLP mice sham operated or castrated at 2
weeks of age were analysed by SDS/PAGE on a 12% polyacrylamide resolving gel. The
order of samples loaded is as follows : lane 1, rat liver isoenzyme mixtures
comprising Yc (Mr 27,500 ), Yb (Mr 26,300) and Ya (Mr 24,800); lanes 2-5,
sham operated controls injected with vehicle; lanes 6-8, sham operated animals
treated with testosterone; lanes 9-12, castrated CFLP mice injected with vehicle;






Electrophoretic analysis of CFLP males surgically operated upon at 8 weeks of aoe.
Cytosols (30ug) from individual mice were analysed by SDS/PAGE on a 12%
polyacrylamide resolving gel. Loadings were as follows lane 1, rat liver standards
(Yc, Yb, Ya), lanes 2-5, sham operated males controls injected with vehicle; lanes
6-9, sham operated males treated with testosterone; lanes 10-11, castrated CFLP
mice injected with vehicle; lanes 12-15, castrated animals treated with
testosterone; lane 16, purified mouse Yf standard.
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Figure 3.02c
Eiectrophpretic analysis of CFLP female cytosols.
Cytosols from individual CFLP female mice (30pg), treated as described in section
were analysed by SDS/PAGE on a 12% polyacrylamide resolving gel. Gel loadings
were as follows lanel, rat liver GST isoenzyme mixture (Yc, Yb, Ya); lanes 2-5,
sham operated controls injected with vehicle; lanes 6-9, sham operated animals
treated with testosterone; lanes 10-13, ovarectomised females injected with
vehicle; lanes 14-16, ovarectomised females treated with testosterone; lane 17,
purified mouse Yf standard.
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alter levels of the Mr 24,800 polypeptide in castrates, although 2 week castrates did
show a slight induction. In females, a polypeptide of similar molecular weight was
also present, but at much lower levels than observed in males (figure 3.02c). No
change in the level were noted either in ovarectomised females or those subjected to
testosterone treatment.
Immunoblotting of these samples with anti-mouse Yf antibody mirrored the pattern
of expression observed in CDNB activity and the changes noted in the level of the
polypeptide of Mr 24,800 (figure 3.03).
It is reasonable to assume that the polypeptide of Mr 24,800, whose expression
changes in castrated male mice and which co-migrates with the purified mouse Yf
standard, is a Yf-type polypetide similar, if not identical to that isolated and
characterised by McLellan and Hayes (1987), since it cross-reacted strongly with
monospecific antisera raised against murine YfYf.
3.03 Androgen Regulation of C57BL/6 Mice
3.03a Treatment of Animals
Male C57BL76 mice were sham operated or castrated at 8 weeks of age. At 11 weeks,
the animals were treated either with testosterone propionate, administered
subcutaneously at 60p.g or 120pg per mouse for 11 consecutive days, or with the
vehicle, corn oil. Intact female C57BL/6 mice also received testosterone propionate
as detailed above for the males. Table 3.04 summarises the treatment groups
obtained and gives the numbers per group.
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Figure 3.03a
Immunohlottina of hepatic cvtosols from CFL.P males castrated at 2 weeks of aae
using anti-fmouse YfYfi loG.
Cytosols (50pg protein / track) were subjected to SDS/PAGE followed by transfer to
nitrocellulose and immunoblotting with anti-(mouse YfYf)lgG. Gel loadings were as
follows; Lanes 1 and 17, purified mouse Yf standard; lanes 2-5, sham operated
controls, lanes 6-8, sham operated males treated with testosterone; lanes 9-12,
castrated males; lanes 13-16, castrated males treated with testosterone.
Figure 3.03b
Immunoblottina of hopatic cvtosols from CFLP mice castrated at 8 weeks of aae.
Cytosols (50^g protein / track) were subjected to SDS/PAGE followed by transfer to
nitrocellulose and analysed by immunoblotting with anti-(mouse YfYf) IgG. The gel
loadings were as follows :- lanes 1,12 and 18, purified mouse liver Yf standard;
lanes 2-5, sham operated controls administered vehicle; lanes 6-9, sham operated
males treated with testosterone; lanes 10-11, blank; lanes 13-14, castrated males
administered vehicle; lanes 15-18, castrated males treated with testosterone.
Figure 3.Q3c
Immunoblottina of ovarectomised CFLP female mice cvtosols using anti-fmouse
YfYfl laG.
Cytosols (50^g protein / track) were subjected to SDS/PAGE, transferred to
nitrocellulose and immunoblotted with anti-mouse Yf anti-sera. Loadings were as
follows ;- lanes 1 and 17, purified mouse liver Yf; lanes 2-5, sham operated
controls receiving vehicle; lanes 6-9, sham operated females treated with
testosterone; lanes 10-13; ovarectomised females administered vehicle; lanes 14-
16, ovarectomised females treated with testosterone.
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Table 3.04 Treatment groups and numbers for C57BLV6 experiment detailed in
in section 3.03a
Group Treatment No. per group
Sham operated males corn oil 5
Sham operated males testosterone 60p.g 4
Sham operated males testosterone 120p.g 4
Castrated males corn oil 3
Castrated males testosterone 60pg 4
Castrated males testosterone 120p.g 6
Females corn oil 4
Females testosterone 60pg 4
Females testosterone 120p.g 4
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3.03b Analysis of Hepatic GST Complement from C57BL76 Mice
Activity towards CDNB and ethacrynic acid were determined for hepatic cytosols
prepared from individual mice treated as described in the previous section. As with
the CFLP mice a 2.5-fold difference in CDNB activity between control males and
females was observed (figure 3.04). On castration, CDNB activity in the male is
reduced towards those levels observed in the females. Administration of testosterone,
at both 60pg and 120pg, reverses this decline but does not totally restore levels to
those seen in sham male controls. No dose-dependency was observed, testosterone
treatment at both concentrations seem to cause a similar induction of activity in
castrates. The administration of testosterone to control animals caused no significant
change in CDNB activity. Treatment with testosterone induced approximately a 1.5-
fold increase in CDNB activity in intact females.
Specific activity measurements towards ethacrynic acid, a GST substrate which is
relatively specific for YfYf are presented in figure 3.05. A similar pattern to that
observed for CDNB was demonstrated. In the male, castration causes a 5-fold
decrease in activity which was partially restored (3-fold) by testosterone
treatment. Androgen treatment in the female induced this activity again by
approximately 1.5-fold.
Analysis of female hepatic cytosols by SDS/PAGE and immunoblotting using antisera
raised against the mouse Yf, Ya3 and Ybi subunits demonstrated that the pattern of Yf
expression reflected changes in activity seen with both CDNB and ethacrynic acid. It
also seems that this induction was dose-dependent, with 120pg testosterone having a
greater effect than 60pg. No change in levels of Ya3 or Yb-type subunits were
detected (figures 3.06 and 3.07).
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Figure 3.04. Levels of CPNB activity in hepatic cytosols from a) C57Biyg male
mice undergoing testosterone treatment after oonadectomv and b) intact C57BL/6
females treated with testosterone.
Mean values for all groups are quoted.
Degrees of significance are assessed relative to control values for each sex.
* P > 0.01













Levels of ethacrvnic acid activity in a) oonadectomised C57BL76 males undergoing
testosterone replacement therapy and b) C57BLV6 females treated with testosterone
Mean values for each group are quoted.
Degress of significance are assessed relative to control values for control males in
(a) and control females in (b).
* P > 0.01
" P > 0.001
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Figure 3.05










Electrophoretic analysis of intact C57BI/6 female mice treated with testosterone
Hepatic cytosols (30jxg protein / track) from individual C57BL/6 females were
analysed by SDS/PAGE on a 12% polyacrylamide resolving gel. The loadings were as
follows lane 1, rat liver isoenzyme mixture (Yc, Yb, Ya); lanes 2-5, females
administered vehicle; lanes 6-9, females treated with testosterone at 60pg / day;




1 2 3 4 5 6
92
Figure 3,07
Immunoblottina of hepatic cvtosols from female C57BL/6 mice treated with
testosterone nsino anti-mouse GST antisera
Hepatic cytosols (50pg protein / track ) from female C57BL/6 mice treated with
testosterone were subject to SDS/PAGE, transferred to nitrocellulose and
immunoblotted against anti-mouse GST antisera. Gel loadings were as follows : -
lanesl and 14, mouse GST markers; lanes 2-5, control females administered
vehicle; lanes 6-9, females treated with testosterone at a dose of 60pg / day; lanes
10-13, females treated with testosterone at 120pg / day.
Panel a. anti-(mouse YfYf) IgG.
Panel b. anti-(mouse Ya3Ya3) IgG.




Figures 3.08 and 3.09 show the results obtained from SDS/PAGE and western
blotting of male cytosolic fraction. The reduction in activities towards the substrates
measured above are mainly due to the changes in the Yf GST,
Small changes in the levels of the Ya3 and Yb-type subunits were observed, however
these were not deemed to be significant. The Yai subunit was not detected.
3.04 Characterisation of Hepatic GST Profiles of the Hpq and Tfm
Mouse Strains
3.04a. Introduction : A brief description of the Hm and Tfm defects
The Hvpoaonadal Mouse (gene symbol hpg)
A mouse mutation has been described, which is inherited in an autosomal recessive
fashion, in which the testes and ovaries fail to develop postnatally ( Cattenach et al.
1977). The primary defect has now been established as a deficiency in the
hypothalamic hormone, gonadotropin-releasing hormone (GnRH), which as the name
suggests controls the release of the gonadotropins - Luteinizing hormone (LH) and
Follicle-stimulating hormone (FSH) from the pituitary gland. The consequent
reduction in the levels of these hormones leads to the observed failure in
reproductive development. These hormones are of crucial importance in the
production and secretion of testosterone from the Leydig cells of the testes. In the
male hpg mouse the testes are atrophied and no androgen is produced.
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Figure 3.08
Electrophoretic analysis of castrated C57BL76 males
Cytosols (30pg/track) from individual C57BI/6 males treated as described in
section 3.03a, were analysed by SDS/PAGE on a 12% polyacrylamide resolving gel.
The order of gel loadings is as follows lanel, rat liver isoenzyme mixture (Yc, Yb,
Ya); lanes, 2-4, sham operated animals administered vehicle; lanes 5-7, sham
operated animals treated with testosterone at 60jxg / day; lanes 8-10, sham operated
animals treated with testosterone at 120pg / day; lanes 11-13, castrated C57BL76
males administered vehicle; lanes 14-16, castrated males treated with testosterone
60pg / day; lanes 17-19, castrated males treated with testosterone at 120pg / day;
lane 20, purified mouse Yf standard.
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Figure 3.09
Immunoblottina of mouse hepatic cvtosols from aonadectomised males under going
testosterone replacement therapy
Hepatic cytosols (50pg protein / track) from gonadectomised C57BI/6 male mice
undergoing testosterone replacement therapy were subject to SDS/PAGE, transferred
to nitrocellulose and immunoblotted against anti-mouse GST antisera. Gel loadings
were as follows lanes 1 and 14, mouse GST markers; lanes 2-3, sham operated
males administered vehicle; lanes 4-5, sham operated males treated with
testosterone at 60pg / day; lanes 6-7, sham operated males treated with testosterone
at 120 pg / day; lanes 8-9, castrated males administered vehicle; lanes 10-11,
castrated animals treated with testosterone at 60pg / day; lanes 12-13, castrated
animals treated with testosterone at 120pg / day.
panel a. anti-(mouse YfYf) antisera.
panel b. anti-(mouse Ya-|Ya-|) antisera.
panel c. anti-(mouse Ya3Ya3) antisera.
panel d. anti-(mouse Yb-|Ybi) antisera.
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The Testicular Feminised Mouse (nene symbol tfm)
Testicular feminisation is an X-linked recessive gene defect which has been well
documented in Man (Hauser,1963). Affected individuals are male
pseudohermaphrodites, characterised by an XY karyotype yet having a female
phenotype. The identification of this disorder in rats (Bardin et at., 1970) and mice
(Lyon and Hawkes, 1970) led to a clearer understanding of the molecular defect
responsible for the impairment of normal sexual differentiation in these males. The
£
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underlying genetic lesion has now ben established. Reduced or undetectable amounts
of the intracellular androgen binding protein in tissues which are normally
responsive to androgens has been observed in these mice (Attardi and Ohno,1974;
Gehring and Tomkins, 1974). Thus, effects which are normally mediated via this
receptor do not occur in these animals.
The hepatic cytosolic GST complement of both mutant strains described above were
characterised by the methods used for the previous two sections. The progenitor
strain, CH3/He, was used as an appropriate control for the hpg mouse. Both sexes
were investigated, with 2 mice per group. Male mice carrying the tfm gene (Xtfm Y)
were analysed together with wild-type male siblings (XY), three mice were obtained
per group.
3.04b Analysis of the Hepatic GST Profile of Hdq and Tfm mice
Hpg males were found to exhibit a female pattern of expression in respect to their
hepatic GST profile. These mutants expressed the Yf subunit in similar amounts to
that found in both the normal and mutant females. Levels of the Ya3 and Yb-type
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subunits did not appear to vary greatly between strains and sexes (figure 3.10 and
3.11). This is confirmed using the marker substrates for GST isozymes, activity
measurements for which are given in table 3.05. CDNB activity in the hpg male liver
was similar to that found in females. Specific activities towards ethacrynic acid were
slightly lower in both males and females of the hpg strain than found in normal
females.
Table 3.Q5 Levels of GST activity in hepatic cvtosols from male and female the
CH3/He and hpg mouse strains. Data from individual mice are
presented. Each sample was assayed in triplicate.
Specific Activity pmoles/min/mg protein
Strain Sex CDNB DCNB Ethacrynic
acid
CuOOH H2C>2
CH3/He Male 1 4.5 0.06 0.06 1.62 1.17
Male 2 5.0 0.06 0.04 1.58 1.18
CH3/He Female 1 2.7 0.05 0.01 1.42 1 .07
Female 2 2.4 0.05 0.01 1.42 1.07
Hpg Male 1 2.6 0.06 0.003 1.69 1.12
Male 2 2.3 0.06 0.005 1.53 1.04
Hpg Female 1 2.5 0.06 0.008 1.70 1.06
Female 2 3.3 0.09 0.005 1.54 0.92
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Figure 3.10
Electrophoretic analysis of hepatic cvtosols from the hpg and CH3/He strains of mice
Hepatic cytosols (30pg protein/track) were analysed by SDS/PAGE using a 12%
polyacrylamide resolving gel. The loadings were as follows lanes 1, rat liver
standards (Yc, Yb, Ya); lanes 2-3, CH3/He male mice; lanes 4-5, CH3/He females;
lanes 6-7, hpg males; lanes 8-9, hpg females; lane 10, purified mouse Yf standard.
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Immunoblottino of hepatic cvtosols from hpg and CH3/He strains of mice
Hepatic cytosols (50pg of protein/track) were subjected to SDS/PAGE, transferred
to nitrocellulose and imunoblotted with antisera raised against purified mouse GST
subunits. Gel loadings were as follows lanes 1 and 10, purified mouse GST
standards; lanes 2-3, CH3/He males; lanes 4-5, CH3/He females; lanes 6-7, hpg
males; lanes 8-9, hpg females.
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Analysis of the tfm mutant was undertaken using the same procedures. A very
similar profile to the hpg male was obtained as is shown in figures 3.12 and 3.13.
Normal siblings (XY) demonstrated a normal male pattern of expression, whereas
males carrying the tfm gene defect showed a feminine phenotype in respect to their
hepatic GST profile. Changes in the other GST subunits investigated were not
observed. Activity measurements for GST marker substrates were also determined
and again showed a very similar pattern to that seen for the hpg males (table 3.06).
Table 3.Q6 Levels of activity in hepatic cvtosols from Tfm males (XflniYI and
their wild-tvpe siblings (XY). Data presented from individual mice.
Each sample was assayed in triplicate.
Specific Activity pmoles/min/mg protein
Karyotype CDNB DCNB Ethacrynic CuOOH H2O2
Acid
Male (XY) 1 5.1 0.08 0.08 2.06 1.49
Male (XY) 2 5.8 0.09 0.10 2.06 1.44
Male (XY) 3 5.6 0.07 0.08 1.96 1.44
Male (X*fmY) 1 3.7 0.07 0.04 2.26 1.62
Male (XtfmY) 2 3.5 0.06 0.03 2.28 1.62
Male (X,fmY) 3 3.6 0.08 0.02 2.06 1 .45
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Figure 3,12
Electrophoretic analysis of hepatic cvtosols from Tfm males and control male
siblings.
Cytosols from individual mice (30pg protein/track) were analysed by SDS/PAGE on
a 12% polyacrylamide resolving gel. The gel was loaded as follows lane 1; rat
liver isoenzyme mixture (Yc, Yb, Ya); lanes 2-4, control male siblings; lanes 5-7,
tfm males; lane 8, purified mouse Yf standard.
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Figure 3.13
Immunoblottina of hepatic cvtosols from control and tfm males using anti-mouse GST
antisera.
Hepatic cytosols (50pg) were subject to SDS/PAGE after which proteins were
electrophoretically transferred to nitrocellulose and immunoblotted against anti-
mouse GST antisera. The gel was loaded as follows lanes 1 and 8, purified mouse Yf
standard; lanes 2-4, normal male siblings; lanes 5-6, tfm males.
Panel a. anti-(mouse YfYf) IgG.
Panel b. anti-(mouse Ya3 Ya3) IgG.
Panel c. anti-(mouse Yb-|Ybi) IgG.
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Figure 3.13






The Yf GST subunit is subject to a marked degree of sexual differentiation in the
mouse liver, this subunit being the predominant form in the male while only a minor
form in the female. This has been characterised very thoroughly by other workers
(Hatayama et at., 1986, McLellan and Hayes, 1987). All wild-type strains
investigated during the course of this work, CFLP, C57BL/6 and CH3/He,
reconfirmed these findings.
Castration of the male reduced levels of Yf to those observed in the female.
Replacement therapy with testosterone reversed this effect in C57BL/6 mice, but
complete restoration of male Yf GST levels did not occur. Testosterone at both
concentrations seemed to produce similar effects, no dose-dependency was observed.
Treatment of intact C57BL/6 female mice with androgen caused an elevation in Yf
levels in the female liver. A dose-dependent increase was observed, testosterone at
120p.g/mouse produced a greater effect than when half that dose was administered.
This induction of YfYf in the female liver did not approach levels observed in control
males, both CDNB and ethacrynic acid activities were approx 2-fold lower in treated
females.
This work confirmed the findings of Hatayama et al. (1986) who obtained similar
results using the BALB/c mouse strain. Castration reduced YfYf levels in the male to
that seen in females. Treatment of intact BALB/c females with testosterone was
shown, by radial immunodiffusion with anti-mouse Yf antisera, to cause an elevation
in the Yf to male levels. This induction in the BALB/c females is greater than that
observed for the C57BL/6 strain, where even in the male complete restoration of the
Yf phenotype was not observed. There are a few possible explanations for this
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differential induction. The duration of treatment could perhaps have been a factor.
Hatayama et at. (1986), investigating the time course of induction, showed that
levels of the Yf subunit, in the BALB/c females reached a plateau approximately 14
days after treatment started. Females of the C57BL/6 strain were subjected to 11
consecutive days of androgen treatment. Levels of Yf were, however, far lower than
than would be predicted at this particular time point in the BALB/c strain and it is
unlikely that a further 3 days treatment would alter levels in the C57BL/6 so
dramatically. Perhaps strain differences in sensitivity to testosterone or its
metabolism could account for this difference in induction between the females, but it
is unlikely that males of the C57BL/6 strain would be less sensitive to testosterone
than females of another strain. The results obtained for the C57BL/6 strain are,
however, more in accord with reports concerning other drug-metabolising systems.
Females are found to be relatively resistant to the effects of androgens, they require
larger doses and a longer duration of treatment to stimulate the male pattern of
expression and even then levels do not completely rise to those observed in the male
eUj »
(Kato, 1968; Berg and Gustafsson, 1973).
It would appear from the results discussed above that androgens regulate the male-
specific expression of the Yf GST isoenzyme in mouse liver. Further confirmation for
this comes from information obtained from the hpg and tfm strains. Male tfm and hpg
mice were found to exhibit a female phenotype in respect to their GST profile. As has
already been detailed in section 3.04, in the hpg mice the testes are in an
undeveloped state and do not produce testosterone. Plasma testosterone levels in tfm
A
mice are also lower than normal mice (Goldstein eta/., 1972). However unlike the
hpg mouse, which can be rescued by treatment with androgens or with LH and FSH
(Ward, 1980), neither testosterone or its androgenic derivatives have any effect on
functions which are normally extremely responsive to androgens in the tfm male
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(Ohno and Lyon, 1970, Dofuku et a!., 1971). It is not entirely clear if this very
noticeable decline in Yf levels is due to the low serum levels of testosterone or the
absence of its intra-cellular binding protein. In this context, it should be noted that
not all androgen-regulated effects occur via the androgen receptor. Paradoxically,
some androgen-regulated processes occur via the oestrogen receptor (Gustafsson and
Stenberg, 1976b; Bardin and Catterall, 1981) .
Hatayama et at., (1986) also showed that the Yf was developmentally regulated,
levels in the immature male being very low and rising rapidly at the onset of
puberty, co-inciding with the production and secretion of high levels of testosterone
from the testes. These observations further suggest that testosterone essentially
regulates expression in the mouse liver of the Yf subunit.
Castrated CFLP mice failed to respond to testosterone. The explanation for this
discrepancy probably lies in the treatment regimes which differed between the
investigations. C57BL/6 mice were injected with a higher dose of testosterone for a
longer duration, i.e. in body weight terms C57BL/6 mice received either a 2mg/kg
or 4mg/kg dose for 11 days. CFLP mice received a primary dose of 2mg/kg followed
by 6 days at 1mg/kg with a 2 day break after day 5. Two observations provide
evidence to this effect. 1. CFLP mice castrated at 2 weeks did show slightly elevated
levels of Yf after treatment with testosterone, although no effect was observed for the
8-week castrates or in the females, this would suggest that this particular dose
might produce marginal effects on the Yf subunit. 2. Mouse kidney exhibits a
sexually differentiated phenotype with respect to P-450 expression, which is
directly mediated via testosterone (Henderson et at., 1990). Analysis of kidney
microsomes from these CFLP mice demonstrated that castration leads to female
pattern of P-450 expression. Treatment of castrates with testosterone partially
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restores the male phenotype but superimposed upon this is the female pattern of
expression. (C.Henderson, personal communication). This would suggest that the dose
administered is not high enough or of sufficient duration to completely restore the
masculinised pattern of expression or suppress that of the female.
Ovarectomy of female CFLP mice had no effect on GST levels. It would appear,
therefore, that the female sex hormones do not have an inhibitory role to play in the
down regulation of Yf in the female. This is in accord with reports on other liver
proteins subject to sexual dimorphism. Oestrogens and progestins do not have a large
role to play in the generation of this differentiated phenotype. Androgens are the
main regulators in this system (Skett, 1987).
Imprinting of the Yf GST
One of the key questions in the regulation of the Yf is its imprintability. Is this
enzyme subject to neonatal programming as has been demonstrated for other drug
metabolising enzymes? Unfortunately, this is not at all clear from the evidence
acquired to date. Most drug and steroid metabolising enzymes conform to the classical
definition of imprinting, described in section 3.01b. Gustaffson, however, was able
to categorise steroid metabolising P-450s into 3 groups according to their
imprinting characteristics (Einarsson etal., 1973; Gustafsson and Steinberg,
1974a,b; Skett and Gustafsson, 1979). These are listed below:
Group 1 - found to be dependent on the continuous presence of androgen to maintain
male levels of activity. Both neonatal and postpubertal castration abolished sex
differences. The basal level of expression was unaffected by imprinting.
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Group 2 - affected by postpubertal castration but enzymic levels did not drop
completely to female levels. Neonatal castration was required to generate a complete
feminisation in this group.
Group 3 - expression was totally independent of androgens.
From the description of the 3 groups, GST YfYf, if imprinted, would appear to be
more closely related to those imprinted enzymes described in group 1. As has been
demonstrated, male-specific expression of Yf is androgen dependent. It does not
however follow the classical description of the imprinted, group 2 enzymes
described by Gustafsson. On castrastion, the level of Yf falls completely to that of the
female rather than the partial drop seen for the imprinted group 2 steroid-
metabolising enzymes.
Group 1 enzymes are also subject to imprinting although it is of a more subtle form.
Neonatal androgens are still required to instigate the male pattern of expression.
Thus, if castration occurs postpubertally the effects can be readily reversed by
androgen treatment. After neonatal castration however, group 1 enzymes cannot be
induced by androgens. Groups can be further subdivided into classes categorised by
their neonatal sensitivity to androgens and the time taken to complete the imprinting
process.
Ideally in the CFLP experiment, if imprinting of Yf occured, neonatal castration
would result in a feminine GST phenotype which would not be effected by testosterone
treatment. As has already been discussed, the dose of testosterone administered was
too low to restore Yf levels in CFLP castrates (2 or 8 week). Gustafsson and his
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colleagues noted that in many cases the imprinting process is completed within 7
days of birth (Gustafsson and Stenberg, 1974, a, b). Thus, 2 week neonatal castrates
would probably have been imprinted and as readily inducible with testosterone as
those mice castrated at 8 weeks. Neonatal castration should probably be performed in
the first few days after birth.
This chapter has established that the Yf subunit is regulated by the male sex hormone
testosterone although no firm conclusions can be drawn as to its imprintability. The
question now raised is whether this hormone is acting directly on the liver to
regulate levels of the Yf or whether the effect is indirect and is mediated via the
pituitary. Chapter 4 seeks to address this question.
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Chapter 4 - Pituitary Regulation Of The Hepatic Yf GST
4.01 Introduction
4.01a The Role of the Pituitary Gland In Hepatic Sexual Dimorphism
Having established that androgens are responsible for the generation and regulation
of sexual dimorphism in a number of liver functions, the question arose as to the
mechanism(s) whereby this phenomenon was achieved. That the pituitary gland has a
major role to play in the aforementioned process was first demonstrated by Denef
(1974) who showed that removal of the pituitary gland (hypophysectomy) abolished
sex differences between male and female rats. Denef suggested that the pituitary was
acting in a permissive manner to allow androgen secretion. However,
hypophysectomised animals were found to be resistant to androgens in respect to
hepatic drug and steroid metabolism. In contrast to castrated animals, administration
of androgens did not restore the normal sexually differentiated pattern in these
animals. These findings indicated that the pituitary was in some manner mediating
the effects of androgens on the liver (Gustafsson and Stenberg, 1974c, 1976a;
Kramer and Colby, 1976; Wilson and Spelsberg, 1976).
Attempts to reverse the effects of hypophysectomy by the implantation of the
pituitary gland under the kidney capsule resulted in a feminine pattern of drug and
steroid metabolism in both male and female rats (Denef, 1974; Gustaffson and
Stenberg, 1976a, Eneroth et ai, 1977). The same effect was also noted in intact
animals of both sexes. From these observations, it was postulated that the implanted
pituitary was secreting a feminising factor, otherwise referred to as "femotropin".
Several laboratories attempted to identify the pituitary hormone responsible for this
117
effect. Table 4.01 lists the hormones produced by the pituitary, their known
functions and their location within the gland.
Several lines of enquiry were pursued in the attempt to answer this question,
including the use of implanted, cloned pituitary tumours. Differential secretion of
pituitary hormones between isolated tumour types, it was hoped, would narrow down
the list of possible pituitary factors. For example, the MtT/F4 tumour secretes
prolactin, growth hormone, and ACTH (Bates et al., 1962). When implanted into
rats, a feminisation of hepatic steroid metabolism is observed. The MtT/Ws,
MtT/W10 and MtT/W15 tumours produce growth hormone and prolactin but little
ACTH. This tumour has a similar effect to the MtT/F4 tumour.(Eneroth et al., 1976)
Purified hormone preparations have also been tested for activity. Growth hormone
was found to be the most active of the pituitary hormones in influencing steroid
c^ic! 6>£>e!.
metabolism (Colby et al., 1974; Wilson,^ 1976; Kramer and Colby, 1976). The
dominant role of growth hormone in the regulation of hepatic drug and steroid
metabolism was demonstrated by Mode et al. (1981). This was further confirmed
when feminising factor was eventually purified and characterised. This factor was
found to be identical to growth hormone (Mode et al., 1983)
Eden (1979) demonstrated a very significant difference in the pattern of growth
hormone secretion in rat between the sexes. In adult males, strikingly regular, high
growth hormone pulses are observed every 3-4 hours, between these peaks, levels
are low or undetectable (Fig 4.01). The female rat, on the other hand, displays a
more continuous pattern of secretion with higher baselines as compared to the male.
This sexually differentiated rhythm of growth hormone release has been shown to
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Figure 4.01 Secretion of growth hormone in male and female rats
900 12-00 15-00 9-00
Clock time
120
patterns of growth hormone secretion in the male (intermittent injection) and in the
female (continuous infusion via osmotic mini-pump) influence steroid metabolism
in a predictable manner.
P-450 16a (male-specific) and P-450 15|3 (female-specific) are useful markers
to probe the mechanisms which generate sex differences in the liver. In an elegant
series of experiments, Gustafsson and his co-workers have shown that these P-450
enzymes are regulated by the growth hormone secretory pattern (for review, see
Zaphiropoulos et al., 1989).
Hypophysectomy of female rats leads to a fall in levels of P-450 15p, no change is
observed in the male where levels are low. Continuous infusion of growth hormone to
normal male animals and hypophysectomised females increased 15p hydroxylase
activity towards normal feminine levels. Intermittent injection of growth hormone
had no effect. (MacGeoch et al., 1984, 1985). In contrast, P-450 16a is dependent
on an intermittent pattern of growth hormone release. Hypophysectomy resulted in a
decline in P-450 16a levels. Continuous infusion of growth hormone caused a
further decline. Intermittent injection of growth hormone restored P-450 16a to
levels observed in the intact adult male. Hypophysectomised females responded in a
*
similar manner (Morgan et al., 1985; Kato et al., 1986)
Treatments which masculinise or feminise drug and steroid metabolism in the liver
have also been found to affect growth hormone secretion. Administration of
oestrogens to male rats feminises the pattern of growth hormone secretion,
androgens masculinise the growth hormone pattern in female rats (Mode et al.,
£
1982). Prolactin, oestrogen (Norstedt,1982), steroid sulfatase (Erikson et al.,
1989), epidermal growth factor receptor (Ekberg et al., 1989; Kashimata et al.,
121
1989) and insulin-like growth factor I (Maitler et at., 1988)are all examples of
hepatic sexually differentiated proteins which have been found to be under the
control of growth hormone secretory pattern .
In the mouse, although less well characterised than the rat, a similar system appears
to be operating. Hepatic prolactin receptors, mouse major urinary proteins (MUPs)
production (which are similar to a2u globulin in the rat )(Norstedt and Palmiter,
1984), and the metabolism of hexobarbital are regulated by the pattern of growth
hormone release (MacLeod and Shapiro, 1989).
Furthermore, neonatal castration in the male results in a feminisation of the growth
hormone secretory pattern. Testosterone treatment during the neonatal period
partially restores the male pattern, further treatment with testosterone during
adulthood fully restores the male pattern of secretion. Thus, in the mechanism
generating sexually dimorphic expression in the liver, androgens are responsible
for imprinting the male-specific pattern of growth hormone secretion in the
neonatal period, which in turn regulates the differences observed in liver proteins
subject to sex-specific expression (Jansson et at., 1985; Jansson and Frohman,
1987).
4.01b Pituitary regulation of Yf
From the results obtained in chapter 3, the sexually differentiated mouse hepatic Yf
subunit would appear to be under the control of androgens. In light of the findings
detailed above for other sexually differentiated systems in the liver, the possible
role of the pituitary was investigated with respect to the Yf subunit. Two lines of
enquiry were undertaken to examine this question.
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Hypophysectomy
Removal of the pituitary gland has been used as a standard technique to investigate
questions of this type. C57BL/6 mice, both male and female, were
hypophysectomised and their hepatic GST profile characterised. However, this line of
enquiry was not pursued in any great depth for a number of reasons; there were
difficulties in obtaining the animals (which had to be transported from the USA after
surgery), problems were also encountered due to incorrectly hypophysectomised
animals and finally the complexity of the situation makes it very difficult to draw
firm conclusions.
The pituitary gland is the main regulator of the endocrine system, itself controlled
by factors released from the hypothalamus. Removal of this gland leads to a shut¬
down of the entire endocrine system. Without the appropriate hormones being
released from the pituitary, the adrenals, the thyroid and the gonads all fail to
function. Figure 4.02 illustrates the many and diverse processes which are
ultimately governed by the pituitary. Thus, for any effect observed it is difficult to
ascertain which pathway is actually involved or indeed whether this phenomenon is
simply a consequence of the system breaking down.
However, in conjunction with hormone replacement therapy, this animal model can
provide very useful information. The advantage here, is that because the entire
endocrine system has been "turned off", effects of a single hormone can be examined
without the situation being confused by possible interactions with other hormones.
Using this technique, it is also possible to determine which hormones are acting
directly to regulate the effect in question and which are acting in an indirect or
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permissive manner, as has been described for the pituitary regulation of hepatic
dimorphism.
The "Little Mouse" Model.
Several mutant mouse strains deficient in a range of endocrine functions are now
used quite extensively to investigate hormone-related phenomena. Charlton (1984)
provides an excellent summary of the most commonly used strains. Several mutants
have now been described which exhibit dwarfism; the Snell dwarf, the Ames dwarf ,
the "little" mouse, the pygmy mouse, and the hypothyroid mouse. The Snell, Ames and
hypothyroid mouse display multiple anterior pituitary hormone deficiencies
whereas the "little" mouse has a specific defect in growth hormone synthesis and
secretion which makes it an excellent model for the study of growth hormone-
regulated processes.
The little mouse mutant, derived from the C57BL76 strain was first reported by
Beamer and Eicher (1976). The defect, inherited in autosomal recessive fashion,
was the product of a single gene locus located on chromosome 6. Mice homozygous for
this recessive mutation were approximately 60% the size of normal mice and their
heterozygote siblings, who display normal growth characteristics. This new mutation
was designated "little", gene symbol (lit).
The pituitary growth hormone content in little mice was found to be 4-8% of normal
mouse levels ( Cheng et al., 1983; Clark and Robinson, 1985). This reduction in
growth hormone content was also reflected in growth hormone mRNA levels, which
were also reported 8% of normal (Cheng et al., 1983). Other pituitary functions are
apparently normal, although there is uncertainty as to the levels of prolactin in the
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little mouse. Some workers have reported prolactin as being decreased in comparison
to the normal mouse (Beamer and Eicher, 1976)5) others have found pituitary
prolactin levels to within the normal range (Philips et al., 1982). Table 4.02 gives
the pituitary profiles of the Little, Ames and Snell dwarfs.
The genetic abnormality in the production of growth hormone has now been
identified. Growth hormone-releasing hormone (GHRH) is a peptide secreted from
the hypothalamus which stimulates growth hormone synthesis and secretion from
pituitary somatotrophs (growth hormone producing cells). This effect is mediated
via a specific receptor on the surface of these cells. In the little mouse, a defect in
this receptor confers resistance to GHRH. Thus, growth hormone is neither
synthesized or released in response to this signal (Clark and Robinson, 1985;
Jansson et al., 1986). The specificity of this defect makes the little mouse an
excellent model for the study of growth hormone mediated processes.
4.01c Aim Of This Chapter
This aim of the work contained in this chapter was to investigate the role of the
pituitary, with special reference to growth hormone, in the sexual differentiation of
the mouse hepatic Yf subunit by : a) investigating the effect of hypophysectomy on
mice, both male and female, of the C57BLy6 strain.
b) undertaking a very thorough characterisation of the growth
hormone deficient little mouse model.
c) examining the effect of hormone replacement therapy on the little
mouse.
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4.02 Analysis of the Hepatic GST Profile in t h e
HvpoDhvsectomised Mouse
4.02a Animal Treatments
Male and female C57BL/6 mice, obtained from Charles River laboratories,
Willmington, Massachusetts, USA, were sham operated or hypophysectomised at 6
weeks of age (four animals per group). Mice were allowed to recover from the
operation for 2 weeks before transportation. After transit, mice were acclimatized at
the ICRF Clair Hall laboratories in Oxford for two weeks before sacrifice. Animals
were killed by cervical dislocation, livers were removed rapidly, frozen and stored
at -70°C. Immediately after sacrifice, blood was collected from each mouse, spun
down in lithium heparin tubes, the plasma collected and frozen at -70°C.
The sham operated females were unfortunately lost during shipment and had to be
replaced with age-matched normal female C57BL/6.
Changes in body weight and measurements of triiodothyronine (T3) levels, a
hormone produced by the thyroid gland, were used to determine the success of the
operative procedure. Completely hypophysectomised mice have a stable or gradually
decreasing body weight, while incompletely hypophysectomised animals increase in
body weight. A decline in plasma T3 levels also indicated that the procedure had been
performed correctly. Figure 4.03 shows changes in body weight over a 2 week period
for hypophysectomised males and females with sham operated males as a comparison.
A decline in plasma T3 was also noted in the hypophysectomised males. Normal
females displayed low levels of T3, which did not change on hypophysectomy (Table
4.03).
It is not known if the low level of T3 observed in the normal female is due to a sex
difference in production and/or metabolism of this hormone between male and female
mice. But this finding would suggest that measurement of body weight changes (refer




Changes in body weight (a) over a two-week period for hvpoDhvsectomised mice of
both sexes and sham operated male controls.
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Table 4.03 Levels of Tq in hvDQDhvsectomised and control C57BL76 mice
Group Animal No. Concentration T3 (nmol/l)
















Assays performed in duplicate.
Significance was assessed relative to control of the same sex. * P > 0.01
hypox, hypophysectomised; ND, not determined.
131
4.02b Analysis of the hepatic GST profile from hvDQDhvsectomised animals
Cytosols, prepared from hypophysectomised animals and their controls, were
assayed for activity towards a panel of GST substrates, specific activity
measurements for which are presented in table 4.04. On removal of the pituitary,
specific activities towards CDNB and ethacrynic acid in the male were found to fall to
levels observed in the hypophysectomised female, which appear to be slightly
elevated as compared to the normal female.
Interestingly, an approximately 2-fold decrease in glutathione peroxidase activity
was also noted, both for CuOOH and H2O2 (which assay total cellular peroxidase
activity and the Se-dependent form respectively). This would suggest that the
removal of the pituitary is, by some mechanism, altering (Se-dependent)
glutathione peroxidase.
Analysis of hepatic proteins by SDS/PAGE and western blotting with antisera towards
mouse GST subunits, demonstrates that on hypophysectomy, a sharp decline in the
levels of Yf in the male occurs (Figures 4.04, 4.05). In the female, a slight decrease
in Yf levels would appear to occur on removal of the pituitary. This change is also
reflected at the mRNA level (figure 4.06).
Interestingly, levels of Yb-type subunits and the Ya3 would appear to be induced in
hypophysectomised animals of both sexes (figure 4.04). This change however is less
evident on immunoblotting (figure 4.05b, 405d). The BHA-inducible Ya-| subunit,
which is normally present in low or undetectable amounts in normal mouse liver
(McLellan and Hayes, 1989), is markedly induced on hypophysectomy in both sexes
(figure 4.05c). This would suggest that, in addition to the Yf GST, the endocrine
system is involved in the regulation of other hepatic GST forms.
132
Table4,04

























































Degreesofsi nificanceassess drelativetm lsh moperatedcontrols.Stand rddevi tionrquoteibr ckl wm values.Unit-pmoles/min/mgprot in.
Figure 4.04
Electrophoretic analysis of hepatic cvtosols from both sexes of hvDQDhvsectomised
and control C57BLV6 mice.
Cytosols from mouse liver (30jj.g of protein/track) were analysed by SDS/PAGE
using a 12% polyacrylamide resolving gel. The gel was loaded as follows lane 1,
rat liver markers (Yc, Yb, Ya); lanes 2-5, hypophysectomised males; lanes 6-9,
hypophysectomised females; lanes 10-13, sham operated males; lanes 14-17, ,
nc>r^al females; lane 18, purified mouse Yf.
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Immunoblottinn of hepatic cvtosols from hvpoDhvsectomised and control C57BI/6
mice of both sexes.
Hepatic cytosols (50jo.g protein/track) were subjected to SDS/PAGE followed by
transfer to nitrocellulose and immunoblotting with antisera against purified mouse
subunits. The gel was loaded as follows lanes 1 and 14, GST markers; lanes 2-4,
hypophysectomised males; lanes 5-7, hypophysectomised females; lanes 8-10,
sham operated males; lanes 11-13, normal females.
Panel a. anti-(mouse YfYf) IgG.
Panel b. anti-(mouse YbiYbi)lgG.
Panel c. anti-(mouse Ya-|Yai)lgG.
Panel d. anti-(mouse Ya3Ya3)lgG.
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Northern blot analysis of hepatic mRNA levels from hvpophvsectomised and control
C57BL/6 mice of both sexes using the rav Vf cDNA.
Hepatic RNA (15jxg) was elecrophoretically size-fractionated using a 1%(w/v)
agarose gel. After electrophoresis, RNA was transferred to nitrocellulose paper by
capilliary action and hybribised overnight at 65°C with a P32CTP-labelled Yf cDNA
probe. Loadings were as follows lane 1, sham male operated controls; lane 2,
oor/nal female controls; lane 3, hypophysectomised males; lane 4,
hypophysectomised females.
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4.03 The hepatic GST complement of the little mouse.
4.03a Hepatic GST content of little mice.
An examination of the hepatic GST profile of the little mouse (lit/lit), both male and
female was undertaken. Two strains of mice were used as controls throughout these
experiments; a) mice heterozygous for the lit gene, (lit/+) which display normal
growth characteristics and b) normal wild-type C57BL/6 mice (+/+), the
progenitor strain from which the little mouse was derived.
Cytosols were prepared from pooled liver samples containing not less than 5 animals
per group. The cytosol preparation was performed in duplicate. The hepatic profile
from these cytosols were analysed by SDS/PAGE, followed by immunoblotting to
investigate the GST profile. Little male mice were found to display a feminine pattern
in respect to their GST profile, Yf levels were similar to those found in the female.
Levels of the Ya3 and Yb-type subunits did not appear to differ significantly between
groups. Interestingly, the Yai subunit was elevated in little mice of both sexes
(figures 4.07, 4.08).
This difference was further confirmed using activity measurements for several GST
substrates, table 4.05 presents the data obtained. A marked decline in CDNB and
ethacrynic acid activity in the little male was observed, as would be expected. Other
substrates measured remained unchanged between little mice and their controls.
Messenger RNA encoding the Yf GST also showed a similar change (figure 4.09).
To further confirm this important observation, purification of hepatic GST from
little mice and controls was undertaken. By this method, a quantitative estimate of
GST subunit levels in little males and females could be obtained.
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Figure 4.07
Electrophoretic analysis of hepatic cvtosolic protein from lit/lit. Iit/+ and +/+
males and females.
Duplicate cytosols preparations were undertaken from pooled liver samples (5
mice/group) from each strain and sex. Cytosolic protein (50^g/track) was analysed
by SDS/PAGE on a 12% (w/v) polyacrylamide resolving gel. Loadings were as
follows lanes 1 and 14, rat lung standards (Yc, Yb, Yf); lanes 2-3, lit/lit female;
lanes 4-5, lit/lit male; lanes 6-7, lit/+ female; lanes 8-9, lit/+ male; lanes 10-
11, +/+ female; lanes 12-13, +/+ male.
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Figure 4.Q7










Immunoblottina of hepatic cvtosols from both sexes of little mice and
heterozvaote and wild-tvpe C57BL/6 controls.
Hepatic cytosols (50p.g) were subject to SDS/PAGE as has been described previously
(see section 2.02d) and immunoblotted against anti-mouse GST antisera.
Figure 4.08 a,d. Loadings were as follows; lanes land 14, purified mouse standard;
lanes 2-3, lit/lit female; lanes 4-5, lit/lit male; lanes 6-7, lit/+ female; lanes 8-
9, lit/+ male; lanes 10-11, +/+ female; lanes 12-13, +/+ male.
Panel a - anti-(mouse YfYf) IgG.
Panel d - anti-(mouse Yb-|Ybi)lgG.
Figures 4.08 b,c. Loadings were as follows ; lanes 1 and 14, purified mouse GST
standards; lanes 2-3, lit/lit male; lanes 4-5, lit/lit female; lanes 6-7, lit/+ male;
lanes 8-9, lit/+ female; lanes 10-11, +/+ male; lanes 12-13, +/+ female.
Panel b - anti-(mouse Ya-|Yai) IgG.
Panel c - anti-(mouse Ya3Ya3) IgG.
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Figure 4.09
Northern blot analysis of little and heterozvaote hepatic mRNA levels using the rat Yf
cDNA.
Hepatic Yf mRNA levels were measured by Northern blot analysis as described in
section 2.12. Liver RNA (20pg) was electrophorectically size-fractionated using a
1% (w/v) agarose gel with 2.2M-formaldehyde. After electrophoresis the RNA was
transferred to nitrocellulose and hydridised overnight at 65°C with the rat Yf cDNA
probe labelled with P32CTP. Loadings were as follows; lanel, lit/lit male; lane 2,
lit/lit female; lane3,Lt/+ male; lane 4.M/+ female.
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4.03b Purification of the hepatic GST mixture from little mice and their controls
Purification of GST from little males and little females (lit/lit), from male and
female heterozygote (lit/+) as well as from wild-type controls (+/+) was
undertaken. GST isoenzyme mixtures were isolated from mouse livers using
glutathione affinity chromatography as described in section 2.05a.
Recovery of GST from the GSH-affinity column ranged from 74% to 94 %. The level
of GST expressed as a percentage of total cytosolic protein was found to be slightly
higher in the wild-type and heterozygote males as compared to females and little
males (table 4.06).
Table 4,06 Recovery of Hepatic GST after GSH-Affinitv Chromatography
Strain Sex Level of GST as a % % CDNB activity retained after
total cytosolic protein GSH-affinity chromatography
Lit/Lit male 2.0 87
female 3.0 94
Lit/ + male 4.0 92
female 2.0 91




SDS/PAGE of purified hepatic isoenzyme mixtures from lit/lit. Iit/+ and +/+ male
and females.
Mouse GST from liver cytosols of each strain and sex were purified by GSH-affinity
chromatography and the subunit content analysed by SDS/PAGE on a 12% (w/v)
polyacrylamide resolving gel. The gel was loaded with 3^g of GST in each lane,
loadings were as follows lanes 1 and 8, rat liver markers, (Yc,Yb, Ya); lane 2,
lit/lit male; lane 3, lit/lit female; lane 4, lit/+ male; lane 5, lit/+ female; lane 6,
+/+ male; lane 7, +/+ female.
Figure 4,11
Immunoblottino of purified hepatic GST isoenzyme mixtures from little males and
females and heterozvoote and wild-type controls of both sexes.
Hepatic mouse GST (3pg protein/track) from each strain and sex were purified by
affinity chromatography, subjected to SDS/PAGE, transferred to nitrocellulose and
analysed by immunob'otting with anti-(mouse YfYf) IgG. The gel was loaded as
follows:- lanel and 8, mouse Yf markers; Iane2, lit/lit male; lane 3, lit/lit female;





Hvdroxvapatite h.p.l.c. analysis of GSH-affinitv purified GST pools
Individual GST subunits were resolved from the GSH affinity purified pools by
hydroxyapatite h.p.l.c. as described in section 2.05b. The h.p.l.c. traces obtained
from little, heterozygote and wild-type males and females are presented in figures
4.12, 4.13, 4.14 respectively.
In all groups and sexes, three distinct peaks were obtained with retention times of
36min, 41min, 50min. From previous work from this laboratory, it is known that
the Yf GST elutes first, followed by Ya class subunits and finally Yb-type subunits
(Hayes et al., 1987; McLellan and Hayes, 1897). Little males displayed a similar
trace to that obtained for female mice. Fractions were collected at 1 min intervals and
assayed for protein and CDNB activity. Fractions from each peak containing the
highest CDNB activity were pooled. The peak of A280-absorbing material eluting at
13min did not contain protein and did not possess any activity towards CDNB; it is
most probably GSH.
Due to the scarcity of starting material, an exhaustive characterisation of purified
peak fractions could not be undertaken however specific activities towards CDNB
were obtained for the purified pooled fractions. These are given in table 4.07. Values
quoted are of a similar order to those determined by McLellan and Hayes (1987).
Peak no.3, containing Yb type subunits, had the highest activity towards CDNB,
followed by peak no.1 (Yf), the Ya (peak no.2) had the lowest specific activity.
Table 4.08 gives the relative yields obtained for individual subunits from h.p.l.c.
analysis. In control males, the Yf GST subunit was found to constitute approximately
70% of total GST, by far the major GST in normal male liver. In contrast, the Yb was
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Finure 4.12 Use of hvdroxvapatite h.D.l.c. to resolve mouse liver GST subunits
from male and female little mice.
Affinity purified pools were subject to chromatography on Bio-gel HPHT. Portions
(2ml, 0.26mg of protein for both sexes) were applied to hydroxyapatite and were
eluted from the h.p.l.c. coloumn at 0.5ml/min with a liear gradient of 10-350 mM-
sodium phosphate which contained 0.5mM-DTT. Protein peaks were detected by
monitoring the absorbance at 280nm. The GST peaks were eluted by monitoring the
absorbance at 280nm. The GST peaks were eluted at 36min, 41min and 50min.
Panels (a) and (b) show elution profiles of hepatic GST from male and female little
mice.




Figure 4.13 Use of hvdroxvapatite h.p.l.c. to resolve mouse liver GST from male
and female heterozyqptes (lit/t).
Affinity purified GST ( 2ml, 0.98mg and 0.31 mg of protein for male and female
respectively) were subject to chromatography on Bio-Gel HPHT as described in the
legend to figure 4.12. GST peaks eluted at 36min, 41min and 50min. Panel (a)
shows the elution profile for hepatic GST from male heterozygotes. Panel (b) shows
the hepatic GST elution profile for female heterozygotes.
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Figure 4.14 Use of hvdroxvapatite h.p.i.c. to resolve mouse liver GST from wild-
tvoe (+/+) males and females of the C57BL76 strain.
Affinity purified GST (2ml, 0.92mg and 0.25mg of protein for male and female
respectively) were subject to chromatography on Bio-Gel HPHT as described in the
legend to figure 4.12. GST peaks eluted at 36min, 41min and 50min. Panels (a) and
(b) show the elution profiles for male and female C57BU6 mice.
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the major GST little males, with the Yf forming only 23% of the total GST content. A
similar situation to that observed in females.
Table 4.07 Specific Activities towards CDNB of purified GST subunits
(units of activity - |xmoles/min/mg protein)
Group Sex Peakl ) Peak2Ul^~) Peak3 C^o— )
(Yf) (Ya) (Yb)
Lit/Lit Male 81.3 20.0 141.3
Female 93.1 18.2 149.0
Lit/ + Male 112.2 28.4 139.0
Female 114.0 17.0 143.6
+ / + Male 93.4 26.9 129.0
Female 105.5 20.6 149.1
4.03c Plasma Testosterone Levels in the Little Male-
Plasma testosterone levels in the little mouse were measured by the method of
Corker et at. (1978). The results are presented in table 4.09 The testosterone
concentration in the little male were found to be very similar to that found in the
heterozygote and wild-type males. In females, testosterone levels are extremely

















































Table 4.09 Testosterone levels in little male mice and heterozvaote and wild-tvne
male controls,
Strain Testosterone Concentration (nmol/l)
Lit/Lit 3.8 (n=9, sd=3.5)
Lit/ + 4.0 (n=8, sd=2.8)
+ / + 3.8 (n=6, sd=4.1)
Abbreviations: n, number; sd, standard deviation.
4.04 Treatment of Little Mice with Growth Hormone and
Testosterone.
Little mice and their heterozygote and wild-type controls were obtained from
Charles Rivers Laboratories, Willmington, Massachusetts. After transit, the mice
were acclimatized at Clair Hall laboratories, Oxford for 2 weeks prior to the
commencement of treatment. Little mice received either testosterone propianote,
subcutaneously injected in corn oil at 120p.g/mouse or recombinant human growth
hormone (Genotropin), injected subcutaneously in sterile water in twice daily doses
of 5pg (0.03 international units). These treatments were administered for 7
consecutive days, the injections being separated by approximately 12 hours to
simulate the male pattern of growth hormone secretion. Control animals received
injection vehicle only. Heterozygote and wild-type controls were subjected to
158
replacement therapy with growth hormone only. A summary of treatment groups and
group numbers is given in table 4.10.
Cytosols, prepared from individual mice, were measured for activity towards CDNB.
No change in CDNB activity was noted in any of the groups after treatment with
either hormone (figure 4.15). Following SDS/PAGE however, a protein of Mr
24,800 was found to have been induced in the little males on treatment with growth
hormone. No effect was observed after testosterone administration (figure 4.16). A
similar pattern of events was demonstrated in the little female (figure 4.17).
Hormone therapy had no appreciable effect on wild-type males and females.
Immunoblotting with anti-mouse YfYf antisera gave a similar pattern of events
(figure 4,18, 4.19). Results obtained for the heterozygotes mirrored those observed
for wild-type controls (data not shown).
4.05 Discussion
4.05a Summary of results.
The aim of the work described in this chapter was to examine the role of the
pituitary gland in the regulation of hepatic GST expression in the mouse. The
evidence presented indicates that the sex-specific regulation of the Yf subunit is
controlled via the pituitary gland, more specifically by growth hormone which is
produced by the pituitary somatotrophs.
Hypophysectomy of male C57BL76 mice results in a sharp decline in the levels of the
Yf subunit. In the female, a slight elevation in hepatic Yf was noted after removal of
the pituitary.
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Table 4.10 Treatment groups for little mice hormone replacement
therapy
Strain Sex Treatment Group number
















Abbreviations: GH - growth hormone
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Figure 4.15
Levels of CDNB activity in hepatic cvtosols from little mice undergoing hormone
replacement therapy.
a. little mice of both sexes treated with growth hormone (GH).
b. little mice of both sexes treated with testosterone (test).
c. heterozygote mice treated of both sexes treated with GH.


























Elecrophoretic analysis of hepatic cytesols from little male mice undergoing
hormone replacement therapy.
Hepatic cytosols (30fig/track) from little male mice undergoing hormone
replacement therapy were analysed by SDS/PAGE using a 12% (w/v)
polyacrylamide resolving gel. The gel was loaded as follows lane 1, rat liver
markers, (Yc, Yb, Ya); lanes 2-4, lit/lit male controls; lanes 5-7, lit/lit males
treated with growth hormone; lanes 8-10, lit/lit male controls; lanes 11-13,
lit/lit males treated with testosterone; lanes 14-16, +/+ male controls; lanes 17-
19, +/+ males treated with growth hormone, lane 20, purified mouse Yf standard.
Figure 4.17
Electrophoretic analysis of hepatic cvtosols from little female mice undergoing
hormone replacement therapy.
Hepatic cytosols (30|j.g/track) from lit/lit females were analysed by SDS/PAGE
using a 12% (w/v) polyacrylamide resolving gel. Loadings were as follows :- lane
1, rat liver markers (Yc, Yb, Ya), lanes 2-4, lit/lit female controls; lanes 5-7,
lit/lit females treated with growth hormone; lanes 8-10, lit/lit females controls;
lanes 11-13, lit/lit females treated with testosterone; lanes 14-16, +/+ controls,
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Immunoblottina of hepatic cvtosols from little males undergoing hormone
replacement therapy.
Hepatic cytosols (50pg protein/track) from little males undergoing hormone
replacemant therapy were subject to SDS/PAGE followed by transfer to nitrocelluose
and immunoblotting with anti-(mouse YfYf) IgG. gel loadings were as follows lanes
1 and 17, mouse Yf standard; lanes 2-4, lit/lit male controls; lanes 5-7, lit/lit
males treated with growth hormone; lanes 8-10, lit/lit males treated with
testosterone; lanes 11-13, +/+ male controls; lanes 14-16, +/+ males treated
with growth hormone.
Figure 4.19
Immunoblottina of hepatic cvtosols from little females undergoing hormone
replacement therapy.
Hepatic cytosols (50p.g protein/track) from little females undergoing hormone
treatment were subject to SDS/PAGE, transferred to nitrocellulose and
immunoblotted with anti-(mouse YfYfjlgG. Gel loadings were as follows :- lanes 1
and 17, mouse Yf standard; lanes 2-4, lit/lit female controls; lanes 5-7, lit/lit
females treated with growth hormone; lanes 8-10, lit/lit females treated with
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Characterisation of the hepatic GST profile in the little mouse demonstrated that the
absence of growth hormone led to a feminine phenotype in the male with respect to
the Yf polypeptide. Northern blot analysis showed that this difference in Yf content
occured at the pretranslational level, although it is not known whether this is due to
an decrease in the transcription of the Yf gene or its stability.
Circulating testosterone levels have not been reported for the little mouse. Fertility
problems have been noted in this mutant strain (Beamer and Eicher, 1976). To
exclude the possibility that low testosterone levels in the little mouse might account
for the finding detailed above, plasma was collected from these mice and testosterone
levels measured. Plasma testosterone concentrations were found to be similar to the
heterozygote and wild-type strains. Moreover the values obtained are in good
agreement with previously quoted levels of testosterone in the C56BL/6 strain
c\
X
(Batty, 1978; Kemp and Drinkwater, 1989). Steroidogenesis in the little mouse has
also been found to be normal as have testicular testosterone levels (Chubb and Nolan,
1985; Chubb, 1987). This would indicate that the lack of testosterone is not the
factor responsible for the low levels of YfYf in the little male.
A marked sexual dimorphism in the expression of P-450 isozymes in mouse kidney
has been noted. Unlike the hepatic P-450 enzymes described in section 4.01a which
are not controlled directly by testosterone, androgens appear to mediate the sexual
differentiation of kidney P-450 enzymes directly. In little males and females, the
P-450 profiles are normal, suggesting again that testosterone levels are not
depressed (Henderson eta!., 1990).
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In the little mouse, testosterone levels are normal and yet in the male a feminine
pattern of GST expression is observed. Moreover, treatment of little mice with
testosterone, at concentrations which have been shown to induce Yf in intact females
and castrated C57BL/6 males, does not restore the expression of Yf to levels
observed in wild-type males. It should be emphasised from the work of Henderson et
al (1990) that enzymes in both castrated and little mice which are directly
controlled via testosterone respond in a normal manner to treatment with this
hormone. These data indicated strongly that testosterone is not regulating Yf levels
through a direct mechanism.
When, however, little mice were subject to replacement therapy with growth
hormone, an elevation in the expression of the Yf subunit was observed in both the
male and female. By contrast, no change was observed in GST expression in controls
treated with growth hormone. This evidence strongly suggests that that growth
hormone deficiency in the little mouse leads to female-type expression of the Yf
subunit, correcting this deficiency by growth hormone administration leads to an
induction of hepatic Yf, although this treatment by no means restores expression of
Yf to normal male levels.
Although growth hormone treatment induced the Yf in little mice, the level of
expression was considerably lower than that found in heterozygote and wild-type
male controls. The low level of induction could possiblq be due to the treatment
regime employed. MacLeod and Shapiro (1989) demonstrated that a daily dose of rat
growth hormone at a concentration of 0.08 i.u. / 100g body weight divided into 2
subcutaneous injections for a duration of 7 days could masculinise drug metabolism
in hypophysectomised and/ or gonadectomised male mice. A similar concentration of
recombinant human growth hormone was used in this study. It is possible that
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growth hormone from another rodent species would be more physiologically active in
the mouse. Other workers have shown human recombinant growth hormone to be
active in the mouse (Norstedt and Palmiter,1984); unfortunately, the international
units used by these workers was not quoted. It is therefore difficult to estimate the
dose administered for comparison to the present work. Human growth hormone has
certainly been used in the rat but at a dose 4 x higher than than has been used in this
experiment(Waxman et a!., 1988),The duration of treatment in most cases was for 7
consecutive days. Probably a higher dose for a longer duration would have shown a
greater effect.
Not only is the dose of growth hormone administered and the duration of treatment
A
important in any observed effect but also the frequency of injection. Janson and his
co-workers looked at the longitudinal bone growth in hypophysectomised animals
receiving growth hormone in subcutaneous injections at different frequencies. A
daily replacement dose of bovine growth hormone was divided into 1,2,4 and 8 daily
injections. A greater response was observed when growth hormone was administered
as 4 daily injections, presumably this mimicked most closely the normal male
secretory pattern (Jansson et al., 1982). For experimental convenience, most
workers employ a twice daily administration of hormone, 12 hours apart.
4.05b Is the Yf GST regulated bv the growth hormone secretion?
In this study, growth hormone was administered as intermittent injections at
approximately 12 hour intervals throughout a 7 day period. This mimicked the male
rhythm of release from the pituitary. Induction of the Yf subunit was noted in the
little mice of both sexes. The converse experiment, involving the chronic
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administration of growth hormone via a mini-osmotic pump, to simulate the female
growth hormone pattern, was not performed due to difficulties in obtaining both mice
and growth hormone. It is not possible therefore to state conclusively that expression
of the Yf subunit is regulated via the male secretory growth hormone pattern but
there are several indications that this is probably the case.
From a simple analysis of the little mouse liver GST complement, growth hormone
appears to be involved in the regulation of the Yf subunit. In the male little mouse
(which possesses a block in growth hormone synthesis), a feminine pattern of GST
expression is observed. When the growth hormone deficiency in little mice was
replaced in the male fashion an increase in the expression of Yf was noted in both the
male as well as the female.
The ability to induce Yf in female little mice by growth hormone treatment is
perhaps surprising, but it seems likely that it is the discontinuous manner in which
this hormone was administered that is responsible for the overexpression of the Yf
GST. The fact that treatment of female C57BL/6 mice with testosterone causes an
induction in levels of Yf appears to contradict the hypothesis that testosterone does
not act directly in the of control Yf expression. However, testosterone treatment has
been shown to masculinise the growth hormone secretory pattern. Removal of the
testes has been found to feminise the male pattern of growth hormone secretion
(Jansson et al., 1985; Jansson and Frohman, 1987). Gonadectomy of the male is also
associated with a decline in the expression of the Yf (see chapter 3). Interestingly,
male rats exhibiting the tfm defect are found to have a growth hormone secretory
pattern similar to that found in neonatally gonadectomised male rats (Millard et al.,
1982). No studies on growth hormone release in the tfm or hpg mouse strains have
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been reported in the literature but the prediction would be that the males of these
mutant mouse strains would exhibit a feminine pattern of growth hormone release.
4.05c Mechanism of action
The mechanism whereby the sexually differentiated rhythm of growth hormone
secretion leads to a dimorphic expression of hepatic proteins between male and
female is one of the key questions in this area, which, as yet, remains unanswered. It
is not known if this effect is regulated directly by growth hormone binding to its
receptor on the surface of the hepatocyte. Alternatively, growth hormone regulation
might occur indirectly via the somatomedins. These are a family of hormones
synthesized and released from the liver in response to growth hormone binding to its
receptor. Close structural and functional similarities have been noted between the
somatomedins and insulin. In humans, three somatomedins are produced, A, B, and C,
and these hormones are also referred to as insulin-like growth factors (IGF).
Somatomedin C is identical to insulin-like growth factor I (IGF I). After release
from the hepatocyte these hormones bind to specific receptors on the surface of a
number of different cell-types, including the liver. Mitogenic responses to growth
hormone occur through the sommatomedins (for review, see Zapf et al., 1981).
Norstedt and Palmiter (1984) have proposed a mechanism based on this dichotomy
of growth hormone action. They propose that proteins induced when growth hormone
is secreted in a femimine pattern, e.g. prolactin receptors, are directly regulated by
growth hormone binding to its receptor. In contrast, growth hormone would regulate
male specific expression indirectly by the synthesis of somatomedin (e.g. IGF I.),
which when secreted from the liver would bind in an autocrine fashion to hepatic
somatomedin receptors and stimulate the synthesis of male-specific proteins.
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It is now well established that most membrane receptors that bind polypeptide
hormones are down-regulated by chronic occupancy. The growth hormone receptor is
unusual in that it is up-regulated by continuous growth hormone stimulation. Thus,
any protein under direct control would be further stimulated by chronic exposure to
growth hormone. This would account for the high levels of female specific proteins
according to the Norstedt and Palmiter model.
Occupancy of the growth hormone receptor liberates a second messenger, as yet
unidentified, which also acts to induce IGF I. This in turn binds to its hepatic
receptor stimulating the production of proteins regulated by this pathway. In the
female, the number of IGF receptors expected would be low due to continuous
synthesis followed by chronic exposure of receptors. By contrast, in the male, the
secretory bursts of growth hormone would presumably lead to a pulsatile emission of
IGF I, hence IGF I receptor concentration would be higher in comparison to the
female. An increase in receptor concentration would lead to an induction of those
proteins controlled via this mechanism, a schematic diagram of this proposal is
shown in figure 4.20
This hypothesis would fit well with findings obtained for the expression of the Yf
subunit. In the little mouse, no growth hormone is present, this results in low levels
of IGF I which in turn leads to a reduced expression of Yf. When growth hormone is
administered to male and female little mice, IGF I is produced, which acting in an
autocrine fashion stimulates the expression of the Yf subunit. In normal females,
continuous secretion of growth hormone down-regulates the IGF receptor which
results in a low level of Yf expression.
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Figure 4.20 Hypothetical scheme for growth hormone action on sexually dimorphic
hepatic proteins.
f
Liver cells exposed to different types of growth hormone stimulation. The figure to
the left shows a situation where no growth hormone is present (e.g. little mice) and
the resulting low production of IGF-I and the mouse major urinary protein (MUP)
which is normally highly expressed in the male. The middle figure indicates a
situation of discontinuous stimulation of growth hormone receptors (exemplified by
male mice), which is postulated to result in discontinuous release of IGF-I, which in
turn induces MUP. The figure to the right shows a continuous stimulation of growth
hormone receptors (exemplified by female mice) which up-regulates growth
hormone receptors, resulting in continuous IGF-I release, which in turn down
regulates IGF-I receptors and results in low MUP production.
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Very little evidence has been obtained to either confirm or deny this hypothesis. A
recently developed culture system for hepatocytes in which the sexually
differentiated expression of proteins is maintained during primary cell-culture will
be a useful model to study this question (Guzelian et al., 1988).
Using this system, induction of P-450 15(1 (female-specific) was observed in
cultured male rat hepatocytes exposed to growth hormone. Isolated female
hepatocytes required the continuous presence of growth hormone to maintain
expression of 150. Moreover, other hormones tested, androgens, oestrogens, IGF I,
IGF II, did not induce P-450 15(3 levels in male or female hepatocytes. This
demonstrates a direct effect of growth hormone on a female specific protein. The
male-specific P-450 16a was not induced in either male or female hepatocytes with
growth hormone. Other factors might be required for the induction of male-specific
proteins or alternatively the pulsatile growth hormone pattern might not have been
simulated properly.
Maitler et al., (198£i have reported recently that IGF I and growth hormone
receptor levels are under the control of the growth hormone secretory pattern.
Intermittent administration of growth hormone leads to an increase in IGF I levels in
hypophysectomised female rats (as compared to chronic exposure) no change in
growth hormone receptor levels was observed. Continuous secretion of growth
hormone leads to an increase in growth hormone receptor levels.
These observations, by no means confirming the scheme put forth by Norstedt and
Palmiter (1984), suggest there might be some basis for this theory. Identification
of responsive elements in growth hormone-regulated genes will hopefully allow for a
clearer understanding of the mechanism of regulation and facilitate the isolation of
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transacting factors involved in initiating transcription from both male- and female-
specific genes. This together with the characterisation of the growth hormone
receptor will provide powerful tools for uncovering the intracellular pathway of
events which lead to sex-specific expression of hepatic proteins.
4.05d Further work
The treatment regime for growth hormone therapy would obviously have to be
modified to achieve maximal expression of the Yf GST subunit in the little mouse.
This type of experiment could also be applied to hypophysectomised mouse model to
confirm the findings from this study. Growth hormone would be administered in both
male and female patterns. It would also be predicted that other mouse models
investigated during the course of this work would also be responsive to growth
hormone therapy.
The pygmy mouse (King, 1950) might provide a very useful model to investigate the
direct versus indirect action of growth hormone. The mutation is inherited as an
autosomal recessive mapped to chromosome 10. Affected mice are approximately
50% the size of normal litter mates. Plasma prolactin and growth hormone levels
have been found to be within the normal range (Sinha et al., 1979). Nissley et al.
(1980) reported that somatomedin production in the pygmy is normal. It is
speculated that the underlying genetic defect in this mutant might be at the IGF
receptor or in the transmission of the signal. Certainly, an investigation of the
hepatic GST complement from these mice might provide a useful insight into the
mechanism of growth hormone regulation of the Yf subunit.
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Although the main focus of this work has been concerned with the endocrine
regulation of the Yf subunit, it would appear from preliminary data that the Yai
subunit is also under the control of growth hormone. Hypophysectomy of both male
and female mice leads to an increase in the levels of Yai. Little mice, again of both
sexes, also display higher levels of this subunit than controls. This would suggest
that the hepatic Yai subunit is repressed by growth hormone, although a fuller
investigation would have to be undertaken to confirm this finding. Other drug
metabolising enzymes have been found to be suppressed by growth hormone
(Waxman et al., 1988).
A slight elevation in Yf has been noted in female mice after hypophysectomy. The Yf
level in the male falls to that of the hypophysectomised female but not to that of the
normal female. This would suggest that a hormone or hormones produced another
endocrine gland is responsible for the suppression of expression in the liver,
although due to the strong positive action of growth hormone this is not noted in the
male. Strong possible candidates would be the adrenals or the thyroid gland. It would
certainly be an interesting study in itself to explore the possible regulation of
hepatic GST by other endocrine systems.
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Chapter 5 - Pituitary Involvement In The Xenobiotic Control Of
Mouse Hepatic GST
5.01 Introduction
The induction of drug-metabolising enzymes by foreign compounds has been
extensively studied since the phenomenon was first described by Brown et al.,
(1954). Particular emphasis has been placed on the cytochrome P-450
monooxygenase system, members of which can be induced by a vast array of foreign
compounds. Indeed, until recently, when a new P-450 nomenclature was introduced
(Nebert et al., 1987), P-450 isoenzymes were classed on the basis of their
regulation by foreign compounds. Four major xenobiotic inducible P-450 gene
families have been described. The P-450 I gene family are inducible by polycyclic
aromatic hydrocarbons (PAH), for example, 3-methycholanthrene (3-MC) and
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). The most extensive family, the P-
450 II gene family are inducible by phenobarbital (PB). The prototype inducer for
the third gene family is pregnenolone 16a-carbonitrile (PCN), hence this class of
P-450 are also referred to as the PCN-inducible P-450. This family, in the rat,
can also be induced by steroids such as the synthetic glucocorticoid dexamethasone
(Dex). Peroxisome proliferators, such as chlofibric acid, induce the forth gene
family (for reviews, see Wolf, 1986; Nebert and Gonzalez, 1987)
Phenobarbital and polycyclic aromatic hydrocarbons (PAH) such as 3-MC have also
been found to induce hepatic GST subunits for the alpha and mu classes in the rat
(Kaplowitz et al., 1975; Hayes et al., 1979; Pickett et al., 1987). Treatment of rats
with these xenobiotics also leads to transcriptional activation of the corresponding
genes (Ding and Pickett, 1985). Phenobarbital has also been reported to induce
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hepatic GST levels in the mouse, however this phenomenon has not been as well
A
characterised at the molecular level in this species (Stockstill , 1982; David
and Nerland, 1983; Davies and Schnell, 1987; Di Simplico et al., 1989).
The aim of this study was to investigate the effect of phenobarbital (PB) and PB-like
inducers on the hepatic GST profile in the mouse. The compounds phenobarbital,
dexamethasone and 1,4-Bis [2-(3,5-dichloropyridyloxy)]-benzene (TCBOP) were
investigated, the structures for which are given in fig 5.01. With respect to the
induction of P-450 genes in the mouse, dexamethasone has been described as a potent
phenobarbital-like inducer (Meechan et al., 1988). TCBOP is again similar to PB in
the induction of members of the mouse P-450 family. It has been estimated that
TCBOP in the mouse is 650 times more potent at inducing P-450 than PB (Poland et
al., 1980). When tested on the rat however, this compound failed to illicit a
response (Poland et al., 1981). Thus, there can be profound differences between
species in their response to foreign compounds.
In the rat, the induction of members of the PB family by PB itself was enhanced after
hypophysectomy. Removal of growth hormone was found to lead to a higher base-line
level of expression of these genes which were further elevated after treatment
(Yamazoe et al., 1987). Thus, the possible effect of the pituitary gland, more
specifically growth hormone, in the modulation of the xenobiotic regulation of mouse
hepatic GST was also investigated. An analysis of the effect of the xenobiotics listed
above in hypophysectomised and "little" mouse models was undertaken.
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Figure 5.01

















5.02 Effect of xenobiotic treatment on hepatic GST content in
C57BL/6 and DBA/2 mice
5.02a Animal treatment
Male and female mice of the C57BL/6 and DBA/2 strains (4 per group) were treated
with the xenobiotic compounds phenobarbital, dexamethasone and TCBOP.
Phenobarbital (in saline) and dexamethasone (in corn oil) were administered
interperitoneally at 80mg/kg/day for 3 days and 100mg/kg/day for 4 days
respectively. Mice were sacrificed 24 hours after the cessation of treatment. One
interperitoneal injection of TCBOP (3mg/kg) was administered and the animals
killed 4 days after treatment. Control animals received corn oil. After sacrifice
livers were removed and rapidly frozen on dry-ice. Tissues were stored at -70°C.
The effect of a single injection of TCBOP (3mg/kg) was monitored over a 12 week
period in both the C57BL/6 and DBA/2 strains, both sexes were investigated. Two
mice per group were sacrificed at 2, 4, 8 and 12 weeks after the initial injection.
5.02b Analysis of hepatic GST content after xenobiotic treatment in the C57BL76
and DBA/2 strains of mice.
Cytosols were prepared from pooled liver samples for each of the treatment groups
described above. Specific activities were determined for CDNB, the general GST
substrate and DCNB which is the substrate relatively specific for the Ybi subunit.
Activity towards these substrates was higher after xenobiotic treatment in both
strains and sexes. Of the xenobiotics studied, TCBOP was the most potent inducer
causing a 5-fold increase in DCNB activity (figures 5.02, 5.03). No difference in
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Figure 5.02
Levels of CDNB activity in hepatic cvtosols from male and female C57BL/6 and



















Levels Pf PCNB activity in hfinmfc cvtosols from male and female CS7RI /fi
PBA/2 strains of mice after treatment with xennhiotir
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Figure 5.03













































DCNB was detected between males and females of the C57BL/6 strain. Levels of DCNB
activity were consistently lower in females of the DBA/2 strain as compared to the
males in both control and xenobiotic treated groups. The sex difference in the
expression of the Yf subunit was reflected in the CDNB activity, females were
consistently lower than males in both control and treated groups.
SDS/PAGE followed by western blotting with antisera raised against purified mouse
GST demonstrated that members of the Yb gene family were induced by xenobiotic
treatment, this occured in both strains and sexes (figures 5.04, 5.05).
Phenobarbital and dexamethasone induced mu class GST to a similar extent
(approximately 2-3-fold). Again, TCBOP was the most potent inducer raising the
levels of the Yb class approximately 5-fold. Possible changes in the expression of Yf
and the Ya class subunits were not investigated since SDS/PAGE revealed that
polypeptides of Mr 25,800 (Ya3) and 24,800 (Yf) did not change markedly after
the administration of these compounds. In the future, a more rigourous analysis of
hepatic GST content will have to be undertaken to characterise fully the changes
which occur in the expression of these enzymes following administration of foreign
compounds. From the compounds investigated, preliminary results would indicate
that it is the Yb gene family in the mouse which is most affected by treatment with
xenobiotics.
The longer term effects of TCBOP treatment on hepatic GST content were investigated.
After treatment of both strains and sexes with a single interperitoneal injection of
TCBOP at a dose of 3mg/kg, CDNB and DCNB activity reached maximum levels 2-4
weeks after treatment, falling gradually back to basal levels. However, even after 12
weeks, activity had not completely declined to that observed in the controls. Induction
was greatest in the C57BL/6 strain (figures 5.06, 5.07). Changes observed in the
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Figure 5.04
Electrophoretic analysis of male and female C57BL/6 and DBA/2 mice treated with
xenobiotics.
Cytosols (30^g) from pooled liver samples were analysed by SDS/PAGE on a 12%
(w/v) polyacrylamide resolving gel. Gel loadings were as follows lanes land 10,
rat lung standards (Yc, Yb, Yf); lane 2, control male; lane 3, control female; lane 4,
male treated with PB; lane 5, female treated with PB; lane 6, male treated with DEX;
lane 7, female treated with DEX; lane 8, male treated with TCBOP; lane 9, female







Electrophoretic analysis of male and female C57BL76 and DBA/2 mice treated with
xenobiotics,
Cytosols (30pg) from pooled liver samples were analysed by SDS/PAGE on a 12%
(w/v) polyacrylamide resolving gel. Gel loadings were as follows lanes land 10,
rat lung standards (Yc, Vb, Yf); lane 2, control male; lane 3, control female; lane 4,
male treated with PB; lane 5, female treated with PB; lane 6, male treated with DEX;
lane 7, female treated with DEX; lane 8, male treated with TCBOP; lane 9, female
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Figure 5.05
Immunoblottina of hepatic cvtosols from male and female C57BI/6 and DBA/2
strains using anti-fmnnse YhjYh-^antisera.
Cytosols (50pg) were subject to SDS/PAGE on a 12% (w/v) polyacrylamide
resolving gel, followed by transfer to nitrocellulose and immunoblotting with anti-
(rat YbiYb-i) IgG. The gel was loaded as follows lanes 1 and 10, rat lung standards
(Yc, Yb, Ya); lane 2, male control; lane 3, female control; lane 4, male treated with
PB; lane 5, female treated with PB; lane 6, male treated with DEX; lane 7, female
treated with DEX; lane 8, male treated with TCBOP; lane 9, female treated with
TCBOP.
Panel a. C57BL/6 mice
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levels of Yb-type subunits reflected the changes described for CDNB and DCNB
(figures 5.08, 5.09). Maximum induction, with the exception of the DBA/2 males,
occured at the 2-week time-point, the mu class GST being elevated approximately 7
to 8-fold.
5.03 Effect of hvDQDhvsectomv on xenobiotic induction of hepatic
GST in C57BL/6 mice.
5.03a Animal treatment
Males and females of the C57BL/6 strain, hypophysectomised or sham operated at 8
weeks of age, were obtained from Charles Rivers Laboratories, Willmington,
Massachusetts. After transportation the animals were allowed to settle for 2 weeks
prior to the commencement of treatment. After acclimatization, animals were treated
with PB, DEX or TCBOP (2-4 animals per group). Phenobarbital (in saline) was
injected interperitoneally at a dose of 80mg/kg/day for 3 days. Dexamethasone (in
corn oil) was administered at 100mg/kg/day for 4 days. Animals were sacrificed 24
hours after the final treatment session. One interperitoneal injection of TCBOP (in
corn oil) was administered and the animals were killed on the fourth day after
treatment. Control animals received corn oil. Information on the treatment groups
and the number of animals per group is given in table 5.01. Tissues were removed
directly after sacrifice, frozen on dry-ice and stored at -70°C.
Plasma thyroxine (T4) levels in control and hypophysectomised were measured
according to the method of Ratcliffe et at. (1974) to ensure that the operative
procedure had been successful (figure 5.10). However, treatment of mice with
xenobiotic compounds would appear to affect plasma T4 levels Treatment with
TCBOP, for example, causes a sharp decline in T4 levels in sham operated animals.
The mechanism underlying this finding is not known. It may be that xenobiotic
compounds affect the production and/or secretion of thyroid hormones from the
thyroid gland. Alternatively, xenobiotics compounds may affect the subsequent
metabolism of the thyroid hormones. Measurement of body weight changes would in
this case constitute a more reliable method of assessing the success of
hypophysectomy.
Figure 5.08
Electrophoretic analysis of hepatic cvtosols from a). C56BI/6 mice and b). DBA/2
mice treated with TCBOP : a time course.
Cytosols (30pg) from pooled liver samples were analysed by SDS/PAGE on a 12%
(w/v)polyacrylamide gel. The gel was loaded as follows lane 1, rat lung standards;
lane 2, control male; lane 3, control female; lane 4, male treated with TCBOP, 2
week time point; lane 5, female treated with TCBOP : 2 week time point; lane 6, male
treated with TCBOP, 4 week time point; lane 7, female treated with TCBOP ; 4 week
time point; lane 8, male treated with TCBOP : 8 week time point; lane 9, female
treated with TCBOP : 8 week time point; lane 10, male treated with TCBOP : 12 week
time point; lane 11, female treated with TCBOP : 12 week time point, lane 12,










Immunoblottinn of hepatic cvtosols from a). C57BL/6 mice and b^. DBA/2 mice
treated with TCBOP : a time course.
Pooled cytosols (50jig) were subject to SDS/PAGE, transferred to nitrocellulose and
blotted against anti-(rat YbiYbi)lgG. The gel was loaded as follows lanes 1 and
12, rat lung standards (Yc, Yb, Yf); lane 2, control male; lane 3, control female;
lane 4, male 2 weeks TCBOP treatment; lane 5, female 2 weeks TCBOP treatment;
lane 6, male 4 weeks TCBOP treatment; lane 7, female TCBOP treatment 4 weeks;









Table 5.01 - A summary of treatments groups for experimental section 5.03a
Operative status Sex Treatment Group number
Sham male corn oil 2
Sham female corn oil 2
Hypox male corn oil 3
Hypox female corn oil 3
Sham male PB 3
Sham female PB 2
Hypox male PB 4
Hypox female PB 4
Sham male DGX 3
Sham female DEX 3
Hypox male DEX 4
Hypox female DEX 4
Sham male TCBOP 3
Sham female TCBOP 3
Hypox male TCBOP 4
Hypox female TCBOP 4
Abbreviations: hypox - hypophysectomy; PB - phenobarbital; DEX -
dexamethasone; TCBOP - 1,4-bis [2-(3,5-dichloropyridyloxy)]-benzene.
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5.03b Analysis of hepatic GST content.
Figure 5.11 presents, in histogram form, the CDNB activities for control and
hypophysectomised animals treated with inducing agents detailed in section 5.03a. An
increase in CDNB activity of approximately 1.5-fold is observed in sham operated
groups of both sexes on treatment with these compounds. A decline in CDNB activity
was observed after the removal of the pituitary in both control and treated groups.
This most probably reflects the drop in the Yf subunit which occurs after
hypophysectomy (refer to section 4.02 ).
SDS/PAGE and western blotting with anti-mouse GST antisera reconfirmed findings
detailed in section 5.02b. Phenobarbital and dexamethasone cause an induction in Yb-
type subunits, TCBOP again was found to be the most powerful inducer (causing at
least a 5-fold induction of mu class gene family members). The constitutively
expressed Ya subunit (Ya3) was not significantly affected. Removal of the pituitary
gland does not appear to influence significantly the induction of the Yb-type subunits
by these xenobiotics. However, a slight elevation in the level of the Yb class is
observed on hypophysectomy.Treatment with TCBOP was observed to increase the
expression of Yai in the livers of male and female mice. Levels of this subunit were
also elevated after hypophysectomy as was also shown in section 4.02. Both
treatments combined led to a further increase in the expression of this subunit
(figures 5.12, 5.13). The effects of phenobarbital and dexamethasone treatment in
relation to this subunit were not investigated. Hypophysectomy of male mice, as has
been demonstrated previously, leads to a marked decline in the normally high
expression of the Yf subunit. Interestingly, in hypophysectomised males treated with























































Elecrophoretic analysis of hepatic cvtosols from sham operated and
hypQPhysectomised animals treated with xenpbiotic.
Pooled cytosols (30p.g) were analysed by SDS/PAGE on a 12% polyacrylamide
resolving gel. Loadings were as follows
Figure 5,12a
lanes 1 and 15, rat liver markers; lane 2, mouse Yf standard; lane 3, sham male;
lane 4, sham female; lane 5, hypox male; lane 6, hypox female; Iane7, sham male
treated with DEX; lane 8, sham female treated with DEX; lane 9, hypox male treated
with DEX; lane 10, hypox female treated with DEX; lane 11, sham male treated with
TCBOP; lane 12, sham female treated with TCBOP; lane 13, hypox male treated with
TCBOP; lane 14, hypox female treated with TCBOP.
Figure 5.12b
lanes 1 and 12, rat liver standards; lanes 2 and 11, mouse Yf marker; lane 3, sham
male; lane 4, sham female; lane 5, hypox male; lane 6 hypox female; lane 7 sham
male treated with PB; lane 8, sham female treated with PB; lane 9, hypox male
treated with PB; lane 10, hypox female treated with PB.
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Immunoblottinc Qf hepatic cvtosols from sham operated or hypophysectomised mice
treated with xenobictics.
Pooled cytosols (50p.g) were subject to SDS/PAGE, transfered to nitrocellulose and
immunoblotted with antimouse GST antisera. Gel loadings were as follows : - lanes 1
and 10, GST markers; lane 2, sham male; lane 3, sham female; lane 4, hypox male;
lane 5, hypox female; lane 6, sham male treated with xenobiotic; lane 7 sham female
treated with xenobiotic; lane 8, hypox male treated with xenobiotic; lane 9, hypox
female treated with xenobiotic.
No. 1 - control and PB treated animals.
No. 2 - control and DEX treated animals.
No. 3 - control and TCBOP treated animals.
Panel a. anti-(mouse YfYaf) IgG.
Panel b. anti-(mouse Ya-|Yai) IgG.
Panel c. anti-(mouse Ya3Ya3) IgG.
Panel d. anti-(mouse YbiYb-i) IgG.
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Immunoblottino of hepatic cvtosols from sham operated or hvDODhvsectomised mice
treated with xenobiotics.
Pooled cytosols (50pg) were subject to SDS/PAGE, transfered to nitrocellulose and
immunoblotted with antimouse GST antisera. Gel loadings were as follows : - lanes 1
and 10, GST markers; lane 2, sham male; lane 3, sham female; lane 4, hypox male;
lane 5, hypox female; lane 6, sham male treated with xenobiotic; lane 7 sham female
treated with xenobiotic; lane 8, hypox male treated with xenobiotic; lane 9, hypox
female treated with xenobiotic.
No. 1 - control and PB treated animals.
No. 2 - control and DEX treated animals.
No. 3 - control and TCBOP treated animals.
Panel a. anti-(mouse YfYaf) IgG.
Panel b. anti-(mouse Ya-|Ya-|) IgG.
Panel c. anti-(mouse Ya3Ya3) IgG.




Unfortunately TCBOP also causes a decline in plasma T4 levels in intact animals. It is
therefore not possible to determine if the operative procedure was carried out
correctly and the pituitaries completely removed from the animals within this
group.
Northern blot analysis with the rat GST cDNA probes described in section 2.12b
demonstrated that the changes observed at the protein level are also reflected at the
mRNA level (figure 5.14).
McLellan and Hayes (1989) characterised a novel alpha class subunit (Ya-|) in the
mouse, inducible by the dietary additive BHA, which by several criteria is more
closely related to the rat Ya subunit than the constitutively expressed Ya3 (see
sections 1.07,1.08. Pearson et al. (1988) described the BHA-mediated induction of
a class alpha mRNA that encoded a protein sharing 95% homology with the rat Ya
subunit. The rat cDNA clone was used as a probe for this species. Thus, the rat Ya
clone used in these experiments to probe mouse hepatic RNA most probably
hybridises to the Yai subunit rather than Ya3. The pattern of expression at the mRNA
level reflects that seen at the protein when mouse hepatic cytosol is immunoblotted
against anti-mouse Yai antisera. This lends further weight to this assumption.
5.04 Effect of xenobiotic inducing agents on the hepatic GST
profile of little mice
5.04a Animal treatments
Male and female little mice (lit/lit) plus heterozygote (iit/+) and wild-type
controls were obtained from Charles Rivers laboratories (Willmington, USA) at the
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Figure 5.14
Northern blot analysis using the rat Yf GST cDNA clone of sham operated and
hvDQDhvsectomised animals treated with xenobiotics.
Hepatic GST mRNA levels were invesigated by northern blot analysis as described in
section 2.12. Liver RNA (15pg) was electrophoretically size-fractionated using a
1% (w/v) agarose gel with 2.2M-formaldehyde. After electrophoresis, the RNA was
transferred to nitrocellulose and hydridised at 65oC overnihgt with the Yf cDNA
clone. Loadings were as follows
Panels a and b. lane 1, sham male; lane 2, sham female; lane 3, hypox male; lane 4,
hypox female; lane 5, sham male treated with PB; lane 6, sham female treated with
PB; lane 7, hypox male treated with PB; lane 8, hypox female treated with PB; lane
9, sham male treated with DEX; lane 10, sham female treated with DEX; lane 11,
hypox male treated with DEX; lane 12, hypox female treated with DEX; lane 13, sham
male treated with TCBOP; lane 14, sham female treated with TCBOP; lane 15, hypox
male treated with TCBOP; lane 16, hypox female treated with TCBOP.
Panel c. lane 1, sham male; lane 2, sham female; lane 3, hypox male; lane 4 hypox
female; lane 5, sham male treated with TCBOP; lane 6, sham female treated with
TCBOP; lane 7, hypox male treated with TCBOP; lane 8, hypox female treated with
TCBOP.
Panel a. probe - the rat Yf cDNA.
Panel b. probe - the rat Ybi cDNA.




age of 8 weeks. After transportation the mice were acclimatized for 2 weeks before
the commencement of treatment. Phenobarbital and dexamethasone were
administered using an identical treatment regime to that undertaken for the
experiments described in sections 5.02a, 5.03a, i.e. PB was injected
interperitoneally (ip) at a dose of 80mg/kg/day for 3 days and Dex was administered
(ip) at 100mg/kg/day for 4 days. Controls received corn oil. A summary of the
treatment groups and the numbers per group is given in table 5.02
5.04b Analysis of hepatic GST content.
Phenobarbital and dexamethasone were found to effect the hepatic CDNB activity in
the little mice in a similar manner to that observed for wild-type C57BL/6 mice in
previous experiments (figure 5.15). For some reason, treatment of the wild-type
did not lead to an increase in CDNB activity, although Yb levels were induced (figure
5.17) These compounds were found to cause an increase in the level of Yb-type
subunits in the livers of both male and female little mice. The constitutively
expressed Ya3 subunit was unaffected (figures 5.16, 5.17)
As has been previously discussed, little mice were found to exhibit a feminine
pattern of GST expression, the Yf being expressed at female levels. A slight increase
in the Yf was observed in the little males treated with PB. It must be emphasized that
the results presented are of a preliminary nature, further work would have to be
undertaken to confirm this finding.
Immunoblotting does not discriminate between different members of the Yb gene
family. It is not known which Yb subunit(s) are actually being induced after
treatment with PB and Dex. The elevation in DCNB activity observed on treatment
with xenobiotics provides strong evidence that the Ybi subunit is induced, this does
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not exclude the possibility that other members of this family (i.e. Yb2 and Yb3) are
also regulated by this treatment (figure 5.18).
Table 5.02 Response of little mice to xenobiotics - a summary of treatment
experimental treatment groups
Phenotype Sex Treatment Animal No.
Lit/Lit male corn oil 3
female corn oil 3
Lit/+ male corn oil 3
female corn oil 3
+ / + male corn oil 3
female corn oil 3
Lit/Lit male PB 3
female PB 3
Lit/+ male PB 3
female PB 3
+ / + male PB 3
female PB 3
Lit/Lit male DEX 4
female DEX 4
Lit/+ male DEX 4
female DEX 4
+ / + male DEX 4
female DEX 4
Abbreviations: PB - phenobarbital; DEX- dexamethasone.
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Figure 5.15
















Electrophoretic analysis of hepatic cvtosols from little and wild-type mice treated
with xenobiotics.
Pooled cytosols (30jig) were analysed by SDS/PAGE on a 12% (w/v) polyacrylamide
resolving gel. Loadings were as follows lanes 1,8,15, rat liver standards
(Yc,Yb,Ya); lane 2, lit/lit male control; lane 3; lit/lit female control; lane 4, lit/lit
male treated with PB; lane 5, lit/lit female treated with PB; lane 6, lit/lit male
treated with DEX; lane 7, lit/lit female treated with DEX; lane 9, +/+ male control;
lane 10, +/+ female control; lane 11, +/+ treated with PB; lane 12, +/+ female
















Immunoblottina of hepatic cvtosols from little and wild-type mice treated with
xenobiotics.
Pooled cytosols (50^g) were subject to SDS/PAGE, followed by transfer to
nitrocellulose and immunoblotted with anti-mouse GST antisera. The gel was loaded
as follows lanesl and 8, GST markers; Iane2, male control; lane 3, female
control; lane 4, male treated with PB; lane 5 female treated with PB; lane 6, male
treated with DEX; lane 7, female treated with DEX.
Panel a. lit/lit mice





Immunoblottino of hepatic cvtosols from little and wild-type mice treated with
xenobiotics.
Pooles cylosols (50^g) were subject to SDS/PAGE, followed by transfer to
nitrocellulose and immunoblotted with anti-mouse GST antisera. The gel was loaded
as follows lanesl and 8, GST markers; Iane2, male control; lane 3, female
control; lane 4, male treated with PB; lane 5 female treated with PB; lane 6, male
treated with DEX; lane 7, female treated with DEX.
Panel a. lit/lit mice





Levels of DCNB activity in little mice and wild-type C57BL/6 mice treated With
xenobiotic.
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5.05a Summary of results
The effect of phenobarbital and the 'phenobarbital-like inducers', dexamethasone and
TCBOP on mouse liver hepatic GST content of both sexes was investigated in two
strains of mice, C57BL/6 and DBA/2. Preliminary results indicate that xenobiotic
treatment resulted in an induction of the Yb gene family. No sex differences in
induction were apparent. Interestingly though, in the DBA/2 strain DCNB activity
was consistently lower in the female. On western blotting however with anti-mouse
Ybi antisera, no notable differences were detected. The Ya3 and Yf subunits did not
appear to be significantly affected by the administration of these compounds. The
increase in DCNB activity is in good accord with the findings of David and Nerland
(1983) who reported DCNB activity was elevated approximately 5-fold after male
mice were placed on a liquid diet of 0.5mg/ml phenobarbital for 7 days. Di Simplico
et at., (1989) have also reported the mu class GST to be induced after phenobarbital
treatment. Interestingly, a greater effect was observed when mice were administered
phenobarbital as part of a their diet as compared to interperitoneal injection.
Phenobarbital and dexamethasone induced hepatic GST to a similar level, the
induction being more pronounced in the C57BL/6 strain. TCBOP was found to be the
most potent compound of the three tested, CDNB activity was elevated approximately
2-fold after TCBOP treatment, while DCNB activity was increased approximately 5-
fold. Maximum induction of the Yb family with TCBOP occured 2-4 weeks after a
single injection of TCBOP at 3mg/kg. Expression gradually fell back towards control
levels over a 8-10 week period. This occurs in both strains and sexes, again the
C57BL/6 mice exhibited a greater response to the compound. Even at the 12 week
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time-point, DCNB activity had not completely fallen to control values. This prolonged
response to TCBOP is also observed for the cytochrome P-450 family and probably
reflects the biological half-life of this compound which has been shown to persist for
up to 30 days after administration (Poland et al., 1980). Differential sensitivity in
the induction of PB inducible P-450 genes also occurs between these strains
although in the opposite orientation. Induction of the coumarin hydroxylase locus by
phenobarbital is greater in the DBA/2 strain than in the C57BL/6 strain (Wood and
Taylor,1979).
5.05b Mechanism of action
Many factors could influence the differential sensitivity observed between the
strains, for example, differences in the metabolism of these compounds, differences
in receptor concentration or affinity towards these compounds. The mechanism of
phenobarbital induction is not yet understood. No receptor has as yet been identified.
It is not known whether the effects of PB and TCBOP treatment are mediated through
the same pathway, but in the case TCBOP there is some evidence to suggest that a
receptor might be involved (Kende et al.,1985; Kelley et al., 1985) Whether this
putative receptor does exist and is related to the hypothetical PB receptor has as yet
to be established.
The pathway by which polycyclic aromatic hydrocarbons (PAH) regulate the
expression of drug metabolising enzymes has been the best documented system to
date. A high affinity cytosolic receptor, the product of the Ah locus, binds to the PAH
inducer. This ligand receptor complex is translocated into the nucleus where its
interaction with DNA results in the transcription of induction-specific mRNAs. This
will be discussed in more detail in chapter 6 (section 6.07). Certain strains of mice
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including the DBA/2 strain lack the Ah receptor. By contrast, C57BL/6 mice are
positive for this receptor. Both strains were affected by the xenobiotics
administered. This is not surprising as induction of PB-inducible genes occurs by a
separate pathway.
5.05c Dexamethasone ; only a synthetic glucocorticoid?
Hormones of the adrenal are subdivided into two distinct groups, a) The
glucocorticoids which affect fat, protein and carbohydrate metabolism as well as
regulating the immune system, b) The mineralcorticoids which control the sodium/
potassium balance. Glucocorticoid actions are mediated via the glucocorticoid
receptor. Dexamethasone is a synthetic steroid with potent glucocorticoid activity
which has been used to simulate the action of natural glucocorticoids. An increasing
body of evidence emphasizes the point that care must be taken when interpreting
effects observed after dexamethasone treatment.
Tredger et al. (1976) showed that natural glucocorticoids, which are normally
rapidly metabolised, had the opposite effect to the potent long-lasting synthetic
compounds, which are slowly metabolised. Natural glucocorticoids were found to
suppress biphenyl hydroxylase and ethylmorphine N-demethylase activity and lead
to a decrease in cytochrome P-450 levels in rat liver. In contrast, dexamethasone
increased these parameters by approximately 2-fold. In the rat, dexamethasone is a
good inducer of a major member the of the PCN P-450 family, in fact dexamethasone
was found to be a more potent inducer than PCN itself. Natural glucocorticoids were
however very poor inducers of this enzyme. The authors concluded that the induction
noted was not mediated via the glucocorticoid receptor (Schuetz and Guzelian, 1984).
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The fact that dexamethasorie acts in a similar way to phenobarbitai and TCBOP would
suggest that dexamethasone is not acting via the glucocorticoid receptor, although
this possibility cannot be ruled out. Unfortunately to date no data have been presented
on the effect of adrenalectomy or replacement therapy with natural glucocorticoids
on hepatic GST content in either the rat or mouse.
Interestingly, the Yb subunit in the rat has been found to bind dexamethasone-21-
methanesulphonate which is an effective affinity label for glucocorticoid binding
proteins (Homma and Listowsky, 1985). The Yb subunit has also been isolated from
rat nucleus complexed to DNA (Bennet et at., 198b). There may be a possibility that
GST might also play a role in the intracellular transport of hormones, acting in this
case as binding proteins. It is difficult to establish whether the presence of GST in
the nucleus is a genuine phenomenon or whether it is simply an artefact of the
preparation
5.05d The involvement of the pituitary oland in the induction of mouse hepatic GST.
Hypophysectomy in the rat has been found to enhance the induction of certain
members of the P-450 family inducible by phenobarbitai. Removal of the pituitary
has been found to increase the basal level of expression of these P-450 genes,
suggesting that certain factors in the pituitary normally repress their expression.
This increase in base-line level is further enhanced by treatment with PB-type
xenobiotics. Evidence presented suggests that the pituitary factor responsible for
this suppression is growth hormone (Yamazoe et at., 1987).
The induction of the mu class family was not significantly affected by
hypophysectomy, this indicates that the pituitary is not involved in influencing the
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induction of this class by xenobiotics. Further confirmation that growth hormone or
its absence does not affect the induction of hepatic GST by xenobiotic compounds is
shown in section 5.04 where little mice of both sexes were found to respond to the
administration of xenobiotics in a normal fashion.
However in the case of the Yai alpha class subunit, hypophysectomy leads to an
increase in the expression of this subunit in both male and female C57BL/6 mice.
This has been demonstrated previously, little mice are found to have increased levels
of this subunit over that found in the heterozygote and wild-type controls (see
section 4.03.). It would therefore appear that the Yai subunit is under repressive
control control of growth hormone. TCBOP treatment also induces the level of this
subunit. With both treatments combined, an additive effect on the induction of this
alpha class member is noted, particularly in the female.
No sex differences in the induction of hepatic GST was readily apparent in either
control or hypophysectomised animals in regard to the Yb-class GST. This is in
contrast to the rat where PB and 3-MC induce hepatic GST in a sex-specific manner
(Igarashi et a!., 1987). PB treatment was found to induce CDNB activity by a greater
fold induction in the adult male as compared to the female, thereby increasing the
differences between the sexes. Treatment with 3-MC elicited a greater response in
the female rat, lessening the difference between the sexes. A similar situation occurs
for other xenobiotic-inducible enzymes which are sexually differentiated (see Skett,
1987). Thus, sex-specific effects noted in foreign compound induction seem to occur
when the proteins themselves are also sexually differentiated.
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5.05e Further work
These data are of a preliminary nature, a more detailed study of TCBOP and its effects
on hepatic GST content would be very interesting, with particular attention to the mu
class GST. Individual Yb-type subunits could be isolated and purified by reverse-
phase h.p.l.c. after treatment with TCBOP. Evidence suggests that the Ybi subunit is
induced after administration of this compound but it is possible that other members
of the family are also more highly expressed.
In respect to the induction of P-450 genes by TCBOP in the mouse, this compound is
estimated to be 650-fold more potent than phenobarbital in its effect. In the rat
however, administration of TCBOP at a similar concentration to that given in the
mouse has no effect on P-450 levels. Its thought that a species difference in the
presence of the receptor for TCBOP is the reason which belies this finding (Poland et
at., 1981). With this hypothesis in mind, the prediction would be that TCBOP would
not affect the induction of hepatic GST in the rat. Furthermore, it would suggest that
phenobarbital and TCBOP, although having similar affects with different intensities
between species, do not act by an identical route. This work presented within this
thesis has concentrated exclusively on the liver, however, TCBOP has also been
shown to affect other tissues most notably the intestine and also the kidney (Poland et
al., 1980). Very little data is available on the effects of xenobiotics in extrahepatic
tissue. An investigation into the effects of the long-lasting TCBOP on tissues other
than the liver would be worthwhile.
Only a brief discussion on the effects of foreign compounds on hepatic GST content has
been given in this section. A fuller account and an in-depth discussion of the
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molecular mechanism by which these compounds exert their effect is given in
chapter 6 section 6.08.
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Chapter 6 - Discussion
6.01 Sex-specific regulation of mouse hepatic YfYf
The major aim of the work presented within this thesis was to investigate the
mechanism which gives rise to the marked sexual dimorphism in the expression of
the mouse hepatic Yf subunit. The evidence presented strongly suggests that the male
sex hormone testosterone regulates the Yf GST through an indirect mechanism.
Androgenic effects on the Yf GST are mediated via growth hormone or more
specifically, through the growth hormone secretory pattern. Figure 6.01 illustrates
the proposed mechanism.
In the male, soon after birth, a brief surge in testosterone production in some
manner, as yet not understood, pre-programmes the hypothalamus such that the
pituitary will secrete growth hormone in a pulsatile fashion when testosterone is
present. Testosterone, produced at the onset of puberty by the Leydig cells of the
testes, acts on this "pre-set" hypothalamus which in turn stimulates the pituitary to
produce growth hormone in a sex-specific manner.
Two factors are produced by the hypothalamus which control the release of growth
hormone from the pituitary somatotrophs. Somatostatin exerts a negative effect on
growth hormone production, and growth hormone-releasing factor (GHRF), which
acts positively on the pituitary to stimulate the synthesis and secretion of growth
hormone. The finer details of this pathway are not completely understood yet but the
evidence suggests that testosterone in some manner regulates the production of
hypothalamic somatostatin to produce the sex-specific rhythm of growth hormone
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secretion (see Zaphiropoulos et al., 1989). The male-specific secretory mode in
some manner signals the expression of male-specific proteins in the liver.
Interference in this pathway, either through mutation (as in the mouse model) or
through inactivation of particular parts of the pathway (by for example surgery,)
leads to a feminine pattern of gene expression. Marked on the diagram (figure 6.01)
are the disruptions to this pathway which occur in the various models which have
been investigated during the course of this work.
How growth hormone binding to its receptor on the surface of the liver actually
regulates expression of the hepatic YfYf and other sexually dimorphic liver proteins
is not known. The proposed mechanism by Norstedt and Palmiter (1984), presented
and discussed in section 4.05c uses the dichotomy of growth hormone action i.e. its
ability to act directly through its receptor or indirectly through the somatomedins,
to fulfil its dual function in regulating both male and female specific expression.
Obviously this represents a key question in this area which should be addressed over
the next few years.
6.02 Why is the Yf subunit subject to sexual dimorphism in
mouse liver?
The reason behind the overexpression of Yf in male mouse liver has not yet been
uncovered but the difference in the levels of this polypeptide between the sexes is
very marked. Expression of the Yf in the male mouse is approximately 10-fold
higher than in the female and two orders of magnitude higher than seen in the rat
liver of either sex (Hatayama et al., 1986).
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Figure 6.P1
Scheme for the regulation of mouse hepatic GST YfYf levels.
In the male, a brief surge of testosterone in the neonatal period in some manner pre-
programmes the hypothalamus in a male-specific fashion. At the onset of puberty,
testosterone in some manner stimulates the male-specific pattern of growth
hormone secretion. It is believed that testosterone controls the release of the
hypothalamic factor somatostatin which acts to inhibit growth hormone release from
the pituitary. The male-specific pattern of growth hormone release, by some
pathway as yet unidentified, acts to regulate the expression of the Yf subunit in
mouse liver. Marked on the diagram are the disruptions to this pathway in the
various models studied during the course of this work, which result in a female level
of YfYf expression.
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As regards other sexually differentiated hepatic proteins, it is thought that the
major purpose behind this dichotomy is the maintenance of the proper hormonal
balance and the ability to respond to these hormones. This obviously differs between
the sexes. It is conceivable that GST YfYf is also involved in maintaining a male-
specific metabolic pathway, acting on a physiological substrate as yet unidentified.
Glutathione S-transferases, in addition to their GSH conjugating activity have also
been shown to have isomerase activity, catalysing the conversion of A5-3-oxo-
steroids to the corresponding A4-isomers (Benson et al., 1977). Steroids have been
reported to interact with the human pi class GST in vitro both as substrates and
inhibitors. However, the kinetics of the reaction would indicate that these
interactions are of minor physiological significance (Dibbelt et al., 1988). This
finding suggests steroids are unlikely candidates for the potentially sex-specific
substrate for the mouse Yf subunit. However due to the possibility of species
differences, this cannot be entirely dismissed.
Until recently, the pi class GST family was thought to contain a single member, the
product of one gene (Okuda et al., 1987). A recent finding challenges this
assumption. Fatty acid ethyl esters (FAEE) are the end products arising from the
nonoxidative metabolism of alcohol. These products are synthesized by two
synthetase enzymes . The major synthetase (pi 4.9) has recently been purified from
human heart muscle. The N-terminal 23 amino acids have been sequenced and found
to be 73% identical to the rat Yf GST and 82% identical to the N-terminal sequence
of the human Yf GST purified from human heart. Catalytic activities were
interchangeable, in that FAEE synthetase was found active in catalysing the
conjugation of CDNB and GSH, while a homogeneous GST isolated from bovine liver
(Mr 26,000) was active in the formation of FAEE (Bora et al., 1989)..
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The Yf has also been shown to be reactive with lipids. Ketterer and his co-workers
demonstrated that form 7-7 (YfYf) purified from primary rat hepatoma had Se-
independent GSH activity towards lipid peroxides (Meyer et al., 1985). GST P
(YfYf) was found by Sato to have significant activity towards 4-hydroxynonenal, a
potent lipid peroxide, although the rat Yk subunit has highest activity (Sato, 1988,
Danielson et al., 1987). Tsuchida et al. (1987) reported that GST form 7-7 also has
significant leukotriene C4 synthase activity, although again a mu class GST purified
from rat brain (Yn-|Yni) has greatest activity.
In rat, no physiological substrate for the Yf GST has been identified. Although, as
detailed above, it would appear to interact with long chain fatty acid compounds,
demonstrating diverse catalytic activities. Bearing in mind the sex-specific
expression of Yf in the mouse and its as yet hypothetical role in a male-specific
process of some sort, possible physiological candidates might be the prostaglandins
or leukotrienes. These are signal- type molecules derived from arachidonic acid. The
prostaglandins, of which there are nine distinct classes, are involved in a wide
variety of physiological processes and would appear to modulate the action of
hormones rather than act as hormones themselves. Thus, Yf might be involved in the
formation of a specific class of these signaling molecules and in this way play a role
in a male-specific process. It must be emphasized that this is purely hypothetical,
but it would certainly be of interest to determine if the mouse Yf GST had any
catalytic activity to the aforementioned putative substrates.
An analysis of the 5' flanking region of the human genomic Yf sequence (Cowell et
al., 1988) reveals a region from position -100 to +300 where the G+C content
reaches 72% and the proportion of CpG dinucleotides is 9.2%. This description is
characteristic of HTF islands (Hpa II tiny fragments). These regions are
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constitutively hypomethylated and are particularly associated with house-keeping
genes, which are intrinsic for the maintenance of all cell-types. Hypomethylation is
a feature associated with genes which are under active transcription. It may be that
Yf has a fundamental biological role in at least certain cell-types. Findings described
below, linking the expression of the rat hepatic Yf GST with that of genes involved in
cellular growth and division, suggest that in the rat hepatocyte the Yf subunit might
have a role to play in preneoplastic proliferation. If that is the case in the mouse,
then it might have profound biological consequences for the animal. This will be
discussed in section 6.03.
6.03 Regulation of hepatic GST in the rat
6.03a Expression of the Yf subunit in altered hepatocvte nodules
With the exception of the mouse, all other rodent species studied so far including the
rat are found to have only trace amounts of the Yf subunit in the liver (Hayes et al.,
1987). By contrast, extrahepatic rat tissue, including the kidney, lung, spleen,
thymus and small intestine, contain significant amounts of this GST. Rat testes, like
the liver were found to exhibit extremely low levels of this subunit (Hayes and
Mantle, 1986a). No sex difference in the hepatic level of the Yf subunit has been
reported in the rat. Due to the low constitutive expression of this subunit in this
species, any slight differences might go unnoticed.
Administration of a single dose of diethlynitrosamine (DEN) followed by three
consecutive doses of 2-acetlyaminofluorene (2-AAF) plus a partial hepatectomy
induces foci of altered hepatocytes referred to as preneoplastic nodules (also
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persistent / hyperplastic nodules). This model is used to study the stages involved in
chemically -induced hepatocellular carcinoma and is referred to as the Solt-Farber
model or the resistant hepatocyte model (Solt and Farber, 1976). As the term
suggests, preneoplastic nodules are thought to serve as precursors in the generation
of liver cancer.
Changes in the glutathione S-transferases and other drug-metabolising enzymes
occur during the formation of preneoplastic nodules. In general, Phase I drug-
metabolising enzymes are depressed whereas Phase II enzymes are elevated. In
addition to GST, the levels of DT-diaphorase and epoxide hydrolase are found to be
increased in these altered hepatocytes (Pickett et al., 1987). As regards individual
GST subunits, all except Yb2 (which is depressed) are elevated in nodule-bearing
livers. The Yf GST is dramatically increased during this precancerous stage to levels
between 10 and 100-fold higher than found in normal rat liver (Satoh et al 1985).
The derepression and /or induction of the Yf is a rapid event occurring soon after the
initiation of the process. On immumohistochemistry, small foci of hepatocytes are
found to stain heavily with antisera raised against YfYf 48 hours after a single
initiating dose with hepatocarcinogen (Moore et al., 1987). Elevation in other
preneoplastic markers such as y-glutamlytranspeptidase were not apparent at this
stage. A similar sequence of events in respect to Yf is observed using models other
than the Solt-Farber to induce neoplasia. (Eriksson et al., 1983; Roomi et al.,
1983). Considerable attention has therefore focussed on the Yf as a possible marker
for preneoplasia.
Unlike other drug-metabolising enzymes, GST YfYf is not affected by xenobiotic
compounds such as phenobarbital and 3-methylcholanthrene (Roomi et al., 1982;
Satoh et al., 1985). However lead nitrate, which induces hepatocyte cell
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proliferation has been found to cause an elevation in Yf GST levels only at a dose
which stimulates cell proliferation (Roomi et at., 1987). Other changes occur in
lead nitrate treated livers which are similar to those exhibited during preneoplasia.
It has been be noted that partial hepatectomy in the rat does not induce YfYf (Power
et at., 1987). This would suggest that an increase in the levels of YfYf is not a
normal feature of cellular growth and proliferation. It is possible therefore that the
Yf is being induced after lead nitrate administration as part of the preneoplastic-
type proliferative response rather than a direct effect of the compound, although this
possibility has not been ruled out. Induction of cell proliferation by lead nitrate
might in future serve as a useful model in which to study those changes commonly
associated with hepatocellular carcinoma.
The role of GST YfYf in the development of neoplastic foci in the liver has yet to be
clarified. The induction of this enzyme during the early initiation stages in all
models tested presents the possibility that Yf might have a fundamental function in
this process, perhaps playing a role in the initiation of altered growth in the
hepatocyte. Recent findings linking the expression of the Yf GST to genes involved in
the control of cellular growth lends credence to this supposition. This will be
discussed in detail in section 6.03b. Other functions have also been proposed which
are briefly discussed below.
Altered hepatocyte foci are resistant to the effects of cytotoxic agents (Farber 1984
a,b). In view of the changes observed in the drug-metabolising enzymes of both
classes, it is not unduly surprising that preneoplastic cells exhibit less
susceptibility than normal cells to toxic chemicals. It may be that the Yf GST subunit
is involved in the generation of this resistant phenotype, although it should also be
noted that other GST forms are also induced which probably contribute to the
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resistant phenotype. The Yf GST has been reported by Ketterer and co-workers as
having Se-independent peroxidase activity towards lipid peroxides (Meyer et al.,
1985). Sato and his colleagues found this subunit to have high activity towards 4-
hydroxynonenal, a potent lipid peroxide derived from arachidonic acid (Sato, 1988).
In view of these findings, Sato has speculated that the induction of the Yf GST may be
related to the prevention of lipid peroxidation which has an important role to play in
tumour promotion (Sato, 1988).
Interestingly, YfYf has been detected in the nucleus by immunohistochemistry.
Preneoplastic hepatocytes, preneoplastic foci from rat hamster pancreas and human
cervix dysplatic cells have been shown to contain Yf in the nucleus. Normal
hepatocytes from the normal male mouse also show nuclear staining. Other GST
subunits were not detected in the nucleus (Sato, 1988). This is in contrast to Bennet
et al. (1986), who found the Ybi subunit complexed to nuclear hepatic DNA,
although this was in normal rat liver. The significance of these findings are not
clear. It may be that the Yf serves as a carrier ligand for some compound as yet
unidentified. Alternatively, as part of a general protective function, GST YfYf might
form a "final barrier" of drug-detoxification enzymes attempting to prevent
reactive electrophiles from interacting with the DNA. Obviously, further work will
have to be undertaken to confirm these findings and to investigate the function of GST
YfYf found within a nuclear location.
6.03b Oncogene mediated expression of the rat hepatic Yf GST.
The mechanism underlying the dramatic derepression of the Yf GST subunit during
preneoplasia has been the subject of considerable interest. A genomic sequence for
the rat Yf GST was obtained by Okuda et al. (1987). Multiple regulatory elements
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have been described which are located 5' to the coding region. Cis-acting elements
were analysed by fusing various lengths of the 5' flanking sequence to the bacterial
chloramphenicol transacetylase gene and transfecting these constructs into a rat
hepatoma cell-line (Sakai et al., 1988).
Two enhancing elements have been identified 2.5kb and 61 bp upstream from the
transcription start site. The upstream enhancer was divided into two domains GPE1
and GPE2. The GPE 1 domain and the downstream enhancer sequence (at 61 bp)
contain a 12-0-tetradecanoylphorbol-3-acetate (TPA) responsive element (TRE).
A silencer region was also described 400bp upstream from the cap site which may
be important in the repression of Yf activity in the normal rat liver. Moreover, the
endogenously expressed Yf GST in rat fibroblast 371 cells was also responsive to
TPA.
Phorbol esters such as TPA are potent tumour promoters, capable of potentiating the
effect of subcarcinogenic doses of an initiating carcinogen. Among the genes
transcriptionally activated by TPA are the oncogenes c-myc and c-fos (Angel et al.,
1989). It has been suggested that the alterations in gene expression following TPA
administration involve a signal transduction cascade, triggered by protein kinase C.
The human pi gene has also been found to contain TRE sequences in the promoter
region (Cowell et al., 1988)
The oncogene c-Ha-ras has also been shown to act through TRE-like sequences
(Imler et al. 1988). This could be highly significant in view of the the fact that
many human tumours are ras-related and GST has been reported also being induced
in a variety of tumour types (Shea and Henner, 1987).
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Recently, it has been shown by two independent groups, that transfection of the ras
gene into cultured cells results in the induction of the Yf GST together with other
genes involved in hepatocarcinogenesis or the drug-resistant phenotype. Burt et
al.( 1988) transfected the viral oncogenes v-Ha-ras and v-raf into a rat liver
epithelial cell-line (RLE). A marked induction of the Yf GST was observed in the
oncogene transfected cells. P-glycoprotein, a 170,000 ATPase-dependent membrane
transport protein believed to actively pump cytotoxic agents out of the cell, was also
elevated in these cells. Transfected cell lines were found to have enhanced resistance
to the effects of the anticancer drugs, vinblastine and adriamycin, as well as the
hepatocarcinogen, 2-acetylaminofluorene.
Li et at., (1988) reported similar findings. The cellular ras gene linked to a
metallothionein promoter, inducible with zinc, was transfected into rat liver
epithelia cells. Again, elevation in the levels of the Yf GST was observed and also in
y-glutamlytranspeptidase (y-GT), another GSH-dependent enzyme elevated during
chemically-initiated carcinogenesis of the liver.
Data demonstrating the inducibility of the Yf with tumour promoters and genes
linked to cellular growth and division, could explain the increase in Yf noted in
preneoplasia and in many tumour types. Activated ras genes do not appear to be a
common feature of carcinogenic lesions (Reynolds et at., 1986), which suggests that
induction of YfYf might be a common feature of the initiation of transformation by
several mechanisms. Power et at. (1987) have concluded that elevation of Yf is
particularly associated with the initiation of the transformed phenotype and does not
have a role to play in either cell proliferation or protection against toxicity.
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in conclusion, the question still remains as to the function of this protein (if any)
during the carcinogenic process. From the findings of various laboratories, which
have been discussed above, it would appear that the Yf subunit has some role to play
in this process. Whether this is in its capacity as an enzyme of detoxification and its
function is protection of cellular components during this process, or whether it has
a more fundamental role to play in cell division and proliferation has yet to be
established.
6.03c The role of growth hormone in the sexualiv differentiated induction of Yf
riurinn preneoolasia
The induction of liver cancer in the resistant hepatocyte model is markedly sex-
dependent. Much faster growth of preneoplastic lesions and an earlier development of
hepatocellular carcinoma is observed in male rats as compared to females (Blank et
at., 1984). This sex-difference in susceptibility to chemical carcinogenesis appears
to be mediated via the growth hormone secretory pattern. Continuous infusion of
growth hormone into male Wistar rats leads to a decline in the development of
preneoplastic lesions to that observed in the female. (Blank et at., 1986; 1987).
Recently, Gustafsson and his co-workers have shown that sex-differences exist in
the expression of c-myc and c-fos during the preneoplastic stage (Halstrom et at.,
1989a). Moreover, the growth hormone secretory pattern regulates the sex-
specific expression of c-myc and c-fos during the early stages of chemical
carcinogenesis (Halstrom et at., 1989b).
The marked induction of the Yf GST during the preneoplastic process has also been
reported to have a remarkable sex-dependence in favour of the male (Sato,1988).
As has been discussed above, the oncogenes c-myc and c-fos are also expressed
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during the early stages of this process in a sex-dependent manner. These oncogenes
have also been reported as being inducible with TPA suggesting that the genes
encoding these proteins also have TRE sequences contained within the 5' noncoding
region (Angel et al., (1989).
The pattern of regulation would appear to be very similar in certain respects
between these oncogenes and the Yf GST and further suggests a common regulatory
link between the genes involved in cellular proliferation, inappropriate or aberrant
expression of which can lead to cancer, and the Yf GST. The significance of these
findings are not clear.
6.04 Sex-related incidence of hepatocarcinoma in the mouse.
Kemp and Drinkwater (1989a) have reported on the susceptibility of six inbred
strains of mice to chemically-induced hepatocellular carcinoma. Between the males
of each strain a significant variation in the incidence of liver tumours was observed.
Females from all strains were significantly more resistant to the effects of
hepatocarcinogens, tumour frequency was much lower than in the male and no strain
differences were observed when the females from different strains were compared.
Furthermore, no sex differences were observed in the development of lung tumours
suggesting that this difference in susceptibility was not manifest in all tissues.
Sex differences in tumour susceptibility are believed to be related to the tumour
promoting ability of androgens. Neonatally castrated mice display a similar
frequency of liver tumours to that seen in the female (Toy, 1981). Females
administered androgens show a higher susceptibility to chemical carcinogenesis than
normal females (Moore et al., 1981). Tfm males lacking the androgen receptor are
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also found to exhibit a feminine frequency of liver tumours (Kemp and Drinkwater,
1989b).
It is interesting to note that all changes detailed above also effect levels of the Yf
subunit in a manner which correlates with the frequency of tumour development.
This might simply relate to general changes in drug-metabolising enzymes which
render the animal more susceptible to the effects of carcinogens. It is worth noting
that in the mouse, females metabolise drugs more efficiently than in the male
(MacCleod and Shapiro, 1989).
Alternatively, the expression of high levels of Yf in the male mouse, a protein which
has been associated in the rat with the preneoplastic process in the liver, might be
associated with this observed predisposition to liver cancer, both spontaneous and
induced. An investigation into the expression of the Yf and its relationship to mouse
oncogene expression might provide a very useful insight into this question.
6.05 Sex-specific expression of GST subunits in the normal
mouse liver.
Sex-differences in the hepatic GST content in normal rat liver have been reported
(Kaplowitz et al., 1975; Hales and Neims, 1976; Lamartiniere 1981; Igarashi et
at., 1985). Male rats exhibit significantly higher levels of Ybi as compared to the
female with a concomitantly higher activity towards DCNB, approximately 2-3 -fold
higher. Alpha class subunits are expressed at higher levels in the female. Thus, sex-
differences exist in activity towards organic peroxides.
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The mechanism underlying this dimorphic expression of GST is at present unclear.
Lamartiniere (1981) investigated the role of the hypothalamic-hypophyseal-
gonadal axis on the expression of rat hepatic GST. The effect of a variety of endocrine
treatments on enzyme activities towards CDNB and DCNB were monitored. The
results obtained suggest the pituitary has a role to play in the sexual differentiation
of rat hepatic GST, but the findings are not entirely clear.
In contrast to the mouse, postpubertal castration in the rat had no effect on the high
DCNB activity found in the male. Administration of exogenous androgen or oestrogen
had no effect on males or gonadectomised males. DCNB activity was observed to
i
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increase in ovarectomised females treated with testosterone.
Neonatal castration of male rats resulted in a significant decrease in DCNB activity.
This would suggest that the the Yb gene family is neonatally imprinted at birth,
however, treatment with testosterone either in the neonatal period or in adulthood
was not capable of restoring the phenotype. Again this is in contrast to the mouse
where testosterone, at the appropriate dose, was able to restore, at least partially,
the sex-specific expression of YfYf after castration.
Hypophysectomy was found to lead to an increase in DCNB activity in both the male
and the female. Transplantation of ectopic pituitaries under the kidney capsule
reversed this effect as did treatment with growth hormone. This would suggest that
growth hormone is acting in a negative fashion in this system. However, lesions of
the arcuate nucleus of the hypothalamus, which would also lead to a shut-down in
growth hormone production and secretion, and indeed was shown to cause an decline
in plasma growth hormone levels, resulted in a decline in DCNB activity. This is
contradiction with earlier results, if growth hormone serves to repress hepatic
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DCNB activity, then this treatment would be expected to increase activity as is the
case on hypophysectomy. Hales and Neims (1976) reported that on hypophysectomy
DCNB activity in the male was decreased as was the level of alpha class GST in the
female. This is more in accordance with findings in other systems. Obviously further
work will be required to resolve this discrepancy between these reports as they
suggest different mechanisms of growth hormone action.
Interestingly, a putative clone encoding the rat Ybi subunit has been isolated from
the rat ventral prostate (Chang et al., 1987). This clone differs by two residues
from that isolated and characterized by Ding et al. (1985) from rat liver. Whether
this is a novel form of Ybi, expressed in a tissue-specific manner remains to be
established. Messenger RNA encoding this subunit was found to be repressed by
androgens. The possibility raised however is that tissue-specific expression of GST
might also occur at the level of regulation, in that the same factor might exert very
different responses on the same gene between tissues .
6.06 Endogenous factors controlling aene expression
The glutathione S-transferases are subject to a marked tissue-specificity in their
expression. This has been noted in rat, mouse and man (Hayes and Mantle, 1986;
Hayes et al., 1987). These differences are observed at the pre-translational level at
least in the rat (Sato et al., 1987). Sadly, virtually nothing is known of the
endogenous factors involved in maintaining the qualitative and quantitative
differences between tissues.
More information has come to light on the sex-specific control of GST. Certainly in
the mouse, testosterone and growth hormone mediate these differences in expression
249
(Hatayama et al., 1986; this thesis). In the rat, although the situation is not as
clear, these hormones would also seem to play a role in this process (see section
6.05). The work presented within this thesis was primarily concerned with the
regulation of the mouse hepatic Yf subunit. It was of interest to note that that the
mouse Yai subunit would also appear to be under the control of growth hormone,
although in this case growth hormone would seem to be having a negative effect on the
expression of this subunit. Further work would have to undertaken to confirm this
finding.
Very little information is available on the role of other endocrine systems in the
control of GST expression. While some reports are available on the effects of thyroid
hormones on hepatic GST content (Arias et al., 1976; Williams et al., 1986; Beckett
et al., 1988), nothing is known of the adrenals and their effect on GST levels either
in hepatic or extrahepatic tissue. It is also important to emphasize that within a
tissue many cell-types exist which also display differences in GST content. In
future, it will be crucial when investigating the regulation of these genes to
ascertain via immunohistochemistry which cell types within the tissue are actually
affected by e.g. xenobiotic treatment. Expression of GST in many individual cell types
will probably be mediated via the elusive factors which govern the cellular
differentiation process.
Hopefully within the next few years more attention will be paid to this vitally
important, but untapped, area of research within this field, providing a better




Studies of rat PB-inducible P-450 enzymes showed that the induction of certain
members of this family by PB was enhanced by hypophysectomy. Growth hormone
appeared to be involved in the suppression of basal levels of these proteins, which
were enhanced when the pituitary was removed, and further increased by xenobiotic
treatment. This work prompted a study, detailed in chapter 5, into the effect of
phenobarbital on the mouse hepatic GST content and possible modulation of this
induction by the pituitary, more specifically growth hormone (Yamazoe et at.,
1987).
Dexamethasone, a synthetic glucocorticoid, and TCBOP, a very potent PB-like
inducer in the mouse were also investigated. Both of these compounds, and
phenobarbital itself, were found to cause an elevation in the mu class in both the
C57BL/6 and DBA/2 strains. The constitutively expressed alpha class subunit (Ya3)
is relatively unaffected by xenobiotic treatment. TCBOP, in addition to being the most
potent inducer of the mu class GST, also caused an elevation in the level of the BHA-
inducible Ya subunit (Ya-|). Removal of the pituitary had a similar effect, and when
both treatments were combined an additive, enhanced induction was observed.
Hypophysectomy did not significantly effect the induction of the mu class GST.
Reports by other workers provide evidence to support these findings. Phenobarbital
was found to increase hepatic levels of Yb-type subunits in the mouse. Interestingly,
a greater effect was observed when phenobarbital was administered in the diet. (Di
Simplico et at., 1989). David and Nerland (1983) found DCNB activity to be induced
5-fold in mouse liver when phenobarbital was administered in the diet.
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All compounds tested to date on the mouse, including the dietary additive BHA and
cafestol palmitate predominantly affect the mu class GST(Di Simplico eta!., 1989).
A lesser effect, or no effect at all, is observed with other GST classes (exception
Ya-|). This is in contrast to the rat where both alpha and mu class GST members are
induced in response to xenobiotic treatment. As with almost all aspects of GST
research, the rat provides the best characterised model in regards to the mechanism
underlying the regulation of GST by xenobiotics. This is dealt with in next section.
6.08 Xenobiotic Regulation of Rat Hepatic GST
Phenobarbital and 3-methylcholanthrene, classical inducers of two major
xenobiotic regulated P-540 families, have been extensively studied with respect to
their effects on rat hepatic GST. Early studies indicated that GST levels are elevated
after the administration of phenobarbital and 3-methylcholanthrene (Kaplowitz et
at., 1975; Hayes et at., 1979). The increase in protein content is also paralleled by
a corresponding increase in mRNA levels. Messenger RNA encoding the Ya, Ybi and
Yb2 subunits are significantly elevated by treatment with these compounds. The
mRNA species encoding the Yc subunit is only marginally affected. Further studies
demonstrated that members of the alpha and mu classes are transcriptionally
activated by xenobiotic treatment (Pickett et at., 1987;1988)
Very little information is available on the underlying mechanism which mediates the
effects of phenobarbital on the expression of drug-metabolising enzymes. In
contrast, the regulatory pathway by which 3-methylcholanthrene and other
polycyclic aromatic hydrocarbons affect the expression of specific genes has been
extensively documented (for review, see Eisen eta!., 1983).
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A cytosolic receptor, termed the Ah receptor binds avidly planar aromatic
hydrocarbons such as TCDD, 3-methylcholanthrene and (5-naphthoflavone. The ligand
receptor complex is then translocated to the nucleus where, by some manner as yet
unclear, transcriptional activation of PAH-inducible genes occurs. A diagram of the
possible pathways in which P-450 and GST expression might be mediated by the Ah
locus is presented in figure 6.02.
In this model, the Ah receptor binds polycylic hydrocarbons forming a ligand
complex that is translocated to the nucleus and interacts with positive regulatory
elements Xenobiotic Responsive Elements, (XRE) leading to the transcriptional
activation of the P-540 gene and possibly GST genes. Alternatively, the receptor-
ligand complex could potentially interact with another regulatory gene leading to the
transcriptional activation of the regulatory gene, producing a transacting protein
which could stimulate the transcription of the GST gene.
Talalay has suggested the possibility that GST substrates act as inducers of GST, by
some mechanism not specified (Talalay et a/.,1988; Spencer et at., 1989). This
suggests another possible variation to the model presented in figure 6.02.
Transcriptional activation of PAH- inducible P-450s results in a corresponding
increase in the levels of protein. This, he speculates, would also result in higher
concentrations of reactive intermediates which are generated by the metabolism of
P-450 substrates. These compounds are of course potential substrates for GST
enzymes and, according to the model proposed by Talalay, they would also act to
induce GST levels. Thus, in this model, elevation of GST levels after xenobiotic
treatment are a consequence of P-450 production and metabolism rather than any
direct effect of the Ah receptor ligand on GST transcriptional activation.
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Cytochrome P-450 Glutathione S-Transierase
Figure 6.02 P-450 and GST regulation bv polvcvclic aromatic hydrocarbons
A model to account for the regulation of the glutathione S-transferase gene
expression is presented along with the current model governing P-450 gene
regulation by polycyclic aromatic hydrocarbons. In this model the Ah or dioxin
receptor binds polycyclic aromatic hydrocarbons (I) forming a receptor ligand
complex that is translocated to the nucleus and interacts with positive regulatory
elements leading to the transcriptional activation of the P-450 gene and possibly the
glutathione S-transferase Ya gene. Alternatively, the receptor ligand complex (I.R)
could potentially interact with a regulatory gene producing a transacting protein
which regulates the expression of the glutathione S-transferase Ya gene. Finally, in
the P-450 system a repressor protein (X) is thought to regulate negatively the
constitutive expression of the P-450 in the absence of ligand.
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It has not yet been fully established which of these models is correct i.e. whether the
Ah locus is acting directly to mediate the transcriptional activation of GST genes or if
the effect is indirect through the activation of an another regulatory factor or P-
450 metabolic products which would in turn act as both substrates for, and inducers
of, GST. Whichever pathway operates in this instance, the Ah receptor is necessary
for the induction of GST by polycyclic aromatic hydrocarbons (Telakowski-Hopkins
et al., 1988; Prochaska et al., 1989).
Pickett and his co-workers, in an elegant series of experiments have investigated
the 5' regulatory region involved in the induction of the rat Ya gene by polycyclic
aromatic hydrocarbons. Telakowski-Hopkins et al., (1988) constructed chimeric
genes using various lengths of the 5' noncoding sequence of the rat Ya gene fused to
the bacterial chloramphenicol acetlytransferase gene (CAT). The expression of CAT
is determined by the regulatory elements contained within the 5' region. Two ex¬
acting regulatory elements were identified, located between 650 - 1550 bp
upstream from the transcription start site. One was required for the induction of the
Ya subunit by pNF and other was necessary for maximum basal levels of expression.
With respect to the PAH-inducible P-450 gene family, gene expression has been
shown to be mediated via xenobiotic responsive domains, located upstream from the
transcriptional start point. These xenobiotic domains have the properties of
transcriptional enhancers. A consensus sequence, given below has been identified
with an invarient 6 bp sequence (underlined) which is conserved between human,
rat and mouse.
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PAH-INPUCIBLE ELEMENT - CONSENSUS SEQUENCE
5' GNTAGCTGGG 3'
C GG
A more detailed account of the rat Ya pNF-inducible element was given by Dr C.B.
Pickett at the 3rd International GST conference held in Edinburgh, 1989. The ex¬
acting PAH-inducible element is located 697 - 723 bp upstream of the
transcriptional start site and appears to contain a unique DNA sequence which
apparently is not related to the P-450 consensus sequence detailed above (Pickett et
al., 1989). This suggests that the Ah locus mediates the induction of P-450 and GST
by xenobiotics via different routes. Obviously further studies will need to be
undertaken to establish if this is indeed the case.
6.09 Regulation Of Mouse Hepatic GST bv the Ah locus
Recombinant inbred strains of mice have been identified which differ in their
response to polycyclic aromatic hydrocarbons such as TCDD, 3-MC and pNF.
Responsive mice such as the C57BL/6 strain have been shown to have 30 to 50-fold
more functional Ah receptor molecules than non-responsive strains such as the
DBA/2 strain (Okey et al., 1979).
Phenobarbital and phenobarbital-like inducers are found to increase the hepatic GST
content of both strains of mouse to similar extents (Felton et al., 1980; this thesis).
This is expected as phenobarbital acts via a different pathway. It is also worth
noting, however, that the strains C57BL/6 and DBA/2 are also genetically distinct at
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the P-450 locus encoding coumarin hydroxlyase activity, with DBA/2 having high
basal activity, while C57BL/6 has a low activity. Phenobarbital is also found to
produce a significantly greater response in the DBA/2 strain. This would suggest
that the factors involved in conferring this difference in responsiveness do not affect
the GST response to phenobarbital.
Felton et al. (1980) investigated the induction of mouse hepatic GST by 3-
methylcholanthrene in both the C57BL/6 and DBA/2 strains. CDNB activity in the
C57BL/6 strain was induced upon treatment with 3-MC or pNF, this was not
observed in the DBA/2 strain. However when progeny from a cross between the two
strains were investigated no association was observed between GST induction and the
presence of the Ah receptor. The authors concluded that the induction of GST by 3-MC
and other polycyclic aromatic hydrocarbons was not mediated via the Ah locus.
Unfortunately, in this report both male and female, mature and immature mice were
used interchangable. The difference in CDNB activity due to the sex-specific
expression of the Yf GST was not recognised. Nor was the fact that the Yf is
developmentally regulated regulated in the male (Hatayama et al., 1986) taken into
account. The lack of association between CDNB activity and the Ah locus is therefore
by no means conclusive and indeed the data obtained from the parental strains would
strongly indicate that induction of mouse hepatic GST is mediated via the Ah locus.
Further evidence for this statement has recently been provided by Daniel et al.
(1989) who have investigated the regulatory elements 5' to a mouse genomic Ya gene
in a similar manner to that described by Telakowski-Hopkins et al., (1988) for the
rat. As in the rat genomic Ya sequence, two cis-acting regulatory elements have been
identified. One located in the sequence between the transcriptional start point and -
0.2 kb was required for basal levels of expression and the other located -0.2 to 1.6
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kb upstream is responsible for the inducible expression of this gene by PAH. A
functional Ah receptor was also required for responsiveness to these compounds.
In contrast to the rat, where the PAH-inducible element has been reported as
containing a unique sequence, the mouse 5' region was found to contain several XRE
sequence motifs. Although whether these elements are actively involved in the
induction of the Ya gene in response to pNF remains to be established.
Sequences required for basal expression were identified in both the rat and mouse.
The element required for basal expression in the rat was found to contain a consensus
HNF1 sequence (hepatocyte nuclear factor 1). This motif has been reported to
mediate liver specific expression by allowing the binding of the HNF1 transacting
factor (Pickett, 1989) The promoter region of the mouse does not contain this
sequence (Daniel et at., 1989).
6.10 Regulatory differences in GST expression
Between species, the qualitative and quantitative expression of GST differs quite
markedly. Tissue-specific as well as sex specific and developmental differences have
been described. Differences also exist between species in their response to
xenobiotic agents (Astrom et at., 1987). Doubtlessly, as more information on the
regulatory factors which govern expression in individual species is acquired it will
also reveal the underlying mechanisms which give rise to these species differences
and perhaps point to any species-specific role in which the this family of drug
metabolising enzymes are possibly involved.
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In this context, Telakowski-Hopkins et at., (1988) found that basal levels of
expression of the chimeric CAT constructs containing the the rat Ya 5' sequence with
the element required for basal expression were lower when transfected into mouse
cells in comparison to rat and human. Absence of a transacting factor in the mouse
cell which is present in both human and rat was speculated to cause this difference in
expression between the three species cell lines. It might also account for the low
levels of Ya1 expression in the mouse liver. Differences between species in either
the transacting factors which can regulate activation or the noncoding flanking
sequences to which they bind will probably prove to be ultimately responsible for
the species differences in regulation, both by endogenous factors such as testosterone
and growth hormone or xenobiotics such as phenobarbital and 3-
methylcholanthrene.
Although the regulatory sequences governing xenobiotic-inducibility have received
most attention to date, from the work presented within this thesis and that of other
workers, it is also clear that the glutathione S-transferases are also regulated by
endogenous factors. In addition to searching for those sequence motifs that confer
xenobiotic-inducibility, it would undoubtedly prove a valuable exercise to identify
those sequences responsible for conferring responsiveness to endogenous factors.
6.11 Clinical Significance of GST Regulation
A wide assortment of chemical compounds, vastly different in structure and toxicity
have been shown to inhibit chemically induced-carcinogenesis in animal models
(Wattenberg,1985). It would appear that these protective agents can be neatly
divided into two classes. Class I protectors, termed bifunctional inducers by Talalay
or type B inducers by Wattenberg, induce both Phase I and Phase II enzyme systems
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and include polycyclic aromatic hydrocarbons, polychlorinated biphenyls and
phenobarbital. The second class, termed monofunctional inducers by Talalay or type
A by Wattenberg, induce Phase II enzymes without causing a corresponding increase
t
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in the levels of Phase l(Watenberg, 1985; Prochaska and Talalay, 1988). Members
of this class include phenolic antioxidants, aromatic isothiocyanates, thiocarbamates.
Of particular interest are the dietary additives BHA, BHT and ethoxyquin which are
present in the human diet. BHA in particular is noted for its low toxicity and has
been shown to protect rodents against the effects of chemical carcinogenesis in
certain target organs (Wattenberg,1978). Numerous groups have reported the
ability of this compound to cause a dramatic elevation in GST content both at the
protein and RNA level, particularly in the liver (Benson et a/., 1979. McLellan and
Hayes, 1989).
Wattenberg and co-workers, in an elegant series of experiments, have demonstrated
a close correlation in the ability of a compound to induce GST in a target organ and
the increase in protection that this compound affords (Sparnins et at., 1982a).
However it should be noted that treatments or events such as preneoplasia which
induce GST seem to induce other Phase II enzymes. Thus a general Phase II response
seems to be elicited under certain conditions which probably confers protection
(Wattenberg, 1985).
Findings by Wattenberg also emphasise the importance of diet in the ability to induce
basal level of GST. Mice fed a standard, crude diet exhibited a higher hepatic GST
activity than mice fed a partially refined diet. Natural chemicals found in common
everyday foods such as cafestol palmitate (coffee) were shown to affect GST activity
in mice (Lam et at., 1982; Sparnins et at., 1982b). This leads to the possibility
that the relatively high levels of GST found in the liver are not totally "pre-set" but
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the concentration observed are in part due to the continual induction of GST by
components in our everyday diet. It therefore follows that differences between
individuals may not simply be due to genetic factors but also to differences in dietary
intake and exposure to other environmental factors.
Compounds which can increase the cell's ability to deactivate harmful electrophiles
while causing no change in the enzymes which generate these reactive species would
in theory provide enhanced protection against toxicity, mutagenesis and cancer. As
discussed above, some evidence has been obtained to support this theory. This
information could provide a basis for possible clinical strategies in the future where
the emphasis could be placed on the prevention of cancer, perhaps by changing the
diet to accentuate the protective effects of the Phase II enzymes or by the
development of a specific, non-toxic inducer of this system, which could be for
example taken by those in high risk cancer groups (Wattenberg, 1985).
Another aspect of cancer therapy where knowledge of the regulatory controls which
mediate GST levels within the cell might prove invaluable is that of cancer
chemotherapy. One of the major problems encountered in chemotherapy is the
phenomenon of tumour cell resistance to drug treatment regimes. This ability can
either be intrinsic to the tumour type or it can be acquired by a tumour type which
is initially responsive to the drug(s).
There are potentially many paths by which resistance can occur, for example, entry
of the drug into cell might be impaired, efflux of the drug might be enhanced, or
changes might occur in the metabolism of the drug ( Harris et al., 1989). In this
case, changes in the GST and other Phase II systems might lead to enhanced
detoxification of the drug. Indeed, the GST content of tumour cells has been found to
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differ from the cell-types from which they were derived ( Shea and Henner, 1987;
Moscow et al., 1989; Howie et al., 1990). The generation of cell lines resistant to
anti-cancer drugs appears to involve both qualitative and quantitative changes in GST
content (Clapper et al., 1987; Hall et al., 1987; Wolf et al., 1987). Transfection of
cDNA clones encoding the GST subunit Ya was found to confer resistance to alkylating
agents (Mannoharan et al., 1987).
This brief summary by no means covers this very active area in GST research but
simply demonstrates that changes in the expression GST subunits do occur during
this process and probably contribute to the overall resistant phenotype. It must be
emphasised however that the degree of resistance observed is probably due to
changes in a variety of cellular components which come into contact with the drug,
from the cell membrane to the nucleus. Certainly, the expression of GST in these
models is aberrant, using either the normal tissue or sensitive cell line as the
standard. It is therefore important to understand the normal regulatory mechanism
which govern GST expression and how the tumour cell manages to evade these normal
controls. In answering these questions it might be possible in the future to devise
methods of preventing this from occuring. Alternatively, our increasing
understanding of the many xenobiotic compounds which affect drug metabolism might
enable the development, in this case of a series of compounds which could potentiate
the harmful effects of the cytotoxic drug.
This section has hopefully served to show that the understanding of the regulatory
mechanisms which control the expression of the glutathione S-transferases and in a
wider sense the drug metabolising system is not simply an interesting academic
exercise, but could also be of important clinical significance.
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